A Multidimensional Understanding of Pain Among Adolescents and Adults with Sickle Cell Disease: A Prospective, Predictive, Correlational Study by Kuisell, Clare
 
 
 
A Multidimensional Understanding of Pain 
Among Adolescents and Adults with Sickle Cell Disease: 
A Prospective, Predictive, Correlational Study 
 
 
by 
 
 
Clare M. Kuisell 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Nursing) 
in the University of Michigan 
2020 
 
 
 
 
 
 
 
Doctoral Committee: 
Professor Ellen Lavoie Smith, Chair 
Professor Raymond J. Hutchinson 
Research Professor Robert J. Ploutz-Snyder 
Associate Professor Terri Voepel-Lewis 
Professor David A. Williams 
 
 
 
 
 
 
 
Clare M. Kuisell 
claremd@umich.edu 
ORCID iD: 0000-0003-4387-4413 
 
 
ii 
 
DEDICATION 
 This dissertation is dedicated to my husband, Ben, for his constant love and support 
throughout my doctoral studies. I would like to also dedicate this dissertation to my parents; 
without them, none of this would have been possible. Lastly, I thank God for giving me this 
incredible opportunity to broaden my understanding of symptom management, patient advocacy, 
and holistic nursing care.  
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
I would like to acknowledge the clinical teams within the Adult and Pediatric 
Comprehensive Sickle Cell Clinics at Michigan Medicine and Mott Children’s Hospital. Albert 
Query, MD, and Sharon Singh, MD, were instrumental in facilitating the implementation of 
study procedures and identifying patients in the clinics. In addition, I would like to acknowledge 
Brianna Finley for her assistance with recruitment and data collection. I would like to 
acknowledge Eric Maslowski and the staff at MoxyTech, Inc., for their assistance with the 
GeoPain @ Home application features and data management.  
Funding for this study was provided by the Hillman Advancing Early Research 
Opportunities Grant, Rackham Graduate Student Research Grant, and the University of 
Michigan School of Nursing New Investigator Award.  
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENTS 
 
DEDICATION............................................................................................................................... ii 
ACKNOWLEDGEMENTS ........................................................................................................ iii 
LIST OF TABLES ....................................................................................................................... vi 
LIST OF FIGURES ................................................................................................................... viii 
LIST OF APPENDICES ............................................................................................................. ix 
ABSTRACT ................................................................................................................................... x 
CHAPTER I: Introduction .......................................................................................................... 1 
Statement of the Problem ............................................................................................................ 1 
Purpose ........................................................................................................................................ 2 
Theoretical Approach .................................................................................................................. 2 
Model Components ..................................................................................................................... 4 
Specific Aims and Hypotheses .................................................................................................. 12 
Future Directions ....................................................................................................................... 13 
References ................................................................................................................................. 16 
CHAPTER II: Review of the Literature ................................................................................... 25 
Types of Pain ............................................................................................................................. 26 
Nociceptive Pathways ............................................................................................................... 27 
Neuropathic and Centralized Pain Pathophysiology ................................................................. 30 
Pain Influencing Factors............................................................................................................ 33 
SCD-related Pain Management ................................................................................................. 56 
Non-opioid analgesics. .......................................................................................................... 58 
Disease modifying therapies. ................................................................................................. 59 
Non-pharmacologic therapies. ............................................................................................... 65 
Gaps ........................................................................................................................................... 71 
References ................................................................................................................................. 75
 
 
v 
 
CHAPTER III: S.P.A.C.E. Symptom Cluster Among Adolescents and Adults with Sickle 
Cell Disease .................................................................................................................................. 91 
Abstract ..................................................................................................................................... 91 
Background ............................................................................................................................... 93 
Methods ..................................................................................................................................... 95 
Results ..................................................................................................................................... 101 
Discussion ............................................................................................................................... 103 
References ............................................................................................................................... 114 
CHAPTER IV: Centralized Pain and Pain Catastrophizing as Predictors of Opioid 
Consumption and Pain Interference  ...................................................................................... 120 
Abstract ................................................................................................................................... 120 
Introduction ............................................................................................................................. 122 
Methods ................................................................................................................................... 124 
Results ..................................................................................................................................... 129 
Discussion ............................................................................................................................... 132 
References ............................................................................................................................... 147 
CHAPTER V: Physiologic and Psychologic Predictors of Opioid Consumption and Pain 
Interference ............................................................................................................................... 152 
Abstract ................................................................................................................................... 152 
Introduction ............................................................................................................................. 154 
Methods ................................................................................................................................... 155 
Results ..................................................................................................................................... 162 
Discussion ............................................................................................................................... 164 
References ............................................................................................................................... 180 
CHAPTER VI: Summary ........................................................................................................ 186 
Results ..................................................................................................................................... 187 
Limitations .............................................................................................................................. 196 
Recommendations for Future Research .................................................................................. 197 
Recommendations for Clinical Practice .................................................................................. 200 
Conclusions ............................................................................................................................. 201 
References ............................................................................................................................... 202 
APPENDICES ........................................................................................................................... 209 
 
 
 
vi 
 
LIST OF TABLES 
Table 1: Summary of Identified Gaps in the Literature and Plans for Addressing                       73           
               the Gaps in the Proposed  Project 
 
Table 2: Demographic Characteristics              108 
Table 3: Descriptive Statistics of S.P.A.C.E. Symptoms           109 
Table 4: Descriptive Statistics of Pain Variables            110 
Table 5: Pairwise Correlations                                                                                           111 
Table 6: Demographic Characteristics                         138 
Table 7: Descriptive Statistics of Baseline Variables                         139 
Table 8: Descriptive Statistics of Longitudinal Variables                                    140 
Table 9: Two-part model of pain catastrophizing and centralized pain on opioid                    141 
consumption for combined two-part model 
 
Table 10: Average marginal effects for pain catastrophizing and centralized pain on                142  
   opioid consumption           
 
Table 11: Two-part model of pain catastrophizing and centralized pain on pain interference    143 
Table 12: Marginal effects of pain catastrophizing and centralized pain on pain interference   144 
 for combined two-part model 
 
Table 13: Demographic Characteristics                                                                                       170 
Table 14: Descriptive Statistics of S.P.A.C.E. Symptoms                                                           171 
Table 15: Two-part model of demographics and S.P.A.C.E. symptoms on opioid                     172 
                 consumption MME 
 
Table 16: Average marginal effects for S.P.A.C.E. symptoms on opioid consumption MME   173 
for combined two-part model 
 
 
vii 
 
Table 17: Two-part model of demographics and S.P.A.C.E. symptoms on pain interference    174 
Table 18: Average marginal effects for S.P.A.C.E. symptoms on pain interference for             175 
  combined two-part model 
 
Table 19: Pain Influencing Factors in Patients with SCD                                                           209 
 
Table 20: Critical Appraisal for Pain Influencing Factors in SCD: Randomized Controlled     233 
Trials 
 
Table 21: Critical Appraisal for Pain Influencing Factors in SCD: Case Control Studies          234 
Table 22: Critical Appraisal for Pain Influencing Factors in SCD: Cross-Sectional Studies      235 
Table 23: Critical Appraisal Pain Influencing Factors in SCD: Cohort Studies                          237 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
Figure 1: The Theory of Unpleasant Symptoms                3 
Figure 2: Adapted Theory of Unpleasant Symptoms                3 
Figure 3: GeoPain @ Home Mobile Application Body Map           112 
Figure 4: Consort Flow Diagram of Study Sample            113   
Figure 5: Predictive margins of centralized pain on opioid consumption MME        145 
Figure 6: Predictive average marginal effects of centralized pain on pain interference              146 
Figure 7: Forest plot of odds ratios and confidence intervals of  S.P.A.C.E.                              176 
    symptoms on opioid consumption MME   
Figure 8: Predictive margins of widespread pain on opioid consumption MME                        177 
Figure 9: Forest plot of Odds Ratios and Confidence Intervals of                                              178 
                S.P.A.C.E. symptoms on pain interference        
Figure 10: Predictive margins of fatigue on pain interference                                                    179 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF APPENDICES 
A – 1: Pain Influencing Factors in Patients with SCD                      209 
A – 2: Critical Appraisal for Pain Influencing Factors in SCD: Randomized Controlled           233 
Trials 
 
A – 3: Critical Appraisal for Pain Influencing Factors in SCD: Case Control Studies               234 
A – 4: Critical Appraisal for Pain Influencing Factors in SCD: Cross-Sectional Studies           235 
A – 5: Critical Appraisal Pain Influencing Factors in SCD: Cohort Studies                               237 
 
 
 
 
x 
 
ABSTRACT 
Sickle Cell Disease (SCD) is a disorder that disrupts the lives of thousands of Americans 
and causes recurring pain. Multidimensional factors including centralized pain, pain 
catastrophizing, and centrally-mediated symptoms, or the S.P.A.C.E. symptom cluster (i.e., sleep 
impairment, widespread pain, depression, anxiety, cognitive function, and fatigue) influence pain 
perception. Having comprehensive knowledge of the SCD-associated pain characteristics could 
lead to more effective pain management approaches. However, little SCD research has evaluated 
the incidence and severity of these multidimensional factors.  
The purpose of this longitudinal study was to: 1) describe the incidence and severity of 
several pain influencing factors including pain catastrophizing, centralized pain, and S.P.A.C.E. 
symptoms (sleep impairment, multifocal pain, depression, anxiety, cognitive function, fatigue) in 
adolescents and young adults with SCD, 2) evaluate the predictive relationships among 
S.P.A.C.E. symptoms, opioid consumption, and pain interference, 3) examine the predictive 
relationships among pain catastrophizing, centralized pain, opioid consumption, and pain 
interference, and 4) characterize the co-occurrence of baseline S.P.A.C.E. symptoms, pain 
interference, opioid consumption, pain intensity, and Pain Area and Intensity Number 
Summation [P.A.I.N.S. (a metric that combines pain intensity and widespread pain)]. 
Forty-eight adolescents and adults with SCD were recruited from Pediatric and Adult 
Sickle Cell Clinics. Participants completed baseline measures of pain catastrophizing, centralized 
pain, S.P.A.C.E. symptoms, pain intensity, and P.A.I.N.S. After the completion of baseline 
measures, participants completed weekly opioid consumption and pain interference surveys. 
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Two-part models were used to analyze the predictive relationships among the 
multidimensional factors, weekly pain interference, and average daily opioid consumption. 
Multiple Spearman correlations were calculated to characterize the co-occurrence of baseline 
S.P.A.C.E. symptom severity scores, pain interference, average daily opioid consumption, pain 
intensity, and P.A.I.N.S.  
Baseline depression, anxiety, and pain catastrophizing severity were low. One-fourth of 
participants were positive for centralized pain. Widespread pain (β=0.16; p < 0.05) and 
centralized pain (β=0.13; p < 0.05) were the only factors that significantly predicted increased 
opioid consumption. Pain catastrophizing had a significant negative relationship with opioid 
consumption (β=-0.03; p < 0.05). Within the pain interference models, fatigue (β=0.04; p < 0.05) 
and centralized pain (β=0.06; p < 0.05) were the only factors that significantly predicted more 
pain interference over time. Many S.P.A.C.E. symptoms (i.e., sleep impairment, anxiety, 
depression, cognitive function, and fatigue) were moderately and significantly correlated with 
one another. Pain interference was moderately and significantly correlated with all but one 
S.P.A.C.E. symptom (depression). Widespread pain was the only S.P.A.C.E. symptom that was 
significantly associated with average daily opioid consumption, pain intensity, and P.A.I.N.S. 
Our findings demonstrate significant predictive relationships between centralized pain, 
opioid consumption, and pain. The results of this study should be interpreted with caution due to 
suboptimal data completion rates, small sample size, and low symptom severity. Routine 
assessment of centralized pain may facilitate the implementation of individualized pain 
management approaches, which may subsequently reduce pain and opioid use and improve 
function and quality of life among patients with SCD.
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CHAPTER I 
Introduction 
Sickle Cell Disease (SCD) is the most commonly inherited red blood cell disease in the 
United States (Norman & Miller, 2011; Vacca Jr & Blank, 2017). One in 375 African Americans 
and those of Middle Eastern Heritage have SCD (Norman & Miller, 2011; Vacca Jr & Blank, 
2017). Those with SCD have genetic mutations resulting in misshapen red blood cells that easily 
adhere to each other and cause vaso-occlusion (Vacca Jr & Blank, 2017). Several complications 
arise from vaso-occlusion including organ damage, cardiovascular and pulmonary complications, 
and pain (Smith & Scherer, 2010). 
Statement of the Problem 
Pain is known as the hallmark of SCD (Platt et al., 1991; Vacca Jr & Blank, 2017). 
Several negative outcomes including frequent health service utilization, reduced function, poor 
quality of life, anxiety, and depression are associated with SCD-related pain (Adam et al., 2017; 
Benton, Ifeagwu, & Smith-Whitley, 2007; Jerrell, Tripathi, & McIntyre, 2011; Smith, Penberthy, 
Bovbjerg, Mcclish, & Roberts, 2008). Although pain and opioid use is substantial among 
patients with SCD, there are few effective pharmacologic and non-pharmacologic treatments that 
reduce the incidence and severity of pain within this population. Considering the 
multidimensional and individualized presentation of pain among patients with SCD may uncover 
effective pharmacologic and non-pharmacologic pain management approaches. Thus, research 
that evaluates the multidimensional pain characteristics, and explores the predictive relationships 
between these characteristics, pain, and opioid consumption is needed. 
 
 
2 
 
Purpose 
 The purpose of this research study is to evaluate the multidimensional impact of pain 
among adolescents and adults with SCD, including the incidence and severity of pain 
catastrophizing, centralized pain, and centrally-mediated S.P.A.C.E. symptoms (i.e., sleep 
impairment, widespread pain, depression, anxiety, cognitive function, and fatigue). Further, the 
predictive relationships among these characteristics and average daily opioid consumption and 
weekly pain interference will be explored. This research will also characterize the co-occurrence 
of S.P.A.C.E. symptoms, average daily opioid consumption, pain interference, pain intensity, and 
Pain Area and Intensity Number Summation (P.A.I.N.S.) (Davis, Kroenke, Monahan, Kean, & 
Stump, 2017; Knoerl, Chornoby, & Smith, 2018; Williams, 2018).  
Theoretical Approach 
The Theory of Unpleasant Symptoms (TOUS) is the theoretical framework (Figure 1) 
that guides this dissertation study (Lenz, Pugh, Milligan, Gift, & Suppe, 1997). According to this 
theory, physiologic, psychologic, and situational factors are all influencing factors that interact 
with each other in relation to the symptom (Lenz et al., 1997). Informed by empirical centralized 
pain literature, this study will examine the relationships among SCD pain-related factors within 
each theoretical construct based on an adapted TOUS framework (Figure 2). Below is a brief 
description of the variables included within the adapted TOUS framework. 
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Figure 1. The Theory of Unpleasant Symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) 
 
 
Figure 2. Adapted Theory of Unpleasant Symptoms 
 
Note. Highlighted text indicates S.P.A.C.E. symptoms; P.A.I.N.S.= Pain Area and Intensity 
Number Summation 
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Model Components 
Physiologic factors.  
The physiologic characteristics included within the adapted theoretical framework are 
genetics, age, sex, sleep, and fatigue. Empirical evidence suggests that genetic factors can 
influence pain sensitivity, analgesic response, and the development of centralized pain 
syndromes (i.e., fibromyalgia, temporomandibular disorders, and migraine)(Andersen & 
Skorpen, 2009; Diatchenko et al., 2005; Emin Erdal, Herken, Yilmaz, & Bayazit, 2001; Gursoy 
et al., 2003; Smith et al., 2012). One genetic factor unique to SCD is sickle cell genotype 
including HbSS, HbSC, HbS β0, HbS β+. However, there is conflicting evidence regarding pain 
differences among the different sickle cell genotypes (Carroll et al., 2016; Carroll, Haywood, 
Hoot, & Lanzkron, 2013; Jacob et al., 2015; McClish et al., 2009; Schlenz, Schatz, & Roberts, 
2016; Sil, Cohen, & Dampier, 2016; Zempsky et al., 2017). The second physiologic factor 
included within the adapted theoretical model is sex. Empirical evidence suggests that females 
have increased pain frequency, sensitivity, and durations compared to males (Bartley & 
Fillingim, 2013; Fillingim, King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009; Smith et al., 
2006). Similarly to sickle cell genotype, there remains conflicting evidence regarding sex 
differences and pain among patients with SCD (Antunes, Propheta, Vasconcelos, & Cipolotti, 
2017; Bakshi, Lukombo, Belfer, & Krishnamurti, 2018; Bakshi, Lukombo, Shnol, Belfer, & 
Krishnamurti, 2017; Brandow et al., 2013; Carroll et al., 2016; Graves & Jacob, 2014; Jacob et 
al., 2015; McClish et al., 2009; Sil et al., 2016; Zempsky et al., 2017). 
Two additional physiologic variables, sleep and fatigue, are also included within the 
S.P.A.C.E. symptom cluster (Williams, 2018). Empirical evidence suggests that sleep 
impairment and pain are associated among patients with several centralized pain conditions, such 
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as chronic low back pain, temporomandibular disorders (TMD), and fibromyalgia (Choy, 2015; 
Heffner, France, Trost, Mei Ng, & Pigeon, 2011; Park & Chung, 2016). Further, research has 
highlighted associations between sleep impairment, pain frequency, pain severity, and SCD-
related complications (Daniel, Grant, Kothare, Dampier, & Barakat, 2010; Moscou-Jackson, 
Finan, Campbell, Smyth, & Haythornthwaite, 2015; Wallen et al., 2014).  
Lastly, fatigue, is a symptom commonly reported among patients with a variety of painful 
conditions (e.g., irritable bowel syndrome, migraine, TMD) (Dailey, Keffala, & Sluka, 2015; 
Lackner, Gudleski, Dimuro, Keefer, & Brenner, 2013; Lau, Lin, Chen, Wang, & Kao, 2015; 
Robinson, Durham, & Newton, 2016). Only one study, however, has investigated the 
relationship between fatigue and pain among patients with SCD (Ameringer, Elswick Jr, & 
Smith, 2014). It is hypothesized that increased sleep impairment and increased fatigue will 
predict increased weekly opioid consumption and pain interference among adolescents and 
young adults with SCD. 
Psychologic factors.  
The psychologic factors within the adapted model are depression, anxiety, 
catastrophizing, and pain control beliefs. Depression and anxiety are two variables that quantify 
affective perturbation within the S.P.A.C.E. symptom cluster (Davis et al., 2017; Knoerl et al., 
2018;  Williams, 2018). It is widely known that depression and pain co-occur in patients with 
centralized pain (Davis et al., 2017; Maletic & Raison, 2009; Strigo, Simmons, Matthews, Craig, 
& Paulus, 2008). Further, empirical evidence suggests that 35-46% of patients with SCD have 
depression (Adam et al., 2017; Jerrell et al., 2011). Studies conducted among patients with SCD 
also support a positive association between depression and pain frequency, multifocal pain, 
lower heat pain thresholds, opioid use, and SCD-related complications (Bakshi, Lukombo, 
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Shnol, Belfer, & Krishnamurti, 2017; Carroll et al., 2016b; Jerrell et al., 2011; McClish et al., 
2009; S Sil, Dampier, & Cohen, 2016; Wallen et al., 2014). Thus, it is hypothesized that 
increased depression will predict increased weekly opioid consumption and pain interference 
among adolescents and young adults with SCD.  
Anxiety is the second psychologic factor included within the adapted theoretical model. 
Empirical evidence suggests that anxiety is strongly associated with several pain conditions such 
as chronic low back pain, migraine, and arthritis (Davis et al., 2017; McWilliams, Cox, & Enns, 
2003; McWilliams, Goodwin, & Cox, 2004; Tsang et al., 2008). There is conflicting evidence, 
however, regarding the association between anxiety and pain among patients with SCD. (Bakshi 
et al., 2018, 2017; Ford, Grasso, Jones, Works, & Andemariam, 2017; Jacob et al., 2015; 
Lemanek, Ranalli, & Lukens, 2009; Moody et al., 2017; Thomas, Stephenson, Swanson, Jesse, & 
Brown, 2013). Pain catastrophizing, an additional psychological factor, is conceptualized as 
irrational thoughts about pain including rumination, magnification and helplessness (Citero et al., 
2007; Quartana & Edwards, 2009). Several studies support the association between 
catastrophizing and pain in patients with various pain conditions and those with SCD (Bakshi et 
al., 2017; Campbell et al., 2016; Ciechanowski, Sullivan, Jensen, Romano, & Summers, 2003; 
Finan et al., 2018; Geisser, Robinson, Keefe, & Weiner, 1994; Graves & Jacob, 2014; Keefe et 
al., 2000; Pavlin, Sullivan, Freund, & Roesen, 2005; Quartana & Edwards, 2009; Severeijns, 
Vlaeyen, van den Hout, & Weber, 2001; Sil, Cohen, et al., 2016). Based on the research 
described above, it is hypothesized that increased anxiety and pain catastrophizing will predict 
increased opioid consumption and pain interference among adolescents and young adults with 
SCD.  
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Pain control beliefs, or beliefs that pain is either controllable or uncontrollable, is the last 
psychologic factor included within the adapted theoretical model. Empirical evidence suggests 
that pain control beliefs influence how a patient processes and manages their pain (Higgins, 
Bailey, LaChapelle, Harman, & Hadjistavropoulos, 2015; Oliveira et al., 2009; Spinhoven et al., 
2004). Limited evidence has investigated the relationship between pain control beliefs and pain 
in patients with SCD. 
Situational factors. 
The situational factors within the model are sickle cell stigma, trauma exposure, and 
social support. Sickle cell stigma is a factor unique to those with SCD. Evidence suggests that 
many clinicians who manage patients with SCD have misperceptions regarding rates of opioid 
misuse and addiction (Wakefield et al., 2017; Zempsky, 2009). Due to clinician bias and false 
assumptions about a patient’s motivation for seeking pain medication, patients suffering with 
VOC-associated pain may not receive adequate treatment for their pain. Two studies have 
highlighted that perceived sickle cell stigma among patients is associated with increased pain 
interference and health care utilization (Bediako et al., 2016; Martin et al., 2018).  
The second situational factor included within the adapted TOUS theoretical model is 
trauma exposure. Pain research in other centralized pain populations (e.g., irritable bowel 
syndrome, fibromyalgia, chronic back pain, chronic daily headaches, and chronic pelvic pain) 
suggests a significant positive relationship between trauma exposure (i.e., abuse, illness, parental 
upheaval, death of a family member or friend) and the development centralized pain disorders 
(Hauser, Kosseva, Uceyler, Klose, & Sommer, 2011; Kanzawa-Lee et al., 2018; Oram et al., 
2012; Phillips & Clauw, 2011; Schofferman, Anderson, Hines, Smith, & Keane, 1993; Spiegel et 
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al., 2015). Few studies have explored the relationship between trauma exposure and pain among 
patients with SCD.  
Lastly, empirical evidence suggests an association between pain and social support in 
centralized pain populations (Forgeron et al., 2010; Snelling, 1994; Zaza & Baine, 2002). 
Research has highlighted that the presence of a centralized pain condition may negatively impact 
a patient’s social support network (Carter, Lambrenos, & Thursfield, 2002; Zaza & Baine, 2002). 
Conversely, patients with more social support are more likely to engage in positive coping 
strategies (Holtzman, Newth, & Delongis, 2004). Limited research has evaluated the association 
between pain and social support among patients with SCD (Carroll et al., 2013). 
Symptoms. 
Pain, widespread pain, and centralized pain are the symptoms included within the 
theoretical model. Widespread pain, or multifocal pain, is also included within the S.P.A.C.E. 
symptom cluster (Williams, 2018). Widespread pain is frequently reported among patients with 
centralized pain conditions such as fibromyalgia, temporomandibular disorder, and urologic 
chronic pelvic pain syndrome (Lai et al., 2017; Slade et al., 2013; Williams, 2018). Further, 
empirical evidence suggests that more than 20% of patients with SCD report pain in more than 
seven body sites (Zempsky et al., 2017). Based on this evidence, it is hypothesized that patients 
with widespread pain will have increased weekly opioid consumption and pain interference.  
Pain intensity, a characteristic used to operationalize the symptom of pain, is included 
within the adapted theoretical model. Pain intensity is frequently assessed within clinical and 
research settings to inform pain management approaches and measure effectiveness. Limited 
research, however, has investigated the co-occurrence of pain intensity with multiple centrally-
mediated symptoms among patients with SCD. For this reason, we seek to understand the co-
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occurrence of centrally-mediated symptoms and pain intensity. Since pain intensity does not 
capture the multidimensional aspect of pain, we will also evaluate Pain Area and Intensity 
Number Summation (P.A.I.N.S.). P.A.I.N.S. is a single variable that combines pain intensity and 
widespread pain and provides a more comprehensive evaluation of the painful experience.  
The third symptom included within the adapted TOUS model is centralized pain. 
Centralized pain arises from altered nociception in the absence of actual or potential tissue 
damage or evidence for disease or lesion of the somatosensory system (Latremoliere & Woolf, 
2009; Marchand, 2008; Woolf, 2011). A growing body of literature suggests that a subset of 
patients with SCD experience centralized pain (Brandow, Stucky, Hillery, Hoffmann, & 
Panepinto, 2013; Campbell et al., 2016; Carroll et al., 2016; Jacob et al., 2015). Research 
conducted in other centralized pain populations suggests that opioids are ineffective for 
centralized pain (Brummett et al., 2013; Corli et al., 2017; Finan et al., 2018; Hanks & Forbes, 
1997; Janda et al., 2015; Phillips & Clauw, 2011; Wasserman, Brummett, Goesling, Tsodikov, & 
Hassett, 2014). This suboptimal pain relief may be manifested by increased daily pain and 
increased daily opioid consumption. Based on this evidence, it is hypothesized that patients with 
SCD experiencing centralized pain will have increased opioid consumption and pain 
interference.  
Interventions. 
Opioid consumption is conceptualized as an intervention within the adapted TOUS 
model. An acute (short-lived) pain episode, also called a vaso-occlusive pain crisis (VOC), is the 
most common complication of SCD (Vacca Jr & Blank, 2017). For this reason, many of the 
treatments available for SCD-related pain focus on managing acute pain episodes. Clinical 
practice guidelines published by the National Heart Lung and Blood Institute (2014) support the 
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rapid initiation of analgesics, opioids and non-opioids, when patients present with VOC. Further, 
in those that present with severe pain, the initiation of parenteral opioids is strongly 
recommended (National Heart, Lung, and Blood Institute, 2014). Although opioids are indicated 
for acute VOC, evidence suggests that they are ineffective in treating the variety of 
pathophysiologic mechanisms that contribute to centralized pain (Brummett et al., 2013; Corli et 
al., 2017; Finan et al., 2018; Hanks & Forbes, 1997; Janda et al., 2015; Phillips & Clauw, 2011; 
Wasserman, Brummett, Goesling, Tsodikov, & Hassett, 2014). Despite this, daily opioid use in 
those with SCD remains substantial (Finan et al., 2018). To guide the implementation of 
effective non-opioid and non-pharmacologic interventions among patients with SCD, it is 
necessary to understand the pain presentation unique to those with SCD. For this reason, we will 
evaluate the predictive relationships among the various centrally-mediated symptoms, pain 
catastrophizing, centralized pain, and opioid consumption. 
Performance. 
The adapted model depicts that influencing factors and symptoms influence an 
individual’s physical or cognitive performance (Lenz et al., 1997). Physical performance will be 
conceptualized within this study as pain interference, or the consequences of pain on relevant 
aspects of one's life (Amtmann et al., 2010). Pain interference has been chosen as a primary 
outcome within this study to provide information regarding the functional impact of pain among 
patients with SCD.  
Cognitive performance is conceptualized as cognitive function and is the last variable 
included within the S.P.A.C.E. symptom cluster (Williams, 2018). Empirical evidence suggests 
that cognitive function and pain are correlated among patients with multiple sclerosis and 
fibromyalgia (Glass, 2009; Kratz, Murphy, & Braley, 2017; Shattuck & Muehlenbein, 2016; D. 
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A. Williams, 2018). However, no studies have examined the predictive relationship between 
cognitive function and pain among patients with SCD. Based on evidence within other pain 
populations, it is hypothesized that decreased cognitive function will predict increased opioid 
consumption and pain interference among adolescents and young adults with SCD (Heffner et 
al., 2011; Park & Chung, 2016; Schaible, 2014; Shattuck & Muehlenbein, 2016). 
This chapter has provided a brief review of several physiological, psychological, 
situational, and cognitive factors that have been associated with pain among patients with SCD. 
These factors included genetics, sex, age, sleep, depression, anxiety, cognitive function, fatigue, 
catastrophizing, pain control beliefs, sickle cell stigma, trauma exposure, social support. 
Although several of the factors discussed require further investigation (e.g., sickle cell stigma, 
trauma exposure, pain control beliefs), their relationships with opioid consumption and pain 
interference will not be explored in the proposed study due to sample size limitations and 
participant burden. The factors that will be investigated within this study were selected based on 
significant gaps identified within the SCD literature. There is a paucity of research that has 
evaluated centralized pain and the severity, co-occurrence, and impact of all centrally-mediated 
symptoms within the S.P.A.C.E. symptom cluster (Davis et al., 2017; Robert Knoerl et al., 2018; 
Shattuck & Muehlenbein, 2016; D. A. Williams, 2018). Further, there is conflicting evidence 
regarding the predictive relationship between catastrophizing and pain among those with SCD. 
For these reasons, the factors that will be explored within this study include centralized pain, 
pain catastrophizing, centrally-mediated symptoms included within the S.P.A.C.E. symptom 
cluster, pain interference, and opioid consumption.  
In summary, the adapted TOUS model has guided the inclusion of several variables 
within the proposed study and their hypothesized relationships. It is hypothesized that several 
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individual factors will predict weekly opioid consumption and pain interference one month after 
baseline phenotyping. Lastly, the co-occurrence of baseline S.P.A.C.E. symptoms, pain 
interference, average daily opioid consumption, pain intensity, and Pain Area and Intensity 
Number Summation (P.A.I.N.S.) will be evaluated via correlation coefficients within this 
population.  
Specific Aims and Hypotheses 
To achieve our overall objective, we will address the following specific aims: 
SA1- Characterize demographic variables (i.e., age, sex, and sickle cell genotype), the 
incidence and severity of centralized pain, pain catastrophizing, and six S.P.A.C.E. 
symptoms (i.e., sleep impairment, widespread pain, anxiety, depression, cognitive function, 
fatigue) measured at baseline among adolescents and adults with SCD.  
SA2- Evaluate the predictive relationships among demographic variables (i.e., age and sex), 
baseline S.P.A.C.E. symptoms (sleep impairment, widespread pain, anxiety, depression, 
cognitive function, fatigue) and opioid consumption and pain interference reported 
longitudinally for one month post-baseline in adolescents and young adults with SCD. 
SA2a- Evaluate the predictive relationships among age, sex, S.P.A.C.E. 
symptoms, and average daily opioid consumption (milligram milliequivalents 
[MME]) measured by weekly opioid surveys.  
SA2b- Evaluate the predictive relationships among age, sex, S.P.A.C.E. 
symptoms, and weekly pain interference measured by the Patient Reported 
Outcome Measures Information System (PROMIS®) Pain Interference measure. 
Hypothesis- Baseline evidence of sleep impairment, widespread pain, anxiety, 
depression, cognitive impairment, and fatigue will predict increased opioid 
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consumption (MME) and pain interference one month post-baseline in 
adolescents and young adults with SCD.  
SA3- Examine the predictive relationships among baseline centralized pain and pain 
catastrophizing severity, opioid consumption, and pain interference within one month of 
baseline phenotyping.  
SA3a- Examine the predictive relationships of baseline centralized pain and pain 
catastrophizing severity, and average daily opioid consumption (MME) measured 
by weekly opioid consumption surveys. 
SA3b- Examine the predictive relationships of baseline centralized pain and pain 
catastrophizing severity, and weekly pain interference measured by the 
PROMIS® Pain Interference measure. 
Hypothesis- Baseline centralized pain severity and pain catastrophizing severity 
will predict increased opioid consumption (MME) and pain interference one 
month post-baseline in adolescents and young adults with SCD. 
SA4- Characterize the co-occurrence of baseline S.P.A.C.E. symptoms, average daily 
opioid consumption, pain interference, pain intensity, and Pain Area and Intensity 
Number Summation (P.A.I.N.S.) measured via an interactive body map within the 
GeoPain @ Home mobile application. 
Future Directions 
The results of this study provide comprehensive information regarding the incidence and 
severity of several centrally-mediated symptoms and pain-related characteristics among 
adolescents and adults with SCD. Further, this research examined the predictive relationships 
among baseline characteristics and opioid consumption and pain interference. Lastly, the 
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findings of this study identified the co-occurrence of several centrally-mediated symptoms, 
opioid consumption, and pain among adolescents and young adults with SCD. Together, these 
findings suggest that centralized pain and many centrally-mediated symptoms factors predict 
opioid consumption and pain that interferes with social, emotional, and physical function. 
Assessment of centrally-mediated symptoms and centralized pain is necessary to improve 
individualized pain management among patients with SCD. Clinicians can use knowledge about 
the incidence and severity of centralized pain and centrally-mediated symptoms to facilitate 
referrals to clinical specialists (e.g., integrative health providers) and ancillary resources (e.g., 
psychiatric). Further, individualized evaluation and management of pain can inform the 
implementation of appropriate non-pharmacologic treatments. Ultimately, individualized pain 
management approaches, informed by centrally-mediated symptoms and pain-influencing 
factors, may reduce pain and opioid use and improve function and quality of life among patients 
with SCD. 
Within the following chapters, I will describe the supporting literature, methods, results, 
and discussion that address each aim of this dissertation project. Chapter 2 includes an overview 
of pain definitions, incidence, characteristics, pathophysiology, and pain unique to patients with 
SCD. Chapter 3 addresses Aims 1 and 4, including a description of the incidence and severity of 
S.P.A.C.E. symptoms and their co-occurrence with opioid consumption and negative pain 
outcomes among adolescents and adults with SCD. The evaluation of the predictive relationships 
among centralized pain severity, pain catastrophizing severity, weekly opioid consumption and 
pain interference (Aim 3) is described in Chapter 4. Further, the evaluation of the predictive 
relationships among baseline S.P.A.C.E. symptoms and weekly opioid consumption and pain 
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interference (Aim 2) is described in Chapter 5. Lastly, Chapter 6 concludes this dissertation with 
a broad discussion of the results of this dissertation project and implications for future research.  
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CHAPTER II 
Review of the Literature 
This chapter begins with an overview of pain definitions, incidence, characteristics, 
pathophysiology, and influencers (physiological, psychological, and situational). This is 
followed by a literature synthesis of research studies involving patients with sickle cell disease 
(SCD), an evaluation of the level of evidence, and an explanation of the gaps in the current 
science. The chapter will conclude with a summary of the gaps that will be addressed by this 
dissertation study. 
Introduction 
Pain is a significant problem within the United States. In 2012, the National Center for 
Health Statistics, Center for Disease Control and Prevention reported that 86.6 million adults had 
pain on some days and 25.5 million had pain every day (Adams, Kirzinger, & Martinez, 2013; 
Medicine, 2011; Nahin, 2015). Additionally, pain costs the nation up to $635 billion each year 
(Medicine, 2011). Despite its profound impact, there are limited effective treatments for chronic 
pain. Further, pharmacologic interventions do not address the complex, inter-related 
multidimensional physiological, psychological, and situational mechanisms of pain (Lenz et al., 
1997). With better knowledge of pain mechanisms, targeted interventions can be developed and 
tested to reduce the myriad of negative sequelae caused by uncontrolled pain (e.g., anxiety, 
depression, increased healthcare costs) (Robinson, Katon, Kroenke, 2003; Medicine, 2011; 
Wade, Price, Hamer, Schwartz, & Hart, 1990). Thus, theory-driven research that explores the 
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multidimensional mechanisms of pain perception is needed to improve the lives of patients with 
daily pain.  
Types of Pain 
Pain is defined as “the unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of damage” (Merskey & Bogduk, 1994). 
There are three pain types that will be discussed within this section: nociceptive pain, 
neuropathic pain, and nociplastic pain. The following paragraphs outline specific mechanism 
definitions and characteristics. 
Nociceptive pain is a painful experience that is short lived with varying intensity and can 
be caused by tissue or bone injury resulting from trauma, surgery, and acute medical conditions 
for example, bone fractures, appendicitis, and nephrolithiasis (Carr & Goudas, 2013; Nicholson, 
2006). Nociceptive pain is characterized by sharp, aching, and pressure sensations.  
Unlike nociceptive pain, neuropathic pain (NP) occurs as a result of nerve injury in the 
periphery or the central nervous system (CNS), and can be acute or chronic (Woolf, 2010). One 
cause of acute NP is surgery-associated axillary or intercostobrachial nerve damage that occurs 
following procedures to manage breast cancer: mastectomy, lumpectomy, axillary node 
dissection, and breast reconstruction. This acute nerve damage results in pain in the axilla, inner 
side of the upper arm, and shoulder (Andersen, Aasvang, Kroman, & Kehlet, 2014; Smith et al., 
2014). Chronic pain is defined as pain that continues past the normal time of healing (Merskey & 
Bogduk, 1994). The normal time of healing may vary based on the origin of injury; however, 
many categorize chronic pain as pain that has lasted longer than three to six months. Causes of 
chronic NP include acute intervertebral disc herniation, cerebrovascular accident, acute herpes, 
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among others (Dubin & Patapoutian, 2010; Woolf, 2010). Common clinical manifestations of 
NP include shooting, burning, numbness, and tingling.  
A third type of pain, nociplastic pain (also termed centralized pain), has been described 
by the International Association for the Study of Pain (IASP) as “pain that arises from altered 
nociception despite no clear evidence of actual or threatened tissue damage causing the 
activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory 
system causing the pain” (2017). Thus, unlike nociceptive and neuropathic pain, centralized pain 
can occur without any damage to the peripheral or central nervous systems. Despite minimal or 
no damage, patients with centralized pain may experience with hyperalgesia (increased pain 
sensitivity), allodynia (pain perception due to a normally non-painful stimulus), widespread pain, 
numbness, burning, and tingling (Bridges, Thompson, & Rice, 2001; Latremoliere & Woolf, 
2009). The following section will include detailed information regarding nociceptive pathways 
and pain perception. 
Nociceptive Pathways 
Nociception is defined as the “neural process of encoding noxious stimuli” (IASP, 2017). 
Several different neural processes make up the nociceptive system to warn the body of actual or 
imminent damage. The nociceptive system provides neural signals to the central nervous system 
that may be interpreted as pain. The following section describes nociceptive processing within an 
individual who has a normally functioning and activated nociceptive system. 
Transduction and Transmission. 
First, sensory fibers located throughout the body alert the nociceptive system of 
potentially dangerous stimuli via electrical signals (McEntire et al., 2016). This process is often 
referred to as transduction and transmission. Transduction refers to the conversion of noxious 
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stimuli into electrical signals via sensory nerve fibers (McEntire et al., 2016). There are two 
types of sensory, or afferent, nerve fibers: thinly myelinated Aδ and unmyelinated C fibers. 
Peripheral tissue damage, resulting from noxious stimuli (e.g., thermal, mechanical, or chemical 
stimuli), causes the release of several chemical substances including serotonin, bradykinin, 
histamine, histamine, prostaglandins, and substance P (McEntire et al., 2016). These substances 
activate the afferent nerve fibers via serotonin (5-HT) receptors and relevant acid-sensing 
(ASIC), transient receptor potential (TRP), and voltage-gated sodium (Nav) ion channels, among 
others (McEntire et al., 2016). The opening and activation of sodium ion channels eventually 
leads to depolarization of an action potential. Transmission refers to the nociceptive process in 
which the action potential travels along the afferent nerve fiber axon to the dorsal horn within the 
spinal cord (Dubin & Patapoutian, 2010; Marchand, 2008). These afferent nerve fibers ultimately 
terminate in the dorsal horn within the spinal cord (Dubin & Patapoutian, 2010; Marchand, 
2008).  
Modulation. 
The third step in the nociceptive pathway is modulation. Modulation refers to activity 
within the CNS that either inhibits or enhances the transmitted input from the periphery 
(Marchand, 2008). Excitatory neurons, inhibitory neurons, and projection cells within the dorsal 
horn influence whether the action potential is transmitted from the periphery to the brain (Alves 
& Lin, 2018). These neurons have both excitatory and inhibitory receptors that are activated by 
neurotransmitters, leading to the overall inhibition or excitation within the dorsal horn (Alves & 
Lin, 2018).  
Inhibition is enhanced via the descending pathway, which involves multiple neuron 
synapses within the brain, rostral ventromedial medulla (RVM), and spinal cord (Dubin & 
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Patapoutian, 2010; Holden, Jeong, & Forrest, 2005). Bidirectional modulation occurs in the 
RVM. Specifically, within the RVM, neurons are frequently referred to as “on” (pronociceptive) 
and “off” (antinociceptive) cells. These cells can increase or decrease their projections to the 
spinal cord, thus impacting overall excitation or inhibition (Aicher, Hermes, Whittier, & 
Hegarty, 2012; Burgess et al., 2002; Ossipov, Dussor, & Porreca, 2010). Further, evidence 
suggests that stimulation of the periaqueductal gray region (PAG) or RVM causes the release of 
the following endogenous opioid peptides: enkephalins, dynorphins, endorphin, serotonin, and 
norepinephrine (Holden et al., 2005; Ossipov et al., 2010). These peptides act as 
neurotransmitters and bind to inhibitory pain receptors within the dorsal horn, producing 
analgesia (Holden et al., 2005; Ossipov et al., 2010).  
 If excitation within the dorsal horn is greater than inhibition, the nerve impulse will be 
transmitted to the brain via ascending tracts (Albe-Fessard, Berkley, Kruger, Ralston, & Willis, 
1985; Alves & Lin, 2018; Flor & Turk, 2011; Schaibl & Richter, 2004). The spinothalamic tract 
is the major pathway for transmission of nociceptive input from the spinal cord to several 
supraspinal areas including: the RVM, PAG, thalamus, amygdala, insular cortex, somatosensory 
cortex, prefrontal cortex, and anterior cingulate cortices (Albe-Fessard et al., 1985; Dubin & 
Patapoutian, 2010; Jones, 1999; Marchand, 2008). 
Pain Perception. 
The fourth and final step in the nociceptive processing pathway occurs when the patient 
perceives the nociceptive input as pain (Dubin & Patapoutian, 2010; Marchand, 2008). As 
previously discussed, once a nerve impulse is transmitted from the dorsal horn, it travels to 
several areas in the brain. Within these supraspinal areas (e.g., the amygdala, hypothalamus, 
periaqueductal grey, and basal ganglia), cognitive processes lend meaning to nociceptive stimuli 
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(Garland, 2012). Specifically, pain perception involves a conscious evaluation of the sensory 
signals (cognitive appraisal), attention to pain, and emotional and behavioral reactions to pain 
(Garland, 2012). A child with SCD, who is distracted by coloring, may perceive their pain as less 
intense compared to a child who is alone in their room and focusing on their pain. This example 
highlights the subjectivity of pain and its dependence on a variety of influencing factors. A 
thorough description of various factors that influence pain perception is provided later in this 
chapter. 
Neuropathic and Centralized Pain Pathophysiology  
 In the previous section, four general physiologic processes were described: transduction, 
transmission, modulation, and perception. In this next section, the focus will be on the unique 
pathophysiologic mechanisms involved in the development of pain in neuropathic and 
centralized pain states.  
Neuropathic Pain. 
Multiple pathophysiologic mechanisms can lead to the development of neuropathic pain. 
First, neuropathic pain occurs following peripheral or central nervous system tissue damage in 
the following areas: peripheral nerve, nerve root, and spinal cord (Baron, Binder, & Wasner, 
2010). Following nerve tissue injury, nerve growth factors are released from injured neurons 
facilitating the growth of new dendrites on the nerve (Cohen & Mao, 2014). An increase in 
dendrites causes an expansion in the receptive field of the nerve, increasing its susceptibility to 
stimulation, or hyperalgesia (Baron et al., 2010; Cohen & Mao, 2014). Further, lesions on the 
injured nerve can generate spontaneous, or ectopic, nerve activity (Baron et al., 2010; 
Latremoliere & Woolf, 2009; Woolf, 2011). Crosstalk between different types of nerve fibers, 
nociceptive, C and Aδ, and non-nociceptive, Aβ, also leads to the clinical characteristics of 
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allodynia and secondary hyperalgesia (Baron et al., 2010; Cohen & Mao, 2014; Gatchel, Peng, 
Peters, Fuchs, & Turk, 2007; Ueda, 2008).  
 As previously described, ectopic activity of afferent nerve fibers occurs following nerve 
injury. After injury, localized edema occurs after the release of several inflammatory mediators 
including substance P and calcitonin gene related peptide. Several other byproducts, for example 
bradykinin, prostaglandins, and cytokines, are also released following the inflammatory 
mediators (Cohen & Mao, 2014; Thacker, Clark, Marchand, & McMahon, 2007). Together, 
these substances sensitize and excite afferent nerve fibers, resulting in decreased pain thresholds 
and ectopic discharges (Cohen & Mao, 2014). Additionally, after nerve injury, there is an 
increased expression of calcium channels within sensory and dorsal horn neurons. Increased 
expression of calcium channels results in increased membrane depolarization and 
hyperpolarization among afferent nerve fibers (Cohen & Mao, 2014; Perret & Luo, 2009; 
Thacker et al., 2007; West, Bannister, Dickenson, & Bennett, 2015). Lastly, evidence suggests 
that spontaneous pain arises from both ectopic activity in primary afferent nerve fibers and 
central sensitization (Costigan, Scholz, & Woolf, 2009). A description of central sensitization is 
provided in the following section. 
Centralized Pain. 
As previously described, centralized pain arises from altered nociception with minimal or 
no tissue damage or evidence for disease or lesion of the somatosensory system (Latremoliere & 
Woolf, 2009; Marchand, 2008; Woolf, 2011). Some examples of centralized pain conditions are 
fibromyalgia, irritable bowel syndrome, temporomandibular disorder, and urinary chronic pain 
pelvic syndromes. Central sensitization is a term used to describe the mechanisms that can 
contribute to centralized pain states. Central sensitization is defined as “increased responsiveness 
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of nociceptive neurons in the central nervous system to their normal or subthreshold afferent 
input” (IASP, 2017). Manifestations of central sensitization include hyperalgesia, secondary 
hyperalgesia, and allodynia (Harte, Harris, & Clauw, 2018; Latremoliere & Woolf, 2009; Woolf, 
2011). Central sensitization can occur with or without ongoing nociceptive input (Harte et al., 
2018). When ongoing nociceptive input is absent, the process is hypothesized to originate in 
supraspinal structures (Harte et al., 2018).  
Several supraspinal mechanisms that maintain centralized pain states have been studied 
(Harris et al., 2007; Napadow et al., 2010; Sarchielli et al., 2007). One study in patients with 
fibromyalgia identified a decreased availability of central µ-opioid receptors within several areas 
of the brain that are known to play a role in pain modulation (Harris et al., 2007). Decreased 
availability of these inhibitory receptors further increases the likelihood of pain transmission 
(Harris et al., 2007). Therefore, patients with centralized pain may have several chemical 
alterations that augment pain facilitation and attenuate pain modulation without the presence of 
actual or threatened tissue damage. 
Neuroplasticity within supraspinal regions is another mechanism that can maintain 
centralized pain. In patients with centralized pain, pro-nociceptive neuroplastic changes have 
been identified within the medial prefrontal cortex, RVM, thalamus, and default mode network 
(Darbari et al., 2015; Kucyi et al., 2014; Mansour, Farmer, Baliki, & Apkarian, 2014). Increased 
connectivity, cortical reorganization, and decreased gray matter have been demonstrated via 
structural brain imaging in several centralized pain populations including irritable bowel 
syndrome, fibromyalgia, chronic low back pain, and SCD (Darbari et al., 2015; Mansour et al., 
2016; May, 2008; Napadow et al., 2010). One study in patients with SCD identified that patients 
with increased pain frequency had increased pro-nociceptive brain connectivity, while patients 
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with decreased pain frequency had increased anti-nociceptive brain connectivity (Darbari et al., 
2015).  
Pain Influencing Factors 
 Several physiological, psychological, and situational factors contribute to the perception 
of pain. Within this section, I will describe the impact these factors have on pain processing 
mechanisms and pain-related outcomes among patients with centralized pain. 
Physiological. 
Genetics. 
Empirical evidence suggests that individuals may have a genetic predisposition to 
developing centralized pain (Diatchenko et al., 2005; Emin Erdal et al., 2001; Gursoy et al., 
2003; S. B. Smith et al., 2012). Recent research has sought to evaluate differences in gene 
frequencies among patients with and without centralized pain. Several studies have identified 
gene frequency differences in patients with fibromyalgia, temporomandibular disorders, and 
migraine compared to healthy controls (Diatchenko et al., 2005; Emin Erdal et al., 2001; Gursoy 
et al., 2003; S. B. Smith et al., 2012). Further, the presence of genetic polymorphisms may also 
influence pain transmission, perception, and analgesic response. Specifically, catechol-O-
methyltransferase (COMT) is an enzyme that inactivates modulatory neurotransmitters including 
dopamine, norepinephrine, and epinephrine. Empirical evidence suggests that COMT variations 
influence susceptibility to pain conditions, pain sensitivity, and opioid response (Andersen & 
Skorpen, 2009; Diatchenko et al., 2005).. Individuals with the 108/158Met allele of COMT have 
higher levels of dopamine within the prefrontal cortex resulting in increased pain sensitivity and 
decreased activation of the µ-opioid system after continuous painful stimuli (Andersen & 
Skorpen, 2009).  
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Sex. 
 Evidence supports differences in pain perception between males and females (Bartley & 
Fillingim, 2013; Fillingim, King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009). 
Specifically, females have increased pain incidence, sensitivity, and duration compared to males 
(Fillingim et al., 2009). Pain sensitivity, pain modulation, and cortical activation are influenced 
by pro- or anti-nociceptive sex hormones including progesterone and oestradiol, among others 
(Bartley & Fillingim, 2013; Fillingim et al., 2009). Specifically, evidence suggests differences in 
pain sensitivity during different phases of the menstrual cycle (Bartley & Fillingim, 2013; Smith 
et al., 2006). One study highlighted that women in a low oestradiol, low progesterone state report 
increased pain sensitivity (Smith et al., 2006).  
Age. 
 Age is another physiologic influencing factor that has been studied within several pain 
populations. Evidence suggests that middle and older age groups have the highest prevalence of 
centralized pain and increased multifocal pain, incidence, and intensity (Fayaz, Croft, Langford, 
Donaldson, & Jones, 2016; Helme & Gibson, 2001; Krueger & Stone, 2008; Rustoen et al., 
2005). Several physiologic processes may influence age differences in pain including reduced 
peripheral nerve fibers, decreased sensory neurons within the dorsal root ganglion, and 
inflammation, among others (Gagliese, 2009; Yezierski, 2013). Much of this research, however, 
is limited to animal models (Gagliese, 2009). Although it is known that pain increases with age, 
future research is needed to determine the mechanisms that influence these differences. 
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Fatigue. 
Evidence supports the co-occurrence of several centrally-mediated symptoms among 
patients with centralized pain syndromes (Clauw & Chrousos, 1997; Phillips & Clauw, 2011). 
First, several studies have highlighted an association between fatigue and pain (Garip, Eser, 
Aktekin, & Bodur, 2011; Nicassio, Moxham, Schuman, & Gevirtz, 2002; Pollard, Choy, 
Gonzalez, Khoshaba, & Scott, 2006). Several body systems that influence pain including the 
endocrine, central nervous, peripheral nervous, and immune systems also exacerbate fatigue 
(Louati & Berenbaum, 2016). Specifically, fatigue and pain have both been associated with the 
following increased inflammatory cytokines: interleukin (IL)-1β, IL-6, IL-17 and tumor necrosis 
factor (TNF)-α (Bower, 2014; Schaible, 2014). One cohort study including 1,466 patients with 
advanced cancer showed a positive association between C-reactive protein (CRP) levels, pain, 
and fatigue (Laird et al., 2013). Further, increased IL-8 and IL-2r levels have also been identified 
in patients with fibromyalgia, suggesting a shared physiologic mechanism between fatigue and 
centralized pain (Gur et al., 2002).   
Sleep. 
Another centrally-mediated symptom that co-occurs with pain is sleep impairment. 
Although sleep quality and sleep disturbances have been shown to influence pain (Allen, Renner, 
Devellis, Helmick, & Jordan, 2008; Campbell et al., 2011; Edwards, Almeida, Klick, 
Haythornthwaite, & Smith, 2008; Palermo & Kiska, 2005; Wolfe, Michaud, & Li, 2006), sleep 
duration may not be impacted among individuals with centralized pain. Patients may, however, 
report sleep as nonrestorative, or the subjective feeling of being unrefreshed upon awakening 
despite the appearance of physiologically normal sleep (Stone, Taylor, McCrae, Kalsekar, & 
Lichstein, 2008).  
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Dopaminergic signaling and cytokine activity are two mechanisms in which pain and 
sleep impairment are hypothesized to relate to each other (Campbell et al., 2011; Finan, Goodin, 
& Smith, 2014; Taylor, Becker, Schweinhardt, & Cahill, 2016). Dopamine, an inhibitory pain 
neurotransmitter, also plays a role in sleep regulation via the promotion and maintenance of 
arousal states. Although it is known that patients with centralized pain have lowered dopamine 
(D2) receptor binding and presynaptic dopamine activity (Finan et al., 2014; Taylor et al., 2016), 
future research is needed to determine the specific underlying dopaminergic mechanisms that 
influence sleep impairments (Finan et al., 2014).  
The immune system is also hypothesized to influence the relationship between sleep and 
pain. Like fatigue, increasing evidence suggests that cytokine activity and pain are interrelated 
(Heffner et al., 2011; Park & Chung, 2016). Studies conducted among patients with centralized 
pain have highlighted the bidirectional associations among sleep, pain, and the following 
proinflammatory cytokines: IL-1β, IL-6, IL-10, and TNF-α  (Heffner et al., 2011; Park & Chung, 
2016). Sleep quality has been shown to mediate the relationship between pain intensity and IL-6 
levels in patients with chronic low back pain (Heffner et al., 2011). Further, research suggests 
positive relationships among daytime sleepiness, poor sleep quality, cytokine levels, pain 
intensity, and pain duration in patients with TMD (Park & Chung, 2016).  
Psychological. 
Depression. 
 As discussed within the centralized pain pathophysiology section, centralized pain can be 
maintained via changes within supraspinal regions that are responsible for pain processing. As in 
centralized pain, structural and functional changes have been identified in patients with 
depression within the following brain areas: the dorsolateral prefrontal cortex, lateral-orbital 
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prefrontal cortex, medial prefrontal cortex, insula, anterior cingulate cortex, amygdala, 
hippocampus, and thalamus (Maletic & Raison, 2009). Given that depression and pain 
perception emerge due to activity in similar cortical regions, these two symptoms may have 
shared physiologic mechanisms, such that depression and pain may give rise to and exacerbate 
the other. (Maletic & Raison, 2009; Strigo et al., 2008). Evidence suggests that patients with 
depression have increased activation of the dorsolateral and ventrolateral prefrontal cortices, 
amygdala, insula, and dorsolateral anterior cingulate cortex when responding to or anticipating 
pain (Bar et al., 2005; Strigo et al., 2008). Further, patients with depression have decreased 
activation of areas within the descending pain modulatory pathway, for example the rostral 
anterior cingulate cortex and PAG (Strigo et al., 2008). Decreased activation of these supraspinal 
areas leads to a decreased ability to inhibit pain (Maletic & Raison, 2009; Strigo et al., 2008). 
Anxiety. 
 Another psychological factor that has been shown to influence pain is anxiety. Evidence 
suggests that anxiety is strongly associated with several centralized pain conditions (e.g., chronic 
back pain and migraine) (Davis et al., 2017; Hanks & LLOYD, 1986; McWilliams et al., 2003, 
2004; Tsang et al., 2008). Anxiety responses also occur within brain areas that perceive pain 
including the amygdala and several cortices: anterior cingulate, posterior cingulate, and 
orbitofrontal (Etkin, Egner, & Kalisch, 2011; Gross & Hen, 2004). Evidence suggests a positive 
relationship between anxiety and increased activation of several pain processing mechanisms 
within the brain including the anterior cingulate, posterior cingulate, and orbitofrontal cortices 
(Kalisch et al., 2005; Ochsner et al., 2006).  
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Catastrophizing. 
Catastrophizing occurs when a patient has irrational thoughts about their pain including 
rumination, magnification and helplessness (Citero et al., 2007; Quartana & Edwards, 2009). 
Pain catastrophizing is often described as an exaggerated, negative cognitive-affective response 
to current or anticipated pain (Quartana & Edwards, 2009). Multiple studies support that 
catastrophizing is associated with pain-related outcomes (Ciechanowski et al., 2003; Geisser et 
al., 1994; Keefe et al., 2000; Pavlin et al., 2005; Quartana & Edwards, 2009; Severeijns et al., 
2001). Additionally, research has identified an association between pain catastrophizing and 
increased activation of the following pain processing areas: dorsolateral prefrontal cortex, 
anterior cingulate cortex, and medial prefrontal cortex (Quartana & Edwards, 2009). Pain 
catastrophizing may also have an impact on pain inhibition. In summation, these findings suggest 
that pain catastrophizing is associated with development and maintenance of pain. 
Pain control beliefs. 
The last psychological variable included in this review is pain control beliefs. These 
include beliefs about internal or external locus of pain control. Patients with internal locus of 
control beliefs think that they have the ability to control their pain (Skevington, 1990). On the 
other hand, a patient with external locus of control beliefs thinks that their pain is controlled by 
others or by chance (Skevington, 1990). Beliefs about pain control can influence how a patient 
processes, treats, and copes with pain (Higgins et al., 2015; Oliveira et al., 2009; Spinhoven et 
al., 2004).  
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Situational. 
Stigma. 
Lack of objective evidence of pain (e.g., bandages, fractures, facial grimaces) can lead to   
stigmatization among patients with centralized pain. Empirical evidence suggests that patients 
with centralized pain may experience stigmatization from multiple sources including health care 
providers, family members, teachers, and peers, among others (Kool, van Middendorp, Boeije, & 
Geenen, 2009; Logan, Catanese, Coakley, & Scharff, 2007; Monsivais, 2013; Wakefield, 
Zempsky, Puhl, & Litt, 2018). Further, stigmatization has been associated with delayed diagnosis 
or misdiagnosis, bias in treatment, social isolation, increased pain burden, and lower quality of 
life (NINDS, 2015; Wakefield et al., 2018).  
Trauma exposure. 
Pain research suggests significant relationships among trauma exposure, the development 
of centralized pain, and increased pain severity and interference (Hauser, Kosseva, Uceyler, 
Klose, & Sommer, 2011; Kanzawa-Lee et al., 2018; Oram et al., 2012; Phillips & Clauw, 2011; 
Schofferman, Anderson, Hines, Smith, & Keane, 1993; Spiegel et al., 2015). Evidence supports 
significant associations between the incidence of fibromyalgia and self-reported physical and 
sexual abuse in childhood and adulthood (W Hauser et al., 2011). Further, sex-variations in pain 
perception may be present following trauma exposure (Bartley & Fillingim, 2013; Fillingim et 
al., 2009). Specifically, females are more likely to have decreased pain sensitivity following 
trauma exposure compared to men (Bartley & Fillingim, 2013; Fillingim et al., 2009).    
Social support. 
The last situational variable included in this review is social support. Those with 
centralized pain often elicit passive coping strategies that negatively influence social support 
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systems, for example self-imposed isolation and victimization (Forgeron et al., 2010; Smith & 
Osborn, 2007; Snelling, 1994; Zaza & Baine, 2002). Additionally, patients with centralized pain 
may have difficulty maintaining friendships (Carter et al., 2002). Researchers agree that the 
presence of centralized pain negatively influences the availability of social support systems; 
however, there is conflicting evidence regarding the relationship of social support and pain-
related outcomes (e.g., pain intensity, frequency, and sensitivity) (Lopez-Martinez, Esteve-
Zarazaga, & Ramirez-Maestre, 2008; Montoya, Larbig, Braun, Preissl, & Birbaumer, 2004; 
Smite, Rudzite, & Ancane, 2012). Two research studies demonstrated a significant association 
between increased perceived social support and decreased pain intensity and interference 
(Lopez-Martinez et al., 2008; Smite et al., 2012). Additionally, patients with fibromyalgia had 
significantly decreased pain sensitivity in the presence of significant others (Montoya et al., 
2004).  
Active coping strategies can also mediate the relationship between social support and 
pain (Holtzman et al., 2004). Specifically, evidence suggests that patients with centralized pain 
that have increased social support receive more encouragement to use active coping strategies 
that decrease their pain (Holtzman et al., 2004).  
Cognitive. 
Cognitive function. 
 The relationship between centralized pain and cognitive function is beginning to gain 
recognition within the literature (Williams, 2018). Evidence suggests that cognition can be 
grouped in a symptom cluster along with sleep, pain, affect (e.g., depression and anxiety), and 
energy deficit (fatigue), or S.P.A.C.E (Schrepf et al., 2018; D. A. Williams, 2018). These 
symptoms are hypothesized to interact with each other via a shared physiologic mechanism—the 
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immune system (Heffner et al., 2011; Park & Chung, 2016; Schaible, 2014). As discussed 
previously, increased levels of cytokines including IL-1β, IL-6, IL-8, and TNF-α, among others, 
are associated with increased levels of pain, fatigue, and sleep disturbance (Heffner et al., 2011; 
Park & Chung, 2016; Schaible, 2014). One meta-analysis supports that IL-1β and IL-6 have 
significant relationships with the S.P.A.C.E. symptom cluster (Shattuck & Muehlenbein, 2016). 
However, cognitive function is an understudied symptom within this cluster. Although 
associations have been found between different cytokine levels and cognitive impairment, further 
research is needed to clarify this relationship (Shattuck & Muehlenbein, 2016). 
Pain in Sickle Cell Disease 
Thus far, this chapter has provided an overview of pain definitions, incidence, 
characteristics, pathophysiology, and influencing factors. What follows is an expanded 
discussion of the unique pain manifestations that are commonly observed in patients with SCD. 
A synthesis of empirical evidence from randomized controlled trials (RCTs) of pharmacologic 
and non-pharmacologic treatments is also presented. The chapter will conclude with a summary 
of the gaps identified within the literature that are addressed by this dissertation study. 
While acute pain/VOC has been recognized as a common complication of SCD, recent 
evidence suggests that a subset of patients with SCD have centralized pain (Brandow, Farley, & 
Panepinto, 2015; Brandow, Farley, & Panepinto, 2014; Brandow & Panepinto, 2016; Brandow, 
Stucky, Hillery, Hoffmann, & Panepinto, 2013; Campbell et al., 2016; Carroll et al., 2016; Jacob 
et al., 2015; O’Leary, Crawford, Odame, Shorten, & McGrath, 2013; Smith & Scherer, 2010; 
Wilkie et al., 2010). One study identified that centralized pain occurs in 37% of patients with 
SCD (Brandow et al., 2015). Additionally, 21.8% of youth with SCD have multifocal pain 
(Zempsky et al., 2017), a common manifestation of centralized pain. Quantitative Sensory 
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Testing (QST) methods have identified that patients with SCD have impaired pain processing 
manifested as decreased thermal and mechanical pain thresholds (Brandow & Panepinto, 2016; 
Campbell et al., 2016; Jacob et al., 2015).  Further, patients with centralized pain have increased 
VOCs, pain intensity, and pain severity compared to patients without centralized pain (Campbell 
et al., 2016; Zempsky et al., 2017).  
Based upon the deep discussion of pain influencing factors described earlier within this 
chapter, it is clear that several physiological, psychological, situational, and cognitive factors co-
occur to influence pain among those with centralized pain. However, there is a lack of 
understanding about how these factors influence pain among those with SCD. The following 
section will synthesize the literature regarding several influencing factors that influence pain 
among those with SCD. 
Pain-Influencing Factors in Patients with SCD 
Articles published within the past 10 years were reviewed and synthesized. Joanna Briggs 
Institute (JBI) critical appraisal tools were used to evaluate each studies’ methodological design 
and potential risks of bias (Joanna Briggs Institute Critical Appraisal Tools, 2017). Detailed 
information regarding the methodological design, findings, and critical appraisal of each study is 
provided within Appendices 1-5. 
Physiological. 
Genetics. 
Pain in patients with SCD co-occurs with several physiological factors. First, genetic 
factors may contribute to pain-related outcomes in patients with SCD. Seven studies have 
evaluated the relationships among SCD genotype, multifocal pain, sensitivity, opioid use, health 
service utilization, pain intensity, and pain frequency (Carroll et al., 2016; Carroll, Haywood, 
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Hoot, & Lanzkron, 2013; Jacob et al., 2015; McClish et al., 2009; Schlenz, Schatz, & Roberts, 
2016; Sil, Cohen, & Dampier, 2016; Zempsky et al., 2017). Out of the seven studies that have 
evaluated the relationship between SCD genotype and pain, six utilized cross-sectional study 
designs (Carroll et al., 2016; Carroll, Haywood, Hoot, & Lanzkron, 2013; Jacob et al., 2015; 
Schlenz, Schatz, & Roberts, 2016; Sil, Cohen, & Dampier, 2016; Zempsky et al., 2017). Only 
one of the cross-sectional studies reported significant differences in pain intensity based on SCD 
genotype (Schlenz et al., 2016) Patients with HbSS and HbSβ0  had higher pain intensity ratings 
than those with HbSC and HbSβ+ (Schlenz et al., 2016). This article, however, has limitations 
(Schlenz et al., 2016). First, its cross-sectional study design limits the ability to support a causal 
relationship between SCD genotype and pain intensity. Further, the pain history interview used 
within this study included retrospective reports of pain intensity, duration, and frequency which 
could be subject to recall bias. The remaining six articles highlighted no significant differences 
in multifocal pain, opioid use, health service utilization, pain intensity, pain sensitivity, and pain 
frequency based on SCD genotype (Carroll et al., 2016; Carroll et al., 2013; Jacob et al., 2015; 
McClish et al., 2009; Sil, Cohen, & Dampier, 2016; Zempsky et al., 2017). This suggests that the 
majority of evidence supports no differences in pain based upon SCD genotype. 
Sex. 
 Although evidence suggests significant differences in pain perception between males and 
females (Bartley & Fillingim, 2013; Fillingim et al., 2009; Smith et al., 2006), there is 
conflicting evidence of sex differences among patient with SCD. Overall, ten studies evaluated 
the relationship between sex and pain (Antunes, Propheta, Vasconcelos, & Cipolotti, 2017; 
Bakshi, Lukombo, Belfer, & Krishnamurti, 2018; Bakshi, Lukombo, Shnol, Belfer, & 
Krishnamurti, 2017; Brandow et al., 2013; Carroll et al., 2016; Graves & Jacob, 2014; Jacob et 
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al., 2015; McClish et al., 2009; Sil et al., 2016; Zempsky et al., 2017). Three out of the ten 
studies found significant sex differences in pain sensitivity and severity among patients with 
SCD (N Bakshi et al., 2017; A M Brandow, Farley, & Panepinto, 2014; Graves & Jacob, 2014). 
Two studies identified that males have increased heat detection threshold and lower neuropathic 
pain scores compared to females (Bakshi et al., 2017; Brandow, Farley, & Panepinto, 2014). The 
third study evaluated the relationships among pain, coping, and sex, and found significant 
negative correlations between worst pain severity, positive behavioral distraction, and negative 
internalizing/catastrophizing among males (Graves & Jacob, 2014). These negative correlations 
were not evident in females (Graves & Jacob, 2014).  
The three studies described above found significant sex differences in pain sensitivity and 
severity among patients with SCD (N Bakshi et al., 2017; A M Brandow et al., 2014; Graves & 
Jacob, 2014). These studies, however, had limitations which could have influenced their results. 
Graves & Jacob (2014) included a measure for pain frequency that asked parents of children with 
SCD to report the number of pain episodes that their child had within the past 12 months. An 
objective measure for pain frequency would have increased the reliability and validity of this 
outcome measure and reduced measurement error. Further, all of these studies evaluated multiple 
influencing factors along with sex including age, depression, anxiety, and catastrophization 
(Bakshi et al., 2017; Brandow et al., 2014; Graves & Jacob, 2014). Two of these studies, 
however, did not statistically correct for multiple comparisons (Bakshi et al., 2017; Graves & 
Jacob, 2014). This increases the likelihood that the significant differences found between males 
and females were due to chance.  
Eight studies found no sex differences among a variety of pain manifestations—pain 
intensity, pain frequency, health care utilization, multifocal pain, neuropathic pain, and pain 
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thresholds assessed via QST (Antunes et al., 2017; Bakshi et al., 2018; Brandow et al., 2013; 
Carroll et al., 2016; Graves & Jacob, 2014; Jacob et al., 2015; McClish et al., 2009; Sil et al., 
2016; Zempsky et al., 2017). Although these studies also had many limitations, this highlights 
that the majority of evidence supports no significant differences in pain between males and 
females with SCD.  
Age. 
It was previously discussed that widespread pain and pain intensity are associated with 
older age (Fayaz et al., 2016; Helme & Gibson, 2001; Krueger & Stone, 2008; Rustoen et al., 
2005). Evidence also supports this association among patients with SCD. Twelve studies have 
evaluated the relationship between age and pain (Antunes et al., 2017; Bakshi et al., 2018, 2017; 
Brandow et al., 2014, 2013; Carroll et al., 2016; Carroll et al., 2013; Graves & Jacob, 2014; 
Jacob et al., 2015; McClish et al., 2009; Sil et al., 2016; Zempsky et al., 2017). Of those, seven 
studies have found significant associations between age and pain (Antunes et al., 2017; Bakshi et 
al., 2017; Brandow et al., 2014, 2013; Carroll et al., 2013; McClish et al., 2009; Sil et al., 2016). 
Five of these studies support significant associations between older age and increased 
widespread pain, pain frequency, neuropathic pain, and lower thermal and mechanical pain 
thresholds (Antunes et al., 2017; Bakshi et al., 2017; Brandow et al., 2013; McClish et al., 2009; 
Sil et al., 2016). One retrospective cohort study identified that patients of ages 18-30 had the 
highest emergency department visit, hospitalization, and re-hospitalization rates compared to all 
other age groups (Brousseau, Owens, Mosso, Panepinto, & Steiner, 2010). Further, one study 
conducted in adults found that age was significantly different between high and low health 
service utilization groups (Carroll et al., 2013). Those in the high utilization group had a mean 
age of 28.6, while those in the low group had a mean age of 38. It is hypothesized that those aged 
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18-30 are at an increased risk for health service utilization due to the transition from pediatric to 
adult care (Brousseau et al., 2010). The two longitudinal studies that evaluated the relationship 
between age and health service utilization rates included both pain and non-pain-related visits, 
which could have confounded the results and reduced the ability to detect a significant difference 
between age and pain-related visits (Brousseau et al., 2010; Carroll et al., 2013).  
Although seven studies found a significant association among age, widespread pain, pain 
frequency, neuropathic pain, and lower pain thresholds, conflicting findings, descriptive study 
designs, and limitations reduce the strength of the evidence. Specifically, of the 12 studies, five 
studies highlighted no age differences based on opioid use, pain intensity, pain frequency, 
multifocal pain, and abnormal pain thresholds determined via QST (Bakshi et al., 2018; Carroll 
et al., 2016; Graves & Jacob, 2014; Jacob et al., 2015; Zempsky et al., 2017). Eight of the studies 
were cross-sectional (Antunes et al., 2017; N Bakshi et al., 2018; A M Brandow et al., 2014; P. 
C. Carroll et al., 2013; Graves & Jacob, 2014; Eufemia Jacob et al., 2015; S Sil, Cohen, et al., 
2016; William T. Zempsky et al., 2017), two were longitudinal (C. P. Carroll et al., 2016a; 
McClish et al., 2009), and two was a case-control study (N Bakshi et al., 2017; Amanda M. 
Brandow et al., 2013). Two of the studies that reported significant results evaluated three or more 
influencing factors and did not statistically correct for multiple comparisons within their analyses 
(Bakshi et al., 2018; Carroll et al., 2013). This reduces the statistical conclusion validity of their 
results and increases the likelihood that the significant associations found between age and pain 
were due to chance. In summary, many of the studies reported above had limitations that 
influenced the internal and statistical conclusion validity of the studies. However, the majority of 
the evidence supports an association between older age and increased pain among patients with 
SCD. 
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Fatigue. 
Another physiological factor that co-occurs with pain is fatigue (Garip et al., 2011; 
Nicassio et al., 2002; Pollard et al., 2006). Limited studies, however, have evaluated the 
association between fatigue and pain in patients with SCD. Only one study was found that 
identified a significant positive association between increased fatigue and increased pain 
intensity and interference measured via a reliable and valid pain measure, the Brief Pain 
Inventory (Ameringer et al., 2014). This study utilized a cross-sectional design limiting 
conclusions regarding the causal relationship between fatigue and pain. Further, the article did 
not include a detailed description of the study setting making it difficult to evaluate the internal 
validity of the study design. The lack of evidence regarding the relationship between fatigue and 
pain in patients with SCD highlights a gap within the literature regarding an important centrally-
mediated symptom that is known to co-occur with pain. 
Sleep. 
The last physiological variable included in this review is sleep. Similar to other 
centralized pain populations including osteoarthritis, rheumatoid arthritis, and fibromyalgia 
(Allen, Renner, Devellis, Helmick, & Jordan, 2008; Campbell et al., 2011; Edwards, Almeida, 
Klick, Haythornthwaite, & Smith, 2008; Wolfe, Michaud, & Li, 2006), SCD research has also 
sough to understand the relationship between sleep and pain (Daniel et al., 2010; Graves & 
Jacob, 2014; Moscou-Jackson et al., 2015; Wallen et al., 2014). Specifically, three studies 
reported that increased sleep disturbance and parasomnias were significantly associated with 
increased pain frequency, pain severity, and SCD complications (Daniel et al., 2010; Moscou-
Jackson et al., 2015; Wallen et al., 2014). One study however, found no significant differences in 
sleep scores based on pain intensity and severity (Graves & Jacob, 2014). Of the four total 
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studies, two were cross-sectional (Graves & Jacob, 2014; Wallen et al., 2014), one was 
longitudinal (Moscou-Jackson et al., 2015), and one was case-control (Daniel et al., 2010).  
Many of the studies that evaluated the relationship between sleep and pain had 
limitations. One longitudinal study (N=75) conducted in adults with SCD included a measure of 
pain interference with no description of the measure’s reliability and validity (Moscou-Jackson et 
al., 2015). Thus, it is unclear whether this measure was able to fully capture pain interference 
among adults with SCD. Additionally, the eligible sample included patients that were 1) treated 
with a stable pain management regimen, 2) free of infection, and 3) stable in terms of the 
management of their sickle cell disease (Moscou-Jackson et al., 2015). This strict inclusion 
criteria limits the generalizability of the findings and the confidence that these significant results 
would be found in a more diverse sample. While many of these studies highlighted a significant 
relationship between pain and sleep, sleep was not compared based on the presence of 
centralized pain. As discussed previously, evidence suggests that sleep disturbances co-occur 
with other centrally-mediated symptoms in patients with the following centralized pain 
conditions: chronic low back pain, TMD, and fibromyalgia (Heffner et al., 2011; Nicassio et al., 
2002; Park & Chung, 2016). Further research is needed to support this relationship among 
patients with SCD that have centralized pain. 
Psychological. 
Depression. 
 There are multiple studies that have investigated the association of psychological 
influencing factors and pain in patients with SCD. Specifically, twelve studies have evaluated the 
association between depression and pain (Bakshi et al., 2018, 2017;  Campbell et al., 2016; 
Carroll et al., 2016; Carroll et al., 2013; Ford, Grasso, Jones, Works, & Andemariam, 2017; 
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Jacob et al., 2015; Jerrell, Tripathi, & McIntyre, 2011; Lemanek et al., 2009; McClish et al., 
2009; Sil et al., 2016; Wallen et al., 2014). Of the twelve studies, five were cohort (C. M. 
Campbell et al., 2016; C. P. Carroll et al., 2016a; Ford et al., 2017; Jerrell et al., 2011; McClish 
et al., 2009), five were cross-sectional (N Bakshi et al., 2018; P. C. Carroll et al., 2013; Eufemia 
Jacob et al., 2015; S Sil, Cohen, et al., 2016; Wallen et al., 2014), one was case-control (N 
Bakshi et al., 2017), and one was a randomized control trial (Lemanek et al., 2009). Seven 
studies support a positive association among depression, pain frequency, multifocal pain, lower 
heat pain thresholds, opioid use, and SCD-related complications (Bakshi et al., 2017; Carroll et 
al., 2016a; Jerrell et al., 2011; McClish et al., 2009; Sil et al., 2016; Wallen et al., 2014). One 
RCT found that patients receiving a massage intervention for 30 days had significantly less 
depression and pain intensity compared to controls (Lemanek et al., 2009).  
Only half of the studies (N=6) evaluated differences in depression between patients with 
and without centralized pain (Bakshi et al., 2018; Campbell et al., 2016; Carroll et al., 2016; Ford 
et al., 2017; Jacob et al., 2015; Sil et al., 2016). Three of these studies were unable to detect any 
differences in depression based on the presence of centralized pain (Campbell et al., 2016; Ford 
et al., 2017; Jacob et al., 2015). These three studies, however, had very small samples (range, 
N=38-50) reducing the power to detect significant differences (Campbell et al., 2016; Ford et al., 
2017; Jacob et al., 2015). There were additional limitations throughout the three studies that 
found no significant differences between patients with and without centralized pain (Campbell et 
al., 2016; Ford et al., 2017; Jacob et al., 2015). One cohort study divided patients based on a self-
report of “the presence of moderate to severe pain on more than 50% of days in the last 6 
months” (Ford et al., 2017). The use of a validated centralized pain PRO measure with strong 
psychometric properties (e.g., sensitivity, specificity) may been more appropriate to use within 
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this study and would increase the confidence in the findings. Overall, there is conflicting 
evidence regarding the relationship between depression and the incidence of centralized pain 
among patients with SCD. Further, study limitations including small sample sizes and a 
dichotomous self-reported centralized pain measure could have confounded the insignificant 
results. Ultimately, further research is needed to investigate whether there are significant 
associations between depression and centralized pain among those with SCD. 
Anxiety. 
There is a limited amount of evidence supporting a positive relationship between anxiety 
and pain among patients with SCD (Bakshi et al., 2018, 2017; Lemanek et al., 2009). Out of 
seven studies that have evaluated this relationship in patients with SCD (N Bakshi et al., 2018, 
2017; Ford et al., 2017; Eufemia Jacob et al., 2015; Lemanek et al., 2009; Moody et al., 2017; 
Thomas et al., 2013), four found no significant associations between anxiety and pain (Ford et 
al., 2017; Jacob et al., 2015; Moody et al., 2017; Thomas et al., 2013). Three of the studies were 
RCTs including a yoga, massage, and healing touch with music intervention (Lemanek et al., 
2009; Moody et al., 2017; Thomas et al., 2013). The limitations of these non-pharmacologic 
RCTs will be discussed in more detail within the following section; some examples of these 
limitations include a lack of blinding between intervention and control groups, small sample 
sizes, and no differentiation between those with and without centralized pain.  
Two additional studies support significant associations among anxiety, centralized pain, 
and higher cold pain thresholds (Bakshi et al., 2018, 2017). However, one case-control study did 
not match cases and controls based on common confounders like age and sex, increasing the 
likelihood that differences between groups were influenced by these confounding variables and 
(Bakshi et al., 2017). Further, this study investigated the relationships among anxiety and several 
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other influencing factors including age, sex, depression, and catatrophization; however, no 
statistical corrections for multiple comparisons were made (Bakshi et al., 2017). Thus, there is an 
increased likelihood that the significant difference in anxiety among patients with SCD was 
found due to chance. Overall, the limitations of the studies described above highlight the need 
for more evidence to understand the relationship between anxiety and centralized pain in patients 
with SCD. 
Catastrophizing. 
The fourth psychological influencing factor included in this review is catastrophizing. 
Five studies have evaluated the relationship between catastrophizing and pain among patients 
with SCD (Bakshi et al., 2017; Campbell et al., 2016; Finan et al., 2018; Graves & Jacob, 2014; 
Sil et al., 2016). One cross-sectional study found that patients with pain had significantly higher 
catastrophizing scores (Sil et al., 2016). However, no significant differences in catastrophizing 
scores were found between those with chronic and episodic pain (Sil et al., 2016). Another cross-
sectional study highlighted a significant negative correlation between worst pain severity and 
negative internalizing/catastrophizing in males (Graves & Jacob, 2014). Catastrophizing, 
however, was only measured using one item within the Pediatric Pain Coping Questionnaire. 
Additionally, this relationship was not found in females. One case-control study found that 
patients with increased catastrophizing had higher cold pain thresholds but lower mechanical 
pain thresholds (Bakshi et al., 2017). As discussed previously, this study did not match cases and 
controls or correct for multiple comparisons within their analysis. The last study that investigated 
the relationship between pain and catastrophizing utilized a longitudinal study design to evaluate 
the difference between those with high and low central sensitization determined via QST 
(Campbell et al., 2016). This study found no significant differences in catastrophizing between 
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the two groups, however, it was the only study to differentiate patients with and without 
centralized pain based on objective testing. Overall, there is conflicting evidence regarding the 
relationship between catastrophizing and pain among patients with SCD. Further, only two 
studies (C. M. Campbell et al., 2016; Patrick H Finan et al., 2018) evaluated the relationship 
between catastrophizing and pain using a predictive study design. Due to these reasons and the 
limitations of the studies described above, further research is needed to evaluate the relationship 
between catastrophizing and pain in patients with SCD. 
Pain control beliefs. 
The psychological variable, pain control beliefs, has been identified as an important 
factor that can influence how a patient processes and treats pain (Higgins et al., 2015; Oliveira et 
al., 2009; Spinhoven et al., 2004). However, no studies, within the past ten years, have explored 
the relationship pain control beliefs and pain among patients with SCD. 
Situational. 
Sickle cell stigma. 
Situational factors also have the ability to influence pain. Multiple research studies have 
identified stigmatization in SCD manifested by racial biases and altered perceptions of opioid 
use and addiction (Zempsky, 2009). It is hypothesized that since a larger percentage of patients 
with SCD are ethnic minorities, they are faced with stigmatization. Further, research evidence 
suggests that ethnic minorities are frequently undertreated for pain compared to non-Hispanic 
whites (Green & Hart-Johnson, 2010). Contrary to minimal addiction and opioid overdose rates, 
evidence suggests clinicians often perceive that patients with SCD are at an increased risk for 
opioid abuse, misuse, and addiction (Zempsky, 2009). Only two cross-sectional articles have 
evaluated the relationship between sickle cell stigma and pain (Bediako et al., 2016; Martin et 
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al., 2018). One study supports a significant positive relationship between perceived stigma and 
increased pain interference (Martin et al., 2018). The findings of this study also support a 
significant negative relationship between increased perceived stigma and pain reduction during 
admission for VOC (Martin et al., 2018). The second study highlighted that sickle cell stigma 
factors including social exclusion, internalized stigma, and expected discrimination were 
significantly associated with acute care visits for SCD pain (Bediako et al., 2016). This study, 
however, utilized self-reported measures for health service use and hospitalizations which may 
be subject to recall bias. Further, this study did not evaluate the effects of potential confounding 
variables, for example anxiety, depression, and opioid use. Overall, there are potential risks of 
bias within the studies that evaluated the relationship between sickle cell stigma and pain. 
Further research is needed to support the evidence that sickle cell stigma is associated with pain 
in patients with SCD.  
Trauma exposure. 
 Another situational variable that has been shown to influence pain is trauma exposure 
(Hauser, Kosseva, Uceyler, Klose, & Sommer, 2011; Kanzawa-Lee et al., 2018; Oram et al., 
2012; Phillips & Clauw, 2011; Schofferman, Anderson, Hines, Smith, & Keane, 1993; Spiegel et 
al., 2015). Only two studies evaluated the relationship between trauma exposure and pain in 
patients with SCD (P. C. Carroll et al., 2013; Ford et al., 2017). One cross-sectional study 
highlighted that there were no significant differences in health service utilization based on 
trauma exposure (Carroll et al., 2013). This study included all health service visits within their 
analyses, not solely those for pain. Many health service utilization visits are unlikely to be 
associated with trauma exposure (e.g., infection) and would have reduced the ability to detect a 
significant difference. One longitudinal cohort study, however, found significant differences in 
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self-reported chronic pain in those that were exposed to interpersonal violence compared to those 
unexposed (Ford et al., 2017). While controlling for age and depression, those who were exposed 
to interpersonal violence were nearly five times more likely to report chronic pain (Ford et al., 
2017). However, as discussed previously, this study utilized a dichotomous measure for 
centralized pain. The lack of a continuous measure for centralized pain may have threatened the 
statistical validity and confounded these findings. In summary, internal and statistical conclusion 
validity threats may have confounded the findings within the few studies that have evaluated the 
relationship between trauma exposure and pain. Further research is needed to support this 
relationship among patients with SCD. 
Social support. 
The last situational variable included in this review is social support (Lopez-Martinez et 
al., 2008; Montoya et al., 2004; Smite et al., 2012). Only one cross-sectional study has evaluated 
this relationship (Carroll et al., 2013). As described above, this study found no significant 
associations between health service utilization and pain. This study included all health service 
visits within their analyses which could have impacted the insignificant results. Further, this 
study did not distinguish patients with and without centralized pain so it is unclear whether the 
relationship between pain and social support would be significant within only those experiencing 
centralized pain. 
Cognitive. 
Cognitive function. 
 As discussed in the previous section, there is a paucity of research that has evaluated the 
relationship between cognitive function and pain among patients with centralized pain. Further. 
no studies have analyzed the relationship between cognitive function and pain among patients 
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with SCD. Further research is needed to support the significant relationship between this 
centrally-mediated symptom and pain within this population. 
 
 
This section provides a comprehensive synthesis of the literature that has investigated the 
association between several physiological, psychological, situational, and cognitive factors and 
pain among patients with SCD. These factors included genetics, sex, age, sleep, fatigue, 
depression, anxiety, catastrophizing, pain control beliefs, sickle cell stigma, trauma exposure, 
social support. The predictive factors included within the proposed study were selected based on 
the gaps identified within the literature presented above. Although many studies evaluated the 
association among several variables and pain, no studies accounted for all centrally-mediated 
symptoms included within the S.P.A.C.E. symptom cluster. Only two out of the 26 studies 
included more than one construct within the S.P.A.C.E. symptom cluster within their research 
designs (i.e., sleep and depression) (C. M. Campbell et al., 2016; Wallen et al., 2014). Empirical 
evidence suggests that a majority of patients with centralized pain present with more than one 
centrally-mediated symptom (Davis et al., 2017). Including only one or two centrally-mediated 
symptom when evaluating associations with pain does not capture this multisymptomatic 
presentation and may not account for individual variability within the sample. This is a major 
gap identified within the literature that informed the inclusion of all the variables within the 
S.P.A.C.E. symptom cluster (i.e., sleep impairment, widespread pain, anxiety, depression, 
cognitive function, fatigue) in the proposed study. 
Although several of the factors discussed require further investigation (e.g., sickle cell 
stigma, trauma exposure, social support), their relationships with opioid consumption and pain 
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interference will not be explored in the proposed study due to sample size limitations. The 
number of potentially eligible adolescents and young adults ages 14-35 years with SCD treated at 
the Michigan Medicine and Mott Children’s Hospital Comprehensive Sickle Cell Clinics is 
insufficient to provide adequate power to detect relationships among all 12 factors described 
above and pain outcomes. Further, the completion of 12 different patient-reported outcome 
survey measures that capture all these factors would pose significant participant burden. For 
these reasons, the proposed aims of this study will focus on the significant gaps found regarding 
centralized pain, pain catastrophizing, and centrally-mediated symptoms included within the 
S.P.A.C.E. symptom cluster. Further, these eight variables address several of the core 
components within the Theory of Unpleasant Symptoms which has guided this study—
physiologic factors (centralized pain, sleep, and fatigue), psychologic factors (depression, 
anxiety, and pain catastrophizing), symptoms (widespread pain), and impact (cognitive function). 
As discussed previously, the gaps identified within the section above highlight a lack of 
understanding regarding the daily impact of several co-occurring influencing factors on pain. 
Limited understanding of the co-occurring factors that influence pain could impact the way pain 
is managed within this population and could explain the lack of effective pharmacologic and 
nonpharmacologic therapies available for patients with SCD. In order to improve pain 
management within this population, it is imperative to understand why the current treatments 
utilized among patients with SCD are ineffective in reducing the daily impact of pain within this 
population. The following section will discuss therapies available to treat pain among patients 
with SCD and evaluate the current evidence regarding SCD-related pain management. 
SCD-related Pain Management 
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There are a variety of therapeutic options available to treat pain among patients with 
SCD. These treatments include opioids, adjuvants, and disease modifying agents that indirectly 
affect pain. Although many of these treatments are employed within this population, one 
prospective cohort study identified that many patients still report frequent daily pain (Smith, 
Penberthy, Bovbjerg, Mcclish, & Roberts, 2008). Further, evidence suggests that almost one-
third of patients with SCD experience pain almost every day (Smith et al., 2008). The following 
section will outline the Clinical Practice Guidelines and RCTs that are used to treat pain in those 
with SCD. Further, this section will identify specific gaps within the current evidence that may 
contribute to inadequate pain management and the pervasive problem of pain within this 
population. 
As discussed previously, VOC is the most common complication of SCD. VOCs often 
require hospitalizations to manage severe pain and to reduce the likelihood of further 
complications. For this reason, many of the treatments available for SCD-related pain focus on 
acute pain. Clinical practice guidelines published by the National Heart Lung and Blood Institute 
(2014) support the rapid initiation of analgesics, opioids and nonopioids, when patients present 
with VOC. Further, in those that present with severe pain, the initiation of parenteral opioids is 
strongly recommended (National Heart, Lung, and Blood Institute, 2014). Although opioids are 
indicated for acute VOC, evidence suggests that they are ineffective in treating the variety of 
pathophysiologic mechanisms that contribute to centralized pain (Brummett et al., 2013; Corli et 
al., 2017; Finan et al., 2018; Hanks & Forbes, 1997; Janda et al., 2015; Phillips & Clauw, 2011; 
Wasserman, Brummett, Goesling, Tsodikov, & Hassett, 2014). Despite this, many patients with 
SCD continue to take opioids every day (Finan et al., 2018). Although the Clinical Practice 
Guidelines for SCD-related pain management focus on the use of analgesics including opioids 
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and non-steroidal anti-inflammatory drugs (NSAIDs), several RCTs have been conducted to 
evaluate the effectiveness of a variety of non-opioid analgesics and disease modifying therapies 
to reduce pain in this population. 
Non-opioid analgesics. 
 One pilot RCT compared the effectiveness of pregabalin to reduce pain and improve 
function compared to a placebo in adults with SCD (N=22) (Schlaeger et al., 2017). Pregabalin 
affects voltage-gated calcium channels to decrease central sensitization and nociceptive 
transmission and is used to treat neuropathic pain (Schlaeger et al., 2017). Patients were included 
in the study if they had a history uncontrolled pain with a current pain score of ≥ 4. Participants 
received pregabalin 75mg twice daily for three months. Doses could be titrated up as needed to a 
maximum of 600mg daily. This RCT reported no significant differences between groups on 
neuropathic pain, pain severity, and composite pain index (Schlaeger et al., 2017).  
This pilot RCT had many limitations. First, six participants out of the total sample did not 
complete the trial, further reducing the sample and the power to detect differences between 
groups. Additionally, participants in the pregabalin and control group differed on all pain scores 
at baseline including average pain index (3.8 vs. 4.8), composite pain index (36.1 vs. 46.5), 
Neuropathic Pain Symptom Index (29.6 vs. 44.5), and Leeds Assessment of Neuropathic Signs 
and Symptoms (S-LANSS) scores (8.0 vs. 9.5). These differences between groups indicate that 
the placebo group had increased pain severity and neuropathic pain at baseline compared to the 
treatment group. Thus, it is likely that large group differences in pain influenced the results 
found between groups. Further, many of the participants did not have neuropathic signs and 
symptoms at the start of the trial. Scores ≥12 on the S-LANSS is indicative of neuropathic pain 
(Bennett, Smith, Torrance, & Potter, 2005). As reported previously, baseline scores for the 
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placebo and treatment groups were 9.5 and 8.0. Therefore, many patients were not experiencing 
neuropathic pain and would not have benefited from the initiation of pregabalin. Overall, results 
of this study may have been more significant if only patients with signs and symptoms of 
neuropathic pain were included and stratified between groups based on baseline pain scores. 
Disease modifying therapies. 
Several studies have investigated the benefits of disease modifying therapies to reduce 
VOC, hospitalizations, and pain intensity in patients with SCD (Ataga et al., 2017; Brousseau et 
al., 2015; Charache et al., 1995; Gladwin et al., 2011; Ferster et al., 1996; Heeney et al., 2016; 
Morris et al., 2013; Niihara et al., 2018; Wang et al., 2011; Wun et al., 2013). First, evidence 
supports the daily use of hydroxyurea, or hydroxycarbamide, in children and adults who 
experience three or more VOCs with severe pain per year (Charache et al., 1995; Ferster et al., 
1996; National Heart, Lung, and Blood Institute, 2014; Wang et al., 2011). Hydroxyurea is a 
myelosuppressive agent that increases fetal hemoglobin (HbF) levels, decreases circulating 
leukocytes and reticulocytes, and increases RBC volume (National Heart, Lung, and Blood 
Institute, 2014). One RCT (N=299) that has greatly influenced current clinical practice 
recommendations identified that hydroxyurea therapy reduced the incidence of VOC (2.5 vs. 4.5 
per year; p≤0.001). Further, fewer patients taking hydroxyurea had acute chest syndrome (25 vs. 
51 patients; p≤,0.001) and underwent transfusions (48 vs. 73; p=0.001)(Charache et al., 1995). 
Those taking hydroxyurea also had significantly longer time to first (3 vs. 1.5 months; p=0.01) 
and second (8.8 vs. 4.6 months; p≤0.001) VOC compared to the placebo group. Two additional 
RCTs also support the use of hydroxyurea in children (Ferster et al., 1996; Wang et al., 2011). 
One RCT (N=22) identified that patients taking hydroxyurea had less hospitalizations (p=0.0016) 
and less days in the hospital (p=0.0027) compared to those taking placebo (Ferster et al., 1996). 
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The other RCT (N=193) identified that those taking hydroxyurea had significantly less pain 
events (63 vs. 121; p=0.004) than those taking placebo (Wang et al., 2011).  
While these hydroxyurea RCTs had positive effects regarding VOC frequency, 
hospitalization rates, and length of hospital stay, they did not assess the effect of hydroxyurea on 
pain severity. Thus, it is unclear whether hydroxyurea is effective in reducing daily pain severity 
among those with SCD. Further, these studies did not differentiate those with and without 
centralized pain in their sample. While hydroxyurea was effective in reducing acute pain 
outcomes in some patients, it may not have been beneficial in those with centralized pain. One of 
the RCTs excluded patients who consistently took more than 30 capsules of oxycodone over two 
weeks (Charache et al., 1995). Thus, it is possible that many patients with centralized pain 
prescribed daily opioids were excluded from this study making it unclear if hydroxyurea would 
have positive effects among those with centralized pain. Lastly, these three RCTs did not assess 
the variety of centrally-mediated factors (e.g., sleep, cognition, depression, anxiety, 
catastrophizing) that are known to influence pain. Since these factors were not measured and/or 
controlled for, it is unclear whether confounding variables influenced the positive findings within 
these samples. 
Evidence supports the effectiveness of two amino acid therapies, L-glutamine and L-
arginine, in reducing pain among patients with SCD (Morris et al., 2013; Niihara et al., 2018). 
Evidence suggests that patients with SCD have decreased availability of the amino acid, 
arginine, which may disrupt many cellular and organ functions (Bakshi & Morris, 2016). One 
RCT (N=38) found that patients taking L-arginine during hospitalization for VOC had a 
significant reduction in parenteral opioid use (1.9±2.0 mg/kg vs. 4.1±4.1mg/kg; p=0.02) and 
lower pain intensity (1.9±2.4 vs. 3.9±2.9; p=0.01) at discharge compared to placebo (Morris et 
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al., 2013). There were no significant differences, however, in hospital length of stay between 
groups (Morris et al., 2013). The second amino acid, L-glutamine, increases the flexibility of 
RBCs and improves oxygen transport within the blood (Niihara et al., 2018). One RCT (N=230) 
found that those taking L-glutamine daily for 48 weeks had fewer VOCs (3.0 vs. 4.0; p=0005) 
and hospitalizations (2.0 vs. 3.0; p=0.005) than those taking placebo (Niihara et al., 2018). 
Although these two amino acid RCTs revealed positive effects among a subset of patients 
with SCD, it is unclear if these effects would have been reported in a more diverse sample. The 
L-arginine trial excluded patients that may have had more severe and/or centralized pain (Morris 
et al., 2013). Two exclusion criteria within this study were 1) patients that had more than 10 
hospitalizations per year, and 2) those who had a history of opioid dependence (Morris et al., 
2013). The authors did not describe how opioid dependence was identified; thus, it is possible 
that patients with centralized pain who are prescribed daily opioids were excluded from the 
study. The inclusion of these patients could have significantly reduced the positive effects found 
among those receiving L-arginine. Further, the study period ended at discharge so it is unclear if 
the drug would have positive effects on daily pain severity post-VOC hospitalization (Morris et 
al., 2013). The RCT of L-glutamine versus placebo also did not differentiate those with and 
without centralized pain (Niihara et al., 2018). Further, this study only assessed outcomes related 
to VOC frequency and acute care utilization rates within the 48-week study period, making it 
unclear whether L-glutamine is effective in reducing daily pain severity (Niihara et al., 2018). 
Lastly, neither of these RCTs controlled for potential centrally-mediated pain influencing factors 
(Morris et al., 2013; Niihara et al., 2018). Overall, the evidence does not provide support for the 
use of amino acid therapy to reduce pain in patients with SCD that have centralized pain and co-
occurring centrally-mediated symptoms. 
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One RCT supports the use of a monoclonal antibody, crizanlizumab, among adolescents 
and adults with SCD that have two or more VOC per year (Ataga et al., 2017). Crizanlizumab 
binds to P-selectin, which contributes to the adhesion of sickled RBCs within blood vessel walls. 
Inhibiting P-selectin with crizanlizumab prevents vaso-occlusion, inflammation, and pain (Ataga 
et al., 2017). The RCT (N=193) compared the effectiveness of high-dose crizanlizumab, low-
dose crizanlizumab, and placebo and found that those who received 14 doses of high-dose 
crizanlizumab over 52 weeks had significantly less VOCs (1.63 vs. 2.98; p=0.01), less 
uncomplicated VOCs (1.08 vs. 2.91; p=0.02), and longer time to first (4.07 vs. 1.38 months; 
p=0.001) and second (10.32 vs. 5.09 months; p=0.02) VOC compared to placebo (Ataga et al., 
2017). There were no significant differences in pain severity and pain interference, assessed via 
the Brief Pain Inventory, between groups. While this RCT supports the effectiveness of 
crizanlizumab to reduce VOC rates and increase the time to VOCs, no effects were found on 
daily pain severity and interference. Thus, patients would still need additional interventions if 
they are experiencing daily pain. While the investigators compared the differences in outcomes 
based on sex, SCD genotype, and number of VOCs in the previous year, they did not evaluate 
outcomes between those with and without centralized pain. Thus, it is unclear if crizanlizumab 
would be effective within this population. Lastly, this study did not assess the effect of 
confounding pain influencing factors that could influence the positive findings. Specifically, the 
presence and/or absence of several centrally-mediated symptoms (e.g., sleep, cognition, 
depression) could have differed among the treatment and placebo groups and may have 
influenced the results. 
Four RCTs evaluated the effectiveness of three additional therapies in reducing pain, 
prasugrel, intravenous (IV) magnesium, and inhaled nitric oxide (NO) (Brousseau et al., 2015; 
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Gladwin et al., 2011; Heeney et al., 2016; Wun et al., 2013). None of these studies found 
significant differences in pain between the treatment and placebo groups (Brousseau et al., 2015; 
Gladwin et al., 2011; Heeney et al., 2016; Wun et al., 2013). Limitations in assay sensitivity may 
explain the negative findings of these four RCTs. Assay sensitivity is defined as the ability to 
distinguish an effective intervention from a less effective or ineffective intervention (Dworkin et 
al., 2012). A detailed evaluation of these studies’ limitations, including limitations in assay 
sensitivity, will be delineated in the following paragraphs.  
Two of the RCTs evaluated the effectiveness a blood cell modifying therapy, prasugrel, 
in reducing pain in patients with SCD (Heeney et al., 2016; Wun et al., 2013). Prasugrel, an anti-
platelet medication, reduces the formation of blood clots. First, one RCT conducted in children 
and adolescents (N=341) showed that the rate of VOC, hospitalization, and analgesic use was not 
significantly different between the prasugrel and placebo groups (Heeney et al., 2016). Further, 
there were no significant differences in daily pain severity, measured via the FACES pain scale, 
between the two groups (Heeney et al., 2016). The second RCT (N=62) evaluated the efficacy of 
prasugrel to reduce pain in adults with SCD (Wun et al., 2013). This study found no significant 
differences in pain frequency and severity between groups (Wun et al., 2013).  
Inhaled NO has been shown to ameliorate several adverse effects of VOC, for example 
vasoconstriction and platelet aggregation (Gladwin et al., 2011). One RCT studied whether 
inhaled NO gas would reduce VOC duration in patients presenting to the Emergency Department 
or hospital unit (N=150)(Gladwin et al., 2011). This study found no significant differences 
between those that received inhaled NO for up to 72 hours and those that received inhaled 
nitrogen placebo based on the following outcomes: time to VOC resolution, length of 
hospitalization, pain severity scores over time, and total dose of opioids (Gladwin et al., 2011). 
 
 
64 
 
Lastly, it is hypothesized that IV magnesium has the potential to benefit those 
experiencing VOC due to its anti-inflammatory and vasodilation effects (Brousseau et al., 2015). 
One RCT evaluated the effectiveness of IV magnesium to reduce length of stay and opioid use in 
children, adolescents, and young adults with SCD (N=204) (Brousseau et al., 2015). This study 
found no significant differences in hospital length of stay and opioid use between those receiving 
IV magnesium versus placebo (Brousseau et al., 2015).  
The four RCTs that evaluated the effectiveness of prasugrel, inhaled NO, and IV 
magnesium on pain did not have significant findings (Brousseau et al., 2015; Gladwin et al., 
2011; Heeney et al., 2016; Wun et al., 2013). It is possible that none of these treatments are 
effective in reducing pain among patients with SCD; however, limitations in assay sensitivity 
could have also influenced the results. Patients within one of the prasugrel RCTs had low pain 
intensity scores at baseline within the prasugrel and placebo groups (1.8 vs. 2.4), highlighting 
potential limitations in assay sensitivity (Wun et al., 2013). The prasugrel RCT could have 
improved assay sensitivity by limiting inclusion to patients with baseline pain ≥ 4 (on a numeric 
rating scale ranging from 0-10), since patients with greater pain are more likely to benefit from 
pharmacologic treatment (Dworkin et al., 2012). The second prasugrel RCT also has limitations 
in assay sensitivity based on patient factors (Gladwin et al., 2011). This RCT reported significant 
differences in patient characteristics between study sites—two of sites enrolled patients with less 
pain, shorter hospitalization times, and less cumulative opioid dose (Gladwin et al., 2011). These 
patient differences may have threatened the internal validity of the study and confounded the 
findings. 
Overall, evidence supports the efficacy of the following four non-opioid therapies in 
reducing pain in SCD: hydroxyurea, L-arginine, L-glutamine, and crizanlizumab (Charache et 
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al., 1995; Ferster et al., 1996; Morris et al., 2013; National Heart, Lung, and Blood Institute, 
2014; Niihara et al., 2018; Wang et al., 2011). As discussed previously, although these drugs are 
effective within these trials, it is unclear whether they are effective in reducing daily pain 
severity among those with centralized pain. Further, since no centrally-mediated factors were 
evaluated within these RCTs, it is unclear whether the presence or absence of these variables 
would have influenced the effects found on pain.  
Non-pharmacologic therapies. 
Within the past ten years, six non-pharmacologic RCTs have been conducted among 
patients with SCD to reduce the incidence of pain (L P Barakat, Schwartz, Salamon, & Radcliffe, 
2010; Miriam O. Ezenwa et al., 2016; Moody et al., 2017; Schatz et al., 2015; Thomas et al., 
2013). Four of these studies demonstrated positive intervention effects; however, these effects 
were minimal (Ezenwa et al., 2016; Moody et al., 2017; Schatz et al., 2015; Thomas, 
Stephenson, Swanson, Jesse, & Brown, 2013). 
One RCT conducted among patients hospitalized for VOC (N=73) compared effects 
between a yoga intervention group and an attention control group on pain, anxiety, length of 
stay, and opioid use (Moody et al., 2017). Participants with a pain score of  ≥7 at admission were 
randomized to the yoga or control group. The yoga intervention included four segments that 
focused on mindfulness, asanas (practicing different body positions with awareness of breath), 
breathing exercises, and guided relaxation (Moody et al., 2017). Those in the control group were 
provided with 30-minute sessions in which the yoga instructor played a nature sounds CD. 
Within the control group, the yoga instructor was available to stay with participants for 30 
minutes, but no exercises were taught. Participants in the yoga group experienced greater 
reduction in mean pain severity (-0.6±0.96 vs. 0.0±1.37; p=0.029) after the first yoga session 
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compared to the control group (Moody et al., 2017). However, no differences were found after 
subsequent sessions (Moody et al., 2017). Further, there were no significant differences between 
groups in total IV opioid use during hospitalization. 
The intervention described above has several limitations. First, participants and 
interventionists were not blinded to the treatment, increasing the likelihood that patients 
randomized to the control arm expected no reduction in pain, which could have subsequently 
influenced the findings. Further, evidence suggests that yoga interventions are beneficial in 
reducing pain among those with centralized pain (Büssing, Ostermann, Lüdtke, & Michalsen, 
2012; Tekur, Nagarathna, Chametcha, Hankey, & Nagendra, 2012; Williams et al., 2005). The 
RCT described above, however, was conducted within an inpatient setting while patients were 
experiencing an acute VOC with severe pain (Moody et al., 2017). Further, this study did not 
differentiate those with and without centralized pain. Thus, the insignificant results could be due 
to the fact that participants were not experiencing centralized pain and, therefore, an intervention 
targeting central pain mechanisms would be ineffective.  
 The second nonpharmacologic RCT conducted among children and adolescents with 
SCD (N=46) evaluated the effectiveness of a Cognitive Behavioral Therapy (CBT) intervention 
on pain, coping, negative thinking, and activity (Schatz et al., 2015). Participants in the CBT 
group received CBT training by a licensed clinical psychologist and were given a smartphone 
that included a CBT skills program facilitating deep breathing, progressive muscle relaxation, 
and guided imagery (Schatz et al., 2015). CBT skill use was recorded by the smartphone when a 
participant opened the skills program. This study found that smartphone-recorded CBT skill use 
significantly predicted next-day pain intensity (x2[12]= 3.91; p=0.048) (Schatz et al., 2015).  
 
 
67 
 
Although this study had positive results, there were group differences at baseline that 
could have influenced the results. Patients within the intervention group had more pain episodes 
that resulted in inpatient admissions and/or ER visits during the previous year than the control 
group (3.8 vs. 5.4) (Schatz et al., 2015). Although this difference was not statistically significant, 
those in the intervention group may have been more willing to participate with CBT skills 
because they had greater pain severity. Another limitation of this RCT is a lack of participant 
blinding. Specifically, those receiving the intervention may have expected their pain to decrease 
during the study period, which could subsequently explain the significant difference in pain 
severity scores between groups. Further, this RCT did not distinguish between those with and 
without centralized pain. Since CBT interventions target central pain mechanisms, it could be 
hypothesized that those with centralized pain would experience the most benefit from practicing 
CBT skills. Thus, the differences between groups may have been more significant if this study 
included only those with centralized pain. Lastly, although this study analyzed the effect of the 
intervention on coping, negative thinking, and activity, it did not control for any other centrally-
mediated pain influencing factors (e.g., sleep, cognition, depression, anxiety) that could have 
influenced the positive findings. 
The third non-pharmacologic RCT conducted among adults with SCD (N=27) compared 
an audio-visual relaxation intervention to an attention control group (Miriam O. Ezenwa et al., 
2016). Those in the intervention group received one 12-minute guided relaxation clip at baseline 
and six additional video clips (2-20 minutes in length) with similar content on a tablet device. 
Participants were instructed to watch at least one video daily but were encouraged to watch a 
video at stress onset and whenever desired. The attention control group participated in a 12-
minute computer-based discussion regarding their SCD experience at baseline. The control group 
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also recorded daily stress and pain scores for the duration of the study period. All patients and 
most study personnel were blinded to group assignments. Participants in the intervention group 
had significantly lower pain scores after the baseline intervention (4.1 vs. 6.3; 95% CI [-3.343, -
0.364]) as well as significant lower composite pain index scores after the two-week study period 
(35 vs. 41.8; 95% CI [-17.872, -0.406]) compared to the control group (Ezenwa et al., 2016). 
However, there were no significant differences in opioid use between groups (Ezenwa et al., 
2016). Also, similarly to the previous two nonpharmacologic RCTs presented, this study did not 
distinguish those with and without centralized pain. Thus, it is unclear if this intervention would 
be effective in reducing pain among those with central pain mechanisms. 
The fourth non-pharmacologic RCT conducted among adults hospitalized for VOC 
(N=17) compared a healing touch with music intervention to an attention control with music 
group (Thomas, Stephenson, Swanson, Jesse, & Brown, 2013). This RCT evaluated the 
effectiveness of the intervention to reduce anxiety, stress, pain, and analgesic use. The 
intervention included four healing touch sessions that were administered for 30 minutes over 
four consecutive days (Thomas et al., 2013). Those in the control group received four 30-minutes 
sessions that included only music (Thomas et al., 2013). There were no significant differences 
found in daily pain between groups except for on Day 4; those in the attention control group had 
significant reductions in present pain post-intervention on Day 4 (4.55 vs. 7.17; p=0.03) 
compared to the intervention group. Further, this study found that those in the intervention group 
had a larger mean change in pain score from pre- to post-intervention on Day 1 (1.67 vs. 0.92; 
p<0.01) compared to the control group. No subsequent differences were found between groups 
(Thomas et al., 2013).  
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Several limitations of this pilot RCT could have influenced the findings. First, this study 
was not powered to detect these differences between groups due to the small sample (N=17) 
(Thomas, Stephenson, Swanson, Jesse, & Brown, 2013). Participants and study personnel were 
not blinded to the intervention. Thus, participants randomized to the intervention group may 
have expected differences in outcomes following the healing touch with music intervention. The 
authors of this study reported that the inpatient setting was not conducive to the intervention 
since there were several interruptions during the intervention and control sessions (Thomas et al., 
2013). These interruptions could have limited the effectiveness of the healing touch with music 
intervention on reducing pain. Similar to the yoga RCT conducted by Moody et al. (2017), this 
RCT was conducted among those hospitalized with VOC and there was no distinction between 
those with and without centralized pain. Thus, it is unclear whether this intervention can reduce 
pain via targeting central pain mechanisms like yoga, exercise, and distraction.  
The fifth nonpharmacologic RCT conducted among those with SCD included a massage 
therapy intervention (Lemanek et al., 2009). Children and their primary caregiver (N=34) were 
randomized to a massage therapy or attention control group (Lemanek et al., 2009). A massage 
therapist visited those within the intervention group at home weekly for four weeks. Further, 
caregivers, trained on proper massage techniques, were asked to give their child massages 
between therapist days (Lemanek et al., 2009). Those in the attention control group were visited 
weekly at home by a research assistant to collect outcome measure forms (Lemanek et al., 2009). 
Children within the study rated their levels of pain each morning and evening. Depression 
measures were given at baseline and study completion while measures of anxiety were given 
weekly (Lemanek et al., 2009). After the 30-day study period, participants in the intervention 
group had significantly less depression (45 vs. 46.7; p=0.05), anxiety (40.1 vs. 43.9; p=0.01), and 
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pain ratings (F=4.11; p=0.05) compared to the control group, highlighting potential mediating 
effects of depression and anxiety on pain. There were no significant differences between groups 
based on health care utilization (Lemanek et al., 2009). 
Although this massage RCT found positive effects, there were limitations within the 
study design. First, participants and study personnel were not blinded, so it is possible that 
participants randomized to the intervention group may have expected differences in outcomes 
following the massage intervention. Similarly, those in the attention control group would not 
expect differences in pain and psychological outcomes since they were not receiving the 
intervention. The authors of this study reported that it is likely this intervention was not 
standardized between participants since caregivers were required to give the massage to their 
children on days the therapist did not come (Lemanek et al., 2009). Similar to the other RCTs 
described above, this study did not distinguish patients with and without centralized pain. Thus, 
it is unclear if this intervention would be effective if it was conducted in only those with 
centralized pain. 
The last RCT, conducted among children and adolescents with SCD (N=53), investigated 
the effectiveness of a cognitive behavioral pain management intervention compared to a disease 
education intervention on pain and coping, school attendance, and health-related hindrance 
(Barakat, Schwartz, Salamon, & Radcliffe, 2010). Participants and a family support person were 
randomized to receive a brief pain intervention or a disease education attention control 
intervention at home. The intervention and control sessions consisted of four 90-minute sessions 
that each included a discussion of SCD and disease management. The cognitive behavioral pain 
management intervention consisted of deep breathing/relaxation, coping, and guided imagery 
while the disease education intervention included communication about disease, management, 
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and health issues. This RCT found no significant differences between groups among all pain, 
psychosocial, and health-related variables (Barakat, Schwartz, Salamon, & Radcliffe, 2010).  
Gaps 
In summary, the previous section provided a thorough review of the literature published 
within the last 10 years that has analyzed the relationships among various physiological, 
psychological, situational, and cognitive factors and SCD-related pain. Factors described above 
include genetics, sex, age, sleep, fatigue, depression, anxiety, catastrophizing, pain control 
beliefs, sickle cell stigma, trauma exposure, social support. Several gaps and limitations within 
the literature have been identified. A comprehensive summary of these gaps and the variables 
selected within the proposed study was provided following the ‘pain-influencing factors in 
patients with SCD’ section. 
Several gaps among pain management RCTs were discussed within the previous section. 
First, the majority of the pharmacologic RCTs have focused on reducing nociceptive pain and 
acute vaso-occlusive crises among patients with SCD. However, recent evidence suggests that 
central sensitization and centralized pain manifestations (e.g., widespread pain) are present 
within a subset of patients with SCD (Brandow et al., 2015; Brandow et al., 2013; Carroll et al., 
2016; Ezenwa et al., 2015; O’Leary et al., 2013; Schaibl & Richter, 2004; Zempsky et al., 2017). 
These findings may support the initiation of non-opioid and nonpharmacologic therapies that are 
known to be effective among other centralized pain populations. Despite evidence supporting the 
implementation of nonpharmacologic interventions among patients with SCD, several of the 
non-opioid and non-pharmacologic RCTs were ineffective or had minimal positive findings. 
As discussed above, it is unclear whether the minimal effects found within the non-opioid 
and non-pharmacologic RCTs are due to the fact that these RCTs were conducted in patients 
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experiencing nociceptive, rather than centralized, pain. Prior to further intervention research, it is 
necessary to understand the pain presentation unique to those with SCD. For this reason, we will 
evaluate the incidence and severity of centralized pain, pain catastrophizing, and centrally 
mediated symptoms via reliable and validated patient-reported outcome (PRO) measures. We 
will also evaluate the predictive relationships among these factors and opioid consumption. 
Table 1 delineates specific approaches within the proposed dissertation project used to address 
many of the gaps discussed. 
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Table 1 
Summary of Identified Gaps in the Literature and Plans for Addressing the Gaps in the Proposed 
Project 
 
Gaps in the Literature Addressing Gaps in the Literature 
1. No studies among patients with SCD 
have evaluated the impact of all 
centrally-mediated variables within the 
S.P.A.C.E. symptom cluster that are 
known to co-occur with centralized 
pain (Shattuck & Muehlenbein, 2016; 
Williams, 2018). 
I will describe the incidence and severity of 
all six S.P.A.C.E. symptoms (i.e., sleep 
impairment, widespread pain, affective 
perturbation [anxiety and depression], 
cognitive function, and energy deficit 
[fatigue]), among adolescents and young 
adults with SCD (Aim 1).  
 
I will use two-part predictive models to 
evaluate the predictive relationships among 
S.P.A.C.E. symptoms, opioid consumption, 
and pain interference one month post-
baseline in adolescents and young adults 
with SCD (Aim 2).  
 
Lastly, I will characterize the co-occurrence 
of individual baseline S.P.A.C.E. 
symptoms, pain interference, average daily 
opioid consumption, pain intensity, and 
Pain Area and Intensity Number 
Summation (P.A.I.N.S.) measured via the 
body map within the GeoPain @ Home 
smartphone application in adolescents and 
young adults with SCD via bivariate 
correlation analyses (Aim 4). 
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2. Approximately 50% of the studies that 
have evaluated the various pain-
influencing factors among patients with 
SCD did not distinguish patients with 
and without centralized pain. 
The ACR 2011 Fibroymaylgia survey 
criteria will be used to measure centralized 
pain. The published literature provides 
evidence of the measure’s internal 
consistency reliability, sensitivity, 
specificity, responsiveness, and content and 
convergent validity (Häuser et al., 2012; 
Neville et al., 2018; Wolfe et al., 2016, 
2011; Wolfe, Walitt, Rasker, Katz, & 
Häuser, 2015).  
 
I will describe the incidence and severity of 
centralized pain among adolescents and 
young adults with SCD (Aim 1). 
 
I will use two-part predictive models to 
evaluate the predictive relationships among 
centralized pain, opioid consumption, and 
pain interference one month post-baseline 
in adolescents and young adults with SCD 
(Aim 3). 
3. There is conflicting evidence regarding 
the predictive relationship between 
pain catastrophizing and pain among 
those with SCD.  
I will describe the incidence and severity of 
pain catastrophizing among adolescents and 
young adults with SCD (Aim 1). 
 
I will use two-part predictive models to 
evaluate the predictive relationships among 
pain catastrophizing, opioid consumption, 
and pain interference one month post-
baseline in adolescents and young adults 
with SCD (Aim 3). 
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CHAPTER III 
S.P.A.C.E. Symptom Cluster Among Adolescents  
and Adults with Sickle Cell Disease  
Abstract 
Introduction: Daily pain is a significant complication of sickle cell disease (SCD). Although 
pain impacts the lives of many patients with SCD, few pharmacologic and non-pharmacologic 
interventions are effective reduce pain among these patients. Research in other pain populations 
(e.g., fibromyalgia, low back pain) suggests that a centrally-mediated symptom cluster, 
S.P.A.C.E., may contribute to and exacerbate pain. No research studies have evaluated the 
severity and co-occurrence of S.P.A.C.E. symptoms among patients with SCD. 
Purpose: The purpose of this research was 1) to describe the incidence and severity of six 
centrally-mediated S.P.A.C.E. symptoms (i.e., sleep impairment, widespread pain, anxiety, 
depression, cognitive function, and fatigue), and 2) to characterize the co-occurrence of 
S.P.A.C.E. symptoms, pain interference, opioid consumption morphine milliequivalents (MME), 
pain intensity, and Pain Area and Intensity Number Summation (P.A.I.N.S.) measured via the 
body map within the GeoPain @ Home smartphone application. 
Patients and Methods: Forty-eight adolescents and adults with SCD completed measures of 
S.P.A.C.E. symptoms, opioid consumption, and pain interference. After survey measure 
completion, participants reported current pain intensity and widespread pain using an interactive 
body map within the GeoPain @ Home smartphone application. Descriptive analyses were 
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conducted to evaluate the severity of S.P.A.C.E. symptoms, pain interference, opioid 
consumption, pain intensity, and P.A.I.N.S. Multiple Spearman correlations were calculated to 
characterize the co-occurrence of individual S.P.A.C.E. symptom severity scores, pain severity, 
opioid consumption, and pain interference. 
Results: Forty-eight adolescents and young adults with SCD ages 14 to 35 (X̄=22.8 years; 
SD=5.9) were included within the study. Sleep impairment (X̄=56.63; SD=9.05) and fatigue 
(X̄=52.99; SD=11.24) were the only S.P.A.C.E. symptoms with mean severity scores higher than 
normative sample means. Mean pain interference (X̄=55.56; SD=10.91) was also higher than the 
normative sample mean. Participants’ pain intensity scores were 3.41, on average (SD=2.57). 
Mean opioid consumption MME was 23.67 (SD=42.58) with a wide range of 0 to 246 MME. 
Sleep impairment, anxiety, depression, and fatigue were all moderately and significantly 
correlated with one another (r range=0.42-0.75; p<0.001). Further, cognitive function was 
negatively and moderately correlated with sleep impairment, anxiety, and fatigue (r range=-0.39 
– -0.54). Besides depression, all S.P.A.C.E. symptoms were moderately and significantly 
correlated with pain interference (p<0.001). Sleep impairment, anxiety, depression, cognitive 
function, and fatigue were not significantly associated with opioid consumption, pain intensity, 
and P.A.I.N.S. 
Conclusion: These findings support the co-occurrence of several centrally-mediated S.P.A.C.E. 
symptoms among adolescents and young adults with SCD. Further, many S.P.A.C.E. symptoms 
(i.e., sleep impairment, widespread pain, anxiety, cognitive function, fatigue) were moderately 
and significantly associated with pain interference. Comprehensive evaluation and management 
of S.P.A.C.E. symptoms may facilitate improvements in social, cognitive, emotional, and 
physical function among patients with SCD.  
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Background 
Pain impacts the lives of many patients with sickle cell disease (SCD) and is the most 
common reason for health service utilization (Platt et al., 1991; Vacca Jr & Blank, 2017). 
Despite the impact pain has on patients with SCD, few pharmacologic and non-pharmacologic 
treatments effectively reduce the incidence and severity of daily pain (National Heart, Lung, 
2014). Pain among patients with SCD is complex—many patients experience acute, nociceptive 
pain episodes, or vaso-occlusive crises, in addition to daily, chronic pain (Finan et al., 2018; 
McClish et al., 2009; Smith et al., 2008).  
Empirical evidence suggests that many symptoms co-occur with pain and increase the 
associated burden experienced by patients with SCD (K Phillips & Clauw, 2011; D. A. Williams, 
2018). Research in chronic pain populations (e.g., fibromyalgia, low back pain, and 
endometriosis) suggests that individuals with a personal history of centrally-mediated symptoms 
are more likely to transition from acute to chronic/centralized pain (Hanish, Lin-Dyken, & Han, 
2017; Keller, Yang, Treadwell, & Hassell, 2017; Merriwether et al., 2017). These centrally-
mediated symptoms, conceptualized as the S.P.A.C.E. symptom cluster, include sleep 
impairment, widespread pain, affective perturbation (anxiety and depression), cognitive 
impairment, and low energy (fatigue) (Williams, 2018). 
S.P.A.C.E. symptoms are hypothesized to interact with each other via several body 
systems such as the immune and central nervous systems. First, regarding the immune system, 
increased levels of cytokines including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor 
alpha (TNF-α,) among others, have been associated with increased levels of pain and fatigue 
(Bower, 2014; Schaible, 2014). Further, one meta-analysis provides evidence that IL-1β and IL-6 
have significant relationships with the S.P.A.C.E. symptom cluster (Shattuck & Muehlenbein, 
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2016). It is hypothesized that S.P.A.C.E. symptoms may co-occur with increased levels of 
cytokines (e.g., IL-1β, IL-6) and TNF-α as an adaptive physiological response to preserve energy 
and promote recovery (Shattuck & Muehlenbein, 2016; Williams, 2018). 
Second, pain processing areas within the central nervous system may also explain the 
relationships among S.P.A.C.E. symptoms and pain (Bar et al., 2005; Ochsner et al., 2006). 
Evidence suggests that patients who have anxiety and depression have increased activation of 
several areas within the brain that perceive pain stimuli (e.g., anterior cingulate cortex, 
amygdala, and insula)(Bar et al., 2005; Etkin et al., 2011; Maletic & Raison, 2009; Ochsner et 
al., 2006; Strigo et al., 2008). It is hypothesized that increased activation of pain perception areas 
may give rise to and exacerbate pain and S.P.A.C.E. symptoms (Bar et al., 2005; Etkin et al., 
2011; Maletic & Raison, 2009; Ochsner et al., 2006; Strigo et al., 2008).  
Empirical evidence suggests that S.P.A.C.E. symptoms may be present among patients 
with SCD (Ameringer et al., 2014; Jerrell et al., 2011; Sharma et al., 2015; Zempsky et al., 
2017). Many research studies have supported the association between affective perturbation 
(anxiety and depression) and pain (Carroll et al., 2016a; Donohoe & Smith, 2018; Hoff, Palermo, 
Schluchter, Zebracki, & Drotar, 2006; Jerrell et al., 2011; Karafin et al., 2018; Sil, Cohen, et al., 
2016). Empirical evidence also supports the association between sleep disturbances and pain 
(Graves & Jacob, 2014; Moscou-Jackson et al., 2015; Wallen et al., 2014). To our knowledge, 
only one study has investigated the relationship between fatigue and pain (Ameringer et al., 
2014). Further, no studies have evaluated the association between cognitive function and pain 
within this population. 
 Although it is known that many patients present with more than one centrally-mediated 
symptom, to date, research among patients with SCD have only focused on one or two of the 
 
 
95 
 
S.P.A.C.E. symptom domains. This major gap in the literature highlights a need for a 
comprehensive evaluation of all S.P.A.C.E. symptoms. A thorough evaluation of the severity and 
co-occurrence of these symptoms within the SCD population may lead to improved pain 
management strategies in the future. Thus, using a prospective, cross-sectional study design the 
study aims were to: 1) the severity of S.P.A.C.E. symptoms and 2)  the co-occurrence of 
S.P.A.C.E. symptoms, pain interference, opioid consumption MME, pain intensity, and Pain 
Area and Intensity Number Summation (P.A.I.N.S.). 
Methods 
Sample and Setting  
Adolescents and adults with SCD (N=48) were recruited between 8/2019-12/2020 from 
the Pediatric and Adult Comprehensive Sickle Cell Clinics at Mott Children’s Hospital and 
Michigan Medicine. Patients were included in the study if they were between the ages of 14 and 
35 and could speak and read English. Patients were excluded from the study if they did not own 
a smartphone. The study was approved by the University of Michigan Institutional Review 
Board.  
Recruitment and Data Collection 
 The principal investigator (PI) or a trained research assistant pre-screened potentially 
eligible patients via chart review, consultation with the patients’ providers, and/or direct 
discussion with potential participants over the phone. Patients, and, in the case of adolescents, 
their parent/guardian were approached during their clinic appointment. The PI or a trained 
research assistant obtained signed informed consent/assent after thorough discussion of study 
procedures as well as benefits and risks of participation. Two participants were consented and 
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completed data collection outside of the clinic because they did not have any upcoming clinic 
appointments.  
After obtaining informed consent, participants reported baseline demographics, the six 
S.P.A.C.E. symptoms, opioid consumption, and pain interference using electronic Qualtrics™ 
surveys via a tablet computer. The order in which participants completed the S.P.A.C.E., opioid 
consumption and pain interference surveys was randomized via the randomizer element within 
Qualtrics™. Following baseline survey completion, the PI or research assistant instructed 
participants on how to download the GeoPain @ Home mobile application on their personal cell 
phones. Participants reported baseline pain intensity and widespread pain using an interactive 
body map within the mobile application.  
Measures 
Demographic Survey. Patients self-reported their age, sex, race, ethnicity, and sickle cell 
genotype within the Demographics survey. Self-reported sickle cell genotype was confirmed by 
the PI or research assistant via electronic medical record (EMR) abstraction. 
PROMIS® Short Form v1.0-Sleep-Related Impairment 8a. The 8-item PROMIS® Short Form 
Sleep-Related Impairment measures perceptions of alertness, sleepiness, and tiredness during 
usual waking hours using a 5-point Likert scale (Cella et al., 2010). Raw scores range from 8 to 
40 with higher scores meaning greater levels of sleep-related impairment. Empirical evidence 
supports the instrument’s internal consistency reliability (α=0.92), concurrent validity, and 
sensitivity in healthy adolescents, females with centralized pain, and adults with SCD (Bernstein 
et al., 1994; Spinhoven et al., 2014). 
ACR 2011 Fibromyalgia Survey Criteria. The ACR 2011 Fibromyalgia Survey criteria contains 
the 19-item Widespread Pain Index (WPI) subscale which evaluates the presence or absence of 
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pain over the last 7 days in 19 different body regions. Scores from the WPI (range = 0-19) were 
used to operationalize widespread pain in this study. Empirical evidence supports the measure’s 
internal consistency reliability (α=0.71), sensitivity, specificity, responsiveness, and validity 
(content and convergent) in patients with centralized pain (Wolfe et al., 2016). 
PROMIS® Short Form v1.0 – Depression 8b. The 8-item PROMIS® Depression Short Form 
measures negative mood, anhedonia, negative views of the self, and negative social cognition 
based on the previous 7 days using a 5-point Likert scale (Cella et al., 2010). Raw scores range 
from 8 to 40 with higher scores indicating greater levels of depression. This measure has 
demonstrated internal consistency reliability (α= 0.93), convergent validity, and sensitivity in 
adults with centralized pain and SCD (Keller et al., 2017; Kroenke, Yu, Wu, Kean, & Monahan, 
2014). 
PROMIS® Short Form v1.0 Anxiety 8a. PROMIS® Anxiety Short Form measures fear, anxious 
misery, and hyper-arousal based on the previous 7 days using a 5-point Likert scale (Cella et al., 
2010). Raw scores range from 8 to 40 with higher scores indicating greater levels of anxiety. 
This measure has demonstrated internal consistency reliability (α= 0.85), convergent and 
discriminant validity, and unidimensionality among adults with centralized pain (Irwin et al., 
2010; Merriwether et al., 2017)  
Multidimensional Inventory of Subjective Cognitive Impairment (MISCI). The 10-item MISCI 
quantifies perceived cognitive abilities and difficulties over the past seven days including mental 
clarity, memory, attention, executive functioning, and language on a 5-point Likert-type scale. 
Raw scores range from 10 to 50 with higher scores indicating better perceived cognitive 
functioning or lower cognitive impairment (Kratz, Schilling, Goesling, & Williams, 2015). 
 
 
98 
 
Empirical evidence supports the MISCI’s internal consistency reliability (α=0.94), and construct 
and convergent validity among adults with centralized pain (Kratz et al., 2015). 
PROMIS® Short Form v1.0-Fatigue 8a. The 8-item PROMIS® Fatigue Short Form measures 
the impact and experience of fatigue in the past week using a 5-point Likert scale (Cella et al., 
2010). Raw scores range from 8 to 40 with higher scores indicating greater levels of fatigue. 
Empirical evidence supports the instrument’s internal consistency reliability (α=0.83), test-retest 
reliability (ICC=0.85), concurrent and divergent validity, and sensitivity in adolescents and 
adults with SCD (Amtmann et al., 2010; Broderick, Schneider, Junghaenel, Schwartz, & Stone, 
2013; Keller et al., 2017). 
PROMIS® Short Form v1.0 – Pain Interference 4a. The 8-item PROMIS® Pain Interference 
Short Form assesses the self-reported consequences of pain on social, cognitive, emotional, 
physical, and recreational activities on the previous 7 days using a 5-point Likert scale (Cella et 
al., 2010). Raw scores range from 8 to 40 with higher scores indicating more activity interference 
due to pain (Cella et al., 2010). Empirical evidence supports the measures’ internal consistency 
reliability (α= 0.90 to 0.99), test-retest reliability (ICC 0.83 to 0.95), and sensitivity in 
adolescents and adults with centralized pain (Amtmann et al., 2010; Broderick et al., 2013). 
Opioid Consumption. Participants reported their opioid consumption via a Qualtrics™ survey. 
Within the opioid consumption survey, participants reported which, if any, opioids they were 
taking, and the average number of pills taken per day within the previous seven days. The PI or 
trained research assistant collected information regarding prescribed opioid dosages via the EMR 
and calculated average daily milligram morphine equivalents (MME) for each participant using 
the Oregon Pain Guidance Opioid Conversion Calculator (2017).  
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GeoPain @ Home Mobile Application. Participants reported current pain intensity and 
widespread pain using the interactive body map within the GeoPain™ @ Home smartphone 
application (app) (MoxyTech Inc., MI). This commercial app is a derivative of a mobile app 
developed at the University of Michigan to optimize data collection among patients with 
migraines, dental pain, and cancer pain (DaSilva et al., 2014; DosSantos et al., 2012; MoxyTech 
Inc., MI). Empirical evidence supports the convergent validity and sensitivity of app in patients 
with centralized pain (DaSilva et al., 2014; Donnell et al., 2015; DosSantos et al., 2012; 
Nascimento et al., 2014). Figure 3 depicts the body map within the GeoPain @ Home app. 
Within the body map, participants report their pain intensity using a color scale from 0 to 10 
(using a slider bar) and shade the area of the body that corresponds to the chosen intensity. The 
body map allows participants to change the pain intensity report for different areas of the body. 
The following three variables were calculated using the GeoPain @ Home body map:  
Pain intensity. Pain intensity was calculated by averaging all self-reported pain intensity 
scores within the body map. Scores range from 0-10, with 0 meaning no pain. 
Widespread pain. We evaluated widespread pain using the widespread pain index within 
the ACR 2011 Fibromyalgia Survey Criteria. To be more precise, we also evaluated widespread 
pain using the GeoPain @ Home body map. Within the body map, widespread pain is the percent 
of the body covered by painted pain cells. GeoPain widespread pain scores range from 0 to 100% 
with 100% indicating all body cells are painted.  
P.A.I.N.S. Pain Area and Intensity Number Summation, or P.A.I.N.S., combines both 
pain intensity and widespread pain  (DaSilva et al., 2014; MoxyTech Inc., MI). To derive 
P.A.I.N.S. percentage scores, pain intensity and widespread pain are multiplied together and 
divided by the total body area with maximum severe pain (pain intensity*widespread pain / 2026 
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[total body area] x 10 [maximum severe pain]). P.A.I.N.S. scores range from 0 to 100% with 
100% indicating maximum severe pain (10/10) throughout the entire body area. Emerging 
empirical evidence supports the divergent validity of P.A.I.N.S. scores with μ-opioid activation 
measured during positron emission tomography (PET) sessions (DaSilva et al., 2014).  
Statistical Analyses 
Electronic survey and mobile application data were exported from Qualtrics™ and the 
GeoPain @ Home internet server and analyzed using Stata software (StataCorp, 2017).  
Descriptive statistics of the centrality and dispersion of all S.P.A.C.E. symptoms were calculated 
and plotted. Descriptive statistics (e.g. means, frequencies, 95% confidence intervals, and 
standard deviations) were calculated for all variables including demographic characteristics, six 
symptoms within the S.P.A.C.E. symptom cluster, opioid consumption MME, pain interference, 
pain intensity, and P.A.I.N.S. For all PROMIS® measures, the raw total scores were converted 
to T-scores (mean=50, standard deviation=10) using the PROMIS® Health Measures Scoring 
Service (“PROMIS® Cooperative Group. Unpublished manual for the Patient Reported 
Outcomes Measurement Information System (PROMIS®) (Version 1.1.v 9)”). Cognitive 
function raw scores were also converted to PROMIS® equivalent T-scores based on previously 
published conversion values (Kratz et al., 2015).  
Opioid Consumption Survey responses were compared with corresponding electronic 
medical record (EMR) dosages and converted to average daily morphine milliequivalents 
(MME) using the Oregon Pain Guidance Opioid Conversion Calculator (2017). Some 
participants (n=6) reported taking opioids that were discontinued. In these instances, average 
daily opioid consumption MME was calculated using dosages from the discontinued 
prescription. Three participants reported taking codeine with no EMR prescription history within 
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three opioid consumption diaries. In these instances, average daily opioid consumption MME 
was calculated based on standard adult-specific dosages of codeine/acetaminophen 
(30/300mg)(Michigan Medicine Clinical Care Guidelines, 2016).  
Spearman correlation coefficients were calculated to characterize the co-occurrence of 
individual S.P.A.C.E. symptom severity scores (i.e., sleep impairment, multifocal pain, anxiety, 
depression, cognitive function, and fatigue), average daily opioid consumption, pain interference, 
pain intensity, and P.A.I.N.S. The Bonferroni correction (Bonferroni, 1935) was used to account 
for multiple pairwise correlations.  
Results 
Demographics 
Forty-eight adolescents and young adults completed S.P.A.C.E. symptom measures. 
Figure 4 identifies the number of patients that were screened, ineligible, and those who declined 
to participate in the study. The three main reasons patients declined to be in the study were 1) an 
inability to complete study measures due to time constraints, 2) patients did not feel comfortable 
downloading GeoPain @ Home app on personal smartphone, and 3) lack of interest. 
Sample demographic information is presented in Table 2. Participants within the sample 
had a mean age of 22.8 years (range: 14-35 years). The majority of the sample was female 
(56.4%), African American (97.9%), and non-Hispanic (97.9%). The most common sickle cell 
genotypes were HbSS (72.9%) or HbSC (20.8%). Lastly, the majority of participants received 
some college education or technical training (33.3%), received a university degree (25%), or 
were in high school (22.9%). 
 Descriptive statistics of all S.P.A.C.E. variables are provided in Table 3. Participants 
reported pain in 4 out of 19 different body regions, on average. Mean cognitive function, anxiety, 
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and depression severity were approximately equal or lower than PROMIS® (or equivalent) 
normative sample means. Sleep impairment (X̄=56.63), and fatigue (X̄=52.99) were the only 
symptoms that were higher than PROMIS® normative sample means, with sleep impairment 
approximately 0.5 standard deviations above the normative sample mean.  
Table 4 provides descriptive information regarding opioid consumption, pain 
interference, GeoPain widespread pain, pain intensity, and P.A.I.N.S. Average daily opioid 
consumption MME varied widely among participants with a range from 0 to 246 MME. 
Participants reported pain interference scores approximately 0.5 standard deviations higher than 
the PROMIS® normative sample mean. Although scores ranged throughout the sample, 
widespread pain, pain intensity, and P.A.I.N.S. mean scores were relatively low. 
 Pairwise correlations among all S.P.A.C.E. variables, average daily opioid consumption 
MME, pain interference, pain intensity, and P.A.I.N.S are presented in Table 5. Several 
S.P.A.C.E. variables were significantly correlated with one another (p<0.001) after correcting for 
multiple comparisons. Specifically, sleep impairment, anxiety, depression, and fatigue were all 
moderately correlated with one another (r range = 0.42-0.75). Further, cognitive function was 
negatively and moderately associated with sleep impairment, anxiety, and fatigue (r range = -
0.39-0.54); however, correlations between cognitive function and anxiety were not statistically 
significant. Widespread pain was the only S.P.A.C.E. variable that was not significantly 
correlated with other S.P.A.C.E. variables; however, widespread pain was moderately correlated 
with fatigue.  
Besides depression, all S.P.A.C.E. symptoms were moderately and significantly 
correlated with pain interference (p < 0.001). Widespread pain was the only S.P.A.C.E. variable 
that had a significant and moderate correlation with average daily opioid consumption (r = 0.47). 
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Besides, widespread pain, no S.P.A.C.E. variables were significantly correlated with opioid 
consumption, pain intensity, and P.A.I.N.S. 
Discussion 
This study described the severity and co-occurrence of physiologic and psychologic 
S.P.A.C.E. symptoms (i.e., sleep impairment, widespread pain, anxiety, depression, cognitive 
function, and fatigue) among adolescents and adults with SCD. Most S.P.A.C.E. symptom 
severity scores were comparable to PROMIS® (or equivalent) normative sample means. Sleep 
impairment and fatigue were the only two symptoms with higher mean severity than PROMIS® 
normative sample means. These findings are consistent with research that has evaluated 
incidence and severity of fatigue and sleep impairment among patients with SCD (Ameringer et 
al., 2014; Daniel et al., 2010; Mann-Jiles, Thompson, & Lester, 2015; Moody et al., 2017; 
Sharma et al., 2015).  
There is conflicting evidence regarding the incidence and severity of anxiety and 
depression among patients with SCD (Bakshi et al., 2018; Jerrell et al., 2011; Laurence, George, 
Woods, & Baltimore, 2006; Ozer, Yengil, Acipayam, & Kokacya, 2014). Mean depression and 
anxiety scores of participants in the current study were lower (better) than normative sample 
means, on average. These low mean scores may be explained by low pain severity within our 
sample. Empirical evidence supports the association among anxiety, depression, and pain (Keller 
et al., 2017). The mean pain intensity (X̄=3.41) within our study highlights that many participants 
had no or minimal pain. Thus, it is possible that depression and anxiety severity was low due to 
low pain intensity. Depression and anxiety scores may have been higher if our study targeted a 
sample with greater pain intensity.  
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Participants in our study reported better perceived cognitive functioning than normative 
sample mean scores, on average. To our knowledge, no research studies have evaluated 
perceived cognitive function among patients with SCD. Widespread pain varied among study 
participants; however, many participants (n=27) reported pain within three or more multiple 
different body sites. These findings add to the emerging evidence that widespread pain is present 
among a subset of patients with SCD (McClish et al., 2009; Zempsky et al., 2017). 
Interestingly, widespread pain was the only S.P.A.C.E. symptom that was not 
significantly correlated with any other symptoms. The lack of statistically significant correlations 
among widespread pain and other centrally-mediated symptoms suggests that it may not be a 
valid contributor to the S.P.A.C.E. symptom cluster. Limited research has investigated the 
relationships among S.P.A.C.E. symptoms and widespread pain. To our knowledge, only one 
study supports a significant positive relationship between widespread pain and one symptom 
within S.P.A.C.E—depression (McClish et al., 2009). This study, however, dichotomized those 
with and without depression based on scores of a continuous patient-reported outcome measure, 
threatening the precision and statistical conclusion validity of the significant findings. To 
quantify depression in our sample, we utilized the PROMIS® Depression Short Form (SF) which 
has been psychometrically validated in SCD populations (Keller et al., 2017; Kroenke et al., 
2014). Thus, the conflicting evidence between our study and one other (McClish et al., 2009) 
may be explained by differences in how depression was evaluated.  
Besides widespread pain, our study highlighted that many S.P.A.C.E. symptoms were 
moderately and significantly correlated with one another. Sleep impairment and fatigue 
moderately correlated with three out of the four remaining S.P.A.C.E. symptoms—anxiety, 
depression, and cognitive function. Further many S.P.A.C.E. symptoms (i.e., sleep impairment, 
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widespread pain, anxiety, cognitive function, and fatigue) were moderately and significantly 
associated with pain interference. Further, our findings suggest that centrally-mediated 
symptoms have an association with pain interference, or the impact pain has on social, cognitive, 
emotional, and physical function (Amtmann et al., 2010). These findings are consistent with 
previous research that supports similar relationships among centrally-mediated symptoms in non-
SCD populations (Davis et al., 2017; Robert Knoerl et al., 2018; Shattuck & Muehlenbein, 
2016). Comprehensive evaluation and management of S.P.A.C.E. symptoms may facilitate 
improvements in social, cognitive, emotional, and physical function among patients with SCD. 
However, many S.P.A.C.E. symptoms may not be considered when evaluating patients during 
routine outpatient clinic visits. Symptom severity in our study was evaluated during outpatient 
clinic visits using PROMIS® short form patient-reported outcome (PRO) measures. Many 
patients were able to complete these measures while waiting to see their provider. Further, 
PROMIS® provides interpretable score ranges that correspond to within normal limits, mild, 
moderate, and severe. Evaluating S.P.A.C.E. symptoms in clinical settings—perhaps with 
PROMIS® short form measures—can facilitate individualized pain management approaches 
such as referrals to specialists (e.g., integrative health and palliative care providers) and ancillary 
psychiatric resources. 
This study also evaluated the relationships among S.P.A.C.E. symptoms, average daily 
opioid consumption, and pain. Widespread pain was the only S.P.A.C.E. symptom significantly 
correlated with opioid consumption, pain intensity, and P.A.I.N.S. Since widespread pain and 
P.A.I.N.S. are both constructs operationalized based on the distribution of pain, strong and 
significant correlations were expected.  
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Low correlations among the remaining S.P.A.C.E. symptoms (sleep impairment, anxiety, 
depression, cognitive function, and fatigue), average daily opioid consumption, and pain conflict 
with empirical evidence among patients with SCD (Ameringer et al., 2014; Carroll et al., 2016b 
James L. Levenson et al., 2008; Moscou-Jackson, Gyasi, Finan, Campbell, & Smyth, Joshua M., 
Haythornthwaite, 2016). These conflicting findings may be explained by low symptom severity 
and our small sample size. First, anxiety and depression severity were low compared to 
PROMIS® normative sample means. Further, based on the mean pain intensity score (X̄=3.41), 
many participants reported no or minimal pain. Low symptom severity may have limited our 
ability to report accurate correlations among S.P.A.C.E. symptoms, opioid consumption, and 
pain. Second, our small sample size may have increased the probability of a Type II error (false 
negative). 
This study has several limitations. First, although this study included both adolescents 
and young adults from two separate outpatient clinics, the sample population was recruited from 
only one academic medical center. Thus, this sample is not fully representative of all adolescents 
and young adults with SCD. Second, many patients (n=6) self-reported taking opioids that were 
not documented in the EMR. Half of these patients (n=3) reported taking an opioid that had been 
discontinued. Empirical evidence suggests that many patients save opioids that have been 
previously prescribed and use them to manage subsequent pain episodes without provider 
guidance/authority (McCabe, West, & Boyd, 2013; Voepel-Lewis, Wagner, & Tait, 2015). 
Further, one self-reported opioid consumption diary was excluded based on suspected entry 
error. Overall, baseline self-reported opioid consumption reports may have been biased due to 
entry error and recall bias. Third, threats to statistical conclusion validity (i.e., low symptom 
severity, small sample size) may have limited the ability to accurately report correlations among 
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S.P.A.C.E. symptoms, opioid consumption, and pain. Lastly, although these findings support 
significant associations between several centrally-mediated symptoms and pain interference, the 
study’s cross-sectional design limits the ability to make causal inferences among S.P.A.C.E. 
symptoms and pain.  
In conclusion, this study is the first to evaluate the severity and co-occurrence of all 
symptoms within a symptom cluster, S.P.A.C.E. Our study found that multiple S.P.A.C.E. 
symptoms (i.e., sleep impairment, widespread pain, anxiety, cognitive function, and fatigue) and 
pain interference are moderately and significantly associated. Our study also found that 
widespread pain was the only S.P.A.C.E. symptom associated with opioid consumption. Due to 
the cross-sectional design of the current study, further research that evaluates the predictive 
relationships among S.P.A.C.E. symptoms, pain interference, and opioid consumption 
longitudinally is needed.  
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TABLE 2 
Demographic Characteristics, N=48 
Variable N (%) 
Age  
Mean (SD) 22.8 (5.9) 
Range 14-35 
Sex  
Female 27 (56.4) 
Male 21 (43.8) 
Race  
African American 47 (97.9) 
More than one race 1 (2.1) 
Ethnicity  
Not Hispanic or Latino 47 (97.9) 
Unknown or do not wish to report 1 (2.1) 
Education  
In middle school 1 (2.1) 
In high school 11 (22.9) 
Did not complete high school 3 (6.3) 
Completed high school 4 (8.3) 
Some college or technical training 16 (33.3) 
University undergraduate degree 12 (25) 
University post graduate degree 1 (2.1) 
Sickle Cell Genotype  
HbSS 35 (72.9) 
HbSC 10 (20.8) 
HbSβ0 1 (2.1) 
HbSβ+ 2 (4.2) 
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TABLE 3 
Descriptive Statistics of S.P.A.C.E. Symptoms, N=48 
Note. SD=standard deviation; PROMIS®=Patient Reported Outcomes Measurement Information 
System; SF=short form; MISCI=Multidimensional Inventory of Subjective Cognitive 
Impairment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Mean SD Minimum Maximum 
PROMIS® Sleep Impairment SF 56.63 9.05 30 75 
Widespread Pain Index 4.02 3.55 0 12 
PROMIS® Depression SF 47.17 9.53 37.1 73.5 
PROMIS® Anxiety SF 49.88 11.42 37.1 80 
MISCI 50.33 4.63 44 61 
PROMIS® Fatigue SF 52.99 11.24 33.1 77.7 
 
 
110 
 
TABLE 4 
Descriptive Statistics of Pain Variables, N=48 
Note. SD=standard deviation; MME=Morphine Milliequivalents; PROMIS®=Patient Reported 
Outcomes Measurement Information System; SF=Short Form; P.A.I.N.S.=Pain Area and 
Intensity Number Summation; +Outlier excluded (n=47); *pain intensity, widespread pain, and 
P.A.I.N.S. data were only available for n=45 
 
 
 
Variable Mean SD Minimum Maximum 
Opioid Consumption MME+ 22.1 42.58 0 246 
PROMIS® Pain Interference SF 55.56 10.91 41.6 75.6 
Pain Intensity* 3.41 2.57 0 9.71 
Widespread Pain (GeoPain)* 2.79% 3.21 0% 13.82% 
P.A.I.N.S.* 1.25% 1.73 0% 7.19% 
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Table 5 
Pairwise Correlations, N=48 
Note. P.A.I.N.S. data was only available for N=45; *Indicates significant correlation after Bonferroni correction p<0.0009; +Outlier 
excluded (n=47) 
 
Item Number 1 2 3 4 5 6 7 8 9 10 11 
(1) Sleep Impairment 1.00    
 
(2) Widespread Pain 0.26  1.00   
 
(3) Anxiety 0.49* 0.21 1.00  
 
(4) Depression 0.46* 0.20 0.75* 1.00 
 
(5) Cognitive Function -0.54* -0.28 -0.39 -0.26 1.00   
 
(6) Fatigue 0.56* 0.37 0.53* 0.42* -0.44* 1.00  
 
(7) Opioid Consumption+ 0.25 0.51* 0.27 0.10 -0.17 0.31 1.00 
 
(8) Pain Interference 0.49* 0.65* 0.47* 0.28 -0.45* 0.59* 0.57* 1.00   
 
(9) Pain Intensity 0.33 0.50* 0.21 0.15 -0.35 0.40 0.28 0.42 1.00 
 
(10) Widespread Pain (GeoPain) 0.17 0.66* 0.22 0.06 -0.20 0.23 0.31 0.53* 0.51* 1.00  
(11) P.A.I.N.S. 0.28 0.67* 0.28 0.13 -0.35 0.35 0.35 0.58* 0.76* 0.92* 1.00 
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Figure 3 
GeoPain @ Home Mobile Application Body Map 
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Figure 4 
Consort Flow Diagram of Study Sample 
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CHAPTER IV 
Centralized Pain and Pain Catastrophizing as Predictors 
 of Opioid Consumption and Pain Interference 
Abstract 
Introduction: Empirical evidence suggests that a subset of patients with SCD have centralized 
pain. Research among other centralized pain populations suggests that many patients with 
centralized pain consume more opioids due to opioid non-responsiveness. Further, individual 
patient factors like pain catastrophizing have been associated with opioid use and misuse. 
Limited research has evaluated the impact that centralized pain and pain catastrophizing have on 
opioid consumption and pain interference among adolescents and young adults with SCD 
Purpose: The purpose of this prospective, predictive study was to 1) describe baseline 
centralized pain and pain catastrophizing among adolescents and young adults with SCD, and 2) 
evaluate the predictive relationships among baseline centralized pain, pain catastrophizing, and 
two primary outcome variables—opioid consumption and pain interference one month post-
baseline. 
Patients and Methods: Forty-eight adolescents and young adults completed baseline measures 
of centralized pain and pain catastrophizing. After baseline, participants received weekly text 
messages which included pain interference and opioid consumption surveys. Multi-predictor 
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two-part models were used to evaluate the predictive relationships among baseline variables, 
pain interference, and opioid consumption.  
Results: Forty-eight adolescents and young adults aged 14-35 (X̄=22.8; SD=5.9) completed 
baseline measures of centralized pain and pain catastrophizing. Thirty-three participants 
completed longitudinal measures of opioid consumption and pain interference throughout the 
one month study period. Twenty-five percent of our sample (n=12) had a centralized pain score ≥ 
13 on the 2011 ACR Fibromyalgia Survey Criteria, indicating positive centralized pain. 
Centralized pain significantly increased the odds of consuming opioids (OR=1.2) and having 
pain interference (OR=1.46). Further, baseline centralized pain was significantly predictive of 
opioid consumption (β=0.13) and pain interference (β=0.05). The average marginal effects of 
centralized pain on opioid consumption and pain interference were 4.06 and 1.05, respectively. 
Thus, as centralized pain scores increased, average daily opioid consumption increased by 4.06 
MME and pain interference scores increased by 1.05 points. Pain catastrophizing scores ranged 
from 0-50, with a mean severity of 16.23 (SD=13.36). Contrary to our hypothesis, pain 
catastrophizing scores significantly predicted less opioid consumption (β=-0.03). Further, pain 
catastrophizing scores had an average marginal effect of -0.77 on average daily opioid 
consumption MME. In the pain interference model, higher pain catastrophizing scores 
significantly increased the odds of having pain interference (OR=1.05). However, pain 
catastrophizing scores did not significantly predict longitudinal pain interference in the subset of 
patients (n=40) that had pain interference scores > 0. 
Conclusion: Patients with centralized pain are at a greater risk of consuming opioids and more 
likely to experience pain that interferes with social, emotional, and physical function. Centralized 
pain can also predict opioid consumption and pain interference over time. Knowledge of the 
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presence of centralized pain can guide identification of high-risk patients and inform 
individualized pain management strategies. Overall, proper identification and management of 
centralized pain may reduce pain and opioid use and improve quality of life among patients with 
SCD.   
Introduction 
 Acute pain, or vaso-occlusive pain crisis (VOC), is the most common reason for health 
service utilization among patients with sickle cell disease (SCD) (Platt et al., 1991; Vacca Jr & 
Blank, 2017). Despite the impact of pain and health service use among these patients, limited 
pharmacologic and non-pharmacologic interventions have a limited effect in managing daily 
pain (Wally R Smith et al., 2008). Research among other pain populations has identified two 
clinical characteristics, centralized pain and pain catastrophizing, among others, that may predict 
daily pain, and opioid response and use (K Phillips & Clauw, 2013; Kristine Phillips & Clauw, 
201; M O Martel et al., 2013; Marc O Martel et al., 2014; Morasco, Turk, Donovan, & Dobscha, 
2013). 
  First, centralized pain is pain that arises from altered nociception with minimal or no 
tissue damage or evidence for disease or lesion of the somatosensory system (Latremoliere & 
Woolf, 2009; Marchand, 2008; Woolf, 2011). Patients with centralized pain often present 
clinically with widespread pain, increased pain sensitivity, reduced physical function, and opioid 
non-responsiveness (K Phillips & Clauw, 2013; Kristine Phillips & Clauw, 2011). Opioid non-
responsiveness is a lack of pain relief or increased pain intensity after opioid use, leading to 
increased opioid consumption (Brummett et al., 2013; Corli et al., 2017; Hanks & Forbes, 1997; 
Janda et al., 2015; Wasserman et al., 2014). Empirical evidence suggests patients with SCD who 
receive chronic opioid therapy present with many centralized pain manifestations—increased 
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pain hyperalgesia, temperature sensitivity, and depressive symptoms and reduced function (C. P. 
Carroll et al., 2016b). However, the presence of centralized pain and the associated risk of opioid 
non-responsiveness is generally not considered by clinicians when prescribing analgesics.  Thus, 
there is a clinical need to determine which individuals with SCD have centralized pain and 
consequently may be more susceptible to opioid misuse. 
In addition to opioid non-responsiveness, a growing body of literature describes patterns 
and personal factors that are linked to opioid use and misuse among patients with chronic or 
centralized pain (Grattan, Sullivan, Saunders, Campbell, & Von Korff, 2012; Jamison, 
Serraillier, & Michna, 2011; M O Martel et al., 2013; Marc O Martel et al., 2014). Several 
studies have found associations between pain catastrophizing and opioid misuse among patients 
with chronic pain (M O Martel et al., 2013; Marc O Martel et al., 2014; Morasco et al., 2013). 
Catastrophizing occurs when a patient has irrational thoughts about their pain including 
rumination, magnification and helplessness (Citero et al., 2007; Quartana, Campbell, & Edwards, 
2009). Pain catastrophizing is often described as an exaggerated, negative cognitive-affective 
response to current or anticipated pain and has been associated with increased pain sensitivity 
and severity among patients with SCD (N Bakshi et al., 2017; Graves & Jacob, 2014). However, 
there is a paucity of literature that has evaluated the relationship between pain catastrophizing 
and opioid use within the SCD population (Patrick H Finan et al., 2018).  
In summary, there are gaps in the literature regarding the relationships among centralized 
pain, pain catastrophizing, opioid consumption, and pain interference. To address these gaps, we 
used prospective, predictive study design and aimed to 1) describe the incidence and severity of 
baseline centralized pain and pain catastrophizing, and 2) evaluate the predictive relationships 
among baseline centralized pain and pain catastrophizing severity, weekly opioid consumption, 
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and pain interference within one month of baseline phenotyping. The overarching hypothesis of 
this study was that baseline centralized pain severity and pain catastrophizing severity would 
predict average daily opioid consumption (MME) and weekly pain interference one month post-
baseline in adolescents and young adults with SCD. 
Methods 
Sample and Setting  
Adolescents and adults with SCD (N=48) were recruited between 8/2019-12/2020 from 
the Pediatric and Adult Comprehensive Sickle Cell Clinics at Mott Children’s Hospital and 
Michigan Medicine. Patients were included in the study if they were between the ages of 14 and 
35 and could speak and read English. Patients were excluded from the study if they did not own 
a smartphone. The study was approved by the University of Michigan Institutional Review 
Board.  
Recruitment and Data Collection 
 Recruitment and baseline data collection procedures were previously described in 
Chapter III. Briefly, potentially eligible patients were pre-screened via chart review and 
discussion with clinic providers. The PI or trained research assistant discussed study procedures, 
obtained informed consent, and collected baseline data with all study participants during their 
outpatient clinic appointment. Two participants who did not have an upcoming outpatient 
appointment met with the PI or trained research assistant outside of clinic to provide informed 
consent and complete baseline data. 
To address the study aims, participants completed electronic Qualtrics™ surveys 
assessing the sample’s demographic characteristics, centralized pain, pain catastrophizing, opioid 
consumption, and pain interference. The survey order was randomized via the randomizer 
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element within Qualtrics™. Following survey completion, the PI or research assistant instructed 
participants on how to download the GeoPain @ Home mobile application (app) on their 
personal cell phone. Participants were instructed on how to use the app and completed their 
baseline data.  
After baseline, participants were instructed to complete the body map in the GeoPain @ 
Home app every day for 30 days. Daily reminders were enabled within the app so that 
participants received a notification every day to fill out the body map. To collect longitudinal 
pain interference and opioid consumption information, participants received a Qualtrics™ SMS 
text message containing a link to the pain interference and opioid consumption surveys every 
Friday for 30 days (four times total).  
Measures 
Demographic Survey. Participants self-reported their age, gender, education level, and sickle 
cell genotype within the baseline demographic survey. Sickle cell genotype was confirmed in the 
electronic medical record (EMR) by the PI or research assistant. 
ACR 2011 Fibromyalgia Survey Criteria. The ACR 2011 Fibromyalgia Survey Criteria was 
used to evaluate the degree of centralized pain (Wolfe et al., 2016). The survey contains two 
subscales, 1) the Widespread Pain Index (WPI) (19 items) evaluating the presence or absence of 
pain over the last 7 days in 19 different body regions, and 2) the Symptom Severity Scale (SSS) 
(6 items) evaluating the severity and presence of six comorbid symptoms. Scores from the WPI 
and the SSS are summed to create a total survey score ranging from 0-31 (Wolfe et al., 2016). 
Empirical evidence supports the measure’s internal consistency reliability (α=0.71), validity 
(content and convergent), and responsiveness (Häuser et al., 2012; Neville et al., 2018; Wolfe et 
al., 2016). Further, evaluations of ACR 2011 Fibromyalgia Survey Criteria’s sensitivity and 
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specificity support the measure’s ability to identify criteria positive patients, or those with 
centralized pain (Wolfe et al., 2016). 
Pain Catastrophizing Scale. The Likert-type Pain Catastrophizing Scale (PCS) assess thoughts 
and feelings about pain within 13-items (Sullivan, Bishop, & Pivik, 1995). Total PCS scores 
range from 0 to 52 with higher scores indicative of greater catastrophic thinking about pain. The 
PCS has demonstrated strong internal reliability (α= 0.93), convergent and discriminant validity, 
and structural validity based on confirmatory factor analysis results (Osman et al., 1997).   
PROMIS® Short Form v1.0 – Pain Interference 4a. The 8-item PROMIS® Pain Interference 
Short Form assesses the self-reported consequences of pain on social, cognitive, emotional, 
physical, and recreational activities over the previous 7 days using a 5-point Likert scale (Cella et 
al., 2010). Raw scores range from 8 to 40 with higher scores indicating more activity interference 
due to pain (Cella et al., 2010). Previous psychometric testing of the PROMIS® Pain 
Interference Short Form supports the measures’ internal consistency reliability (α= 0.90 to 0.99), 
test-retest reliability (ICC 0.83 to 0.95), and sensitivity in adolescents and adults with centralized 
pain (Amtmann et al., 2010; Broderick et al., 2013). 
Opioid Consumption. Participants self-reported which, if any, opioids they were taking, and the 
average number of pills taken per day within the previous seven days within the Qualtrics™ 
Opioid Consumption survey. The average number of pills taken per day were converted into 
average daily milligram morphine equivalents (MME) using the Oregon Pain Guidance Opioid 
Conversion Calculator (2017). Participants completed the Opioid Consumption survey at 
baseline and every Friday for 30 days (four times total). 
GeoPain @ Home Mobile Application. Daily pain intensity was included as a covariate within 
our predictive models. Participants reported daily pain intensity using a color scale from 0 to 10 
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within the GeoPain™ @ Home interactive body map (MoxyTech Inc., MI). After selecting their 
pain intensity, participants shaded the corresponding body area. If varying pain intensity was 
reported in different body regions, all intensity scores were averaged to derive an overall body 
map pain intensity score. Participants were instructed to complete a body map daily throughout 
the 30-day study period. Daily pain intensity scores were aggregated into an average weekly pain 
intensity score. Thus, each participant had one baseline pain intensity score and four average 
weekly pain intensity scores.  
Statistical Analyses 
Electronic survey and mobile application data were exported from Qualtrics™ and the 
GeoPain @ Home internet server and analyzed using Stata software (StataCorp, 2017). 
Descriptive statistics (e.g. means, frequencies, 95% confidence intervals, and standard 
deviations) were calculated for all variables and covariates including demographic 
characteristics, pain catastrophizing, centralized pain, pain intensity, opioid consumption MME, 
and pain interference. For all PROMIS® Pain Interference SF scores, the raw total scores were 
converted to T-scores (mean=50, standard deviation=10) using the PROMIS® Health Measures 
Scoring Service (“PROMIS® Cooperative Group. Unpublished manual for the Patient Reported 
Outcomes Measurement Information System (PROMIS®) (Version 1.1.v 9)”).  
The Oregon Pain Guidance Opioid Conversion Calculator (2017) was used to convert 
opioid use into average daily morphine milliequivalents (MME) based on Opioid Consumption 
Surveys and corresponding electronic medical record (EMR) dosages. We excluded one opioid 
consumption diary based on suspected entry error (700 MME). Six participants reported taking 
opioids that were discontinued. In these instances, average daily opioid consumption MME was 
calculated from the discontinued prescriptions. Further, three participants reported taking 
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codeine with no EMR prescription history. Since it is possible that these participants were 
prescribed opioids from outside institutions, we utilized standard-adult dosages of 
codeine/acetaminophen (30/300mg) from Chronic Pain Clinical Practice Guidelines to calculate 
average daily opioid consumption MME for these three participants (Michigan Medicine Clinical 
Care Guidelines, 2016). 
To evaluate the predictive relationships among centralized pain, pain catastrophizing,  
and our two outcome variables, pain interference and opioid consumption, we ran a series of 
multi-predictor two-part models for mixed discrete-continuous outcomes. All models 
incorporated the nesting of observations within person due to the longitudinal experimental 
design (cluster-adjusted standard errors). Two-part models simultaneously use a logit model to 
predict the probability of a binary zero versus a positive outcome, and also an ordinary least 
squares regression model to predict the positive outcome (Belotti, Deb, Manning, & Norton, 
2015). Since pain interference scores range from 8-40, with a score of 8 representing no pain 
interference, we rescaled the total scores with a range from 0-32.  Using two-part models for our 
analyses allowed us to include all pain interference and opioid consumption data, including zero 
values. We evaluated the centrality and dispersion of pain interference and opioid consumption 
data with and without zero values. The distribution of each dependent variable was right skewed 
even when analyzing positive values. For this reason, we used ordinary least squares (OLS) 
linear regression models with logged non-zero dependent variables to predict the positive values 
within each two-part model. Since both our dependent variables were logged, we used a 
nonparametric smearing retransformation method, Duan’s smearing retransformation, to produce 
interpretable fitted values of the two-part models (Duan, 1983). Consistent with Duan (1983), we 
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used nonparametric bootstrapping to re-estimate the model and re-compute the standard errors 
and confidence intervals (Belotti et al., 2015; Duan, 1983). 
Age and sex were two demographic covariates included in the models. Additionally, to 
account for the effect of pain intensity on pain interference and opioid consumption, we included 
longitudinal pain intensity scores as a covariate within each model. Three participants were 
unable to download the GeoPain @ Home mobile app on their personal cell phone to provide 
baseline and longitudinal pain intensity data. Thus, baseline pain intensity scores were reported 
by 45 participants. After baseline, 34 participants completed a total of 746 daily body maps out 
of a possible 1440 (51.8% adherence). Baseline and average weekly pain intensity scores 
comprised 162 total pain intensity scores that were used in the predictive analyses.  
Results 
Demographics 
Sample demographic information of all participants (N=48) is presented in Table 1. 
Briefly, participants had a mean age of 22.8 years (SD= 5.9; range: 14-35 years). The majority of 
the sample were female (56.4%), African American (97.9%), and non-Hispanic (97.9%). The 
most common sickle cell genotypes were HbSS (72.9%) and HbSC (20.8%).  
Data Completion 
 All participants (N=48) completed baseline demographics pain catastrophizing, 
centralized pain, opioid consumption, and pain interference surveys. After baseline, participants 
were sent weekly pain interference and opioid consumption surveys via a Qualtrics™ SMS text 
message. Throughout the four-week study period, 33 participants completed 91 pain interference 
and 91 opioid consumption surveys (47.4% adherence).  
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Descriptive Statistics of Baseline Variables 
 Baseline centralized pain, pain catastrophizing, pain intensity, pain interference and 
opioid consumption descriptive statistics are provided in Table 2. Centralized pain scores ranged 
from 1 to 20 with an average score of 8.96 in our sample. A total of 12 participants (25%) had a 
centralized pain score ≥ 13, indicating positive centralized pain. Mean pain catastrophizing 
scores were relatively low (X̄= 16.23), with a wide total score range from 0-50, with higher 
scores signifying greater catastrophic thinking about pain. However, 75% (n=36) of our sample, 
had total pain catastrophizing scores that were ≤ 25.  At baseline, participants reported opioid 
consumption of 22.1 MME per day, on average. Baseline pain interference scores ranged from 
41.6-75.6 with a mean score of 55.56. 
Descriptive Statistics of Longitudinal Variables 
 Descriptive statistics of longitudinal daily opioid consumption MME and pain 
interference are provided within Table 3. Mean opioid consumption was 18.58 MME per day 
with a wide range of 0 to 150 MME. Pain Interference scores were about 0.5 standard deviations 
higher than the PROMIS® normative sample mean, on average. Lastly, average weekly pain 
intensity scores (X̄= 2.56) were relatively low throughout the 30-day study period. 
Opioid Consumption Model Results 
Table 4 provides the results of the two-part model that evaluated the predictive 
relationships among centralized pain, pain catastrophizing, and average daily opioid 
consumption MME. Higher centralized pain scores increased the odds of consuming opioids 
[Odds Ratio (OR)=1.2; 95% Confidence Interval (CI)= 1.04 – 1.38]. In the sample that 
consumed opioids (n=30), centralized pain scores predicted higher opioid consumption (β=0.13; 
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CI = 0.08 – 0.19). Pain catastrophizing scores did not significantly increase the odds of 
consuming opioids (OR= 0.99; CI = 0.94 – 1.05). In the sample that consumed opioids (n=30), 
pain catastrophizing scores significantly predicted less opioid consumption (β=-0.03; CI = -0.06 
– -0.01). 
 Table 5 provides the average marginal effects for each independent variable on average 
daily MME for the combined two-part model. Both effects were significant at the 5% level. The 
marginal effect of centralized pain on average daily MME is depicted in Figure 5. As centralized 
pain scores increased, opioid consumption increased by 4.06 MME while controlling for age, 
sex, pain intensity, and pain catastrophizing. As pain catastrophizing scores increased, opioid 
consumption decreased by -0.77 MME while controlling for age, sex, pain intensity, and 
centralized pain. 
Pain Interference Model Results 
Table 6 includes the results of the two-part model which evaluated the predictive 
relationships among the independent variables and longitudinal pain interference scores. Similar 
to the opioid consumption model, higher centralized pain scores significantly increased the odds 
of having pain interference (OR=1.46; CI = 1.21 – 1.76). In the subset of patients with pain 
interference scores >0 (n=40), baseline centralized pain scores were positively and significantly 
predictive of longitudinal pain interference (β=0.06; CI = 0.02 – 0.21). Higher pain 
catastrophizing scores significantly increased the odds of having pain interference (OR=1.05; CI 
= 1.01 – 1.1). However, pain catastrophizing scores did significantly predict longitudinal pain 
interference in the sample that had pain interference scores > 0 (n=40). 
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Average marginal effects of centralized pain and pain catastrophizing on pain 
interference are provided in Table 7. Age, gender, and pain intensity were all controlled for when 
calculating average marginal effects of centralized pain and pain catastrophizing on pain 
interference. Centralized pain had a significant marginal effect of 1.05 on pain interference 
(Figure 6). As centralized pain scores increased, pain interference scores also increased by 1.05. 
Pain catastrophizing did not have significant average marginal effect on pain interference.  
Discussion 
 In this study we aimed to 1) describe the incidence and severity of baseline centralized 
pain and pain catastrophizing, and 2) evaluate the predictive relationships of baseline predictors 
(i.e., centralized pain and pain catastrophizing) on average daily opioid consumption and weekly 
pain interference within one month of baseline phenotyping.  
 Twenty-five percent of the participants in our study were positive for centralized pain 
based on the ACR 2011 Fibromyalgia Survey Criteria. This percentage is comparable with other 
research studies that have evaluated centralized pain among patients with SCD (Amanda M. 
Brandow et al., 2013; C. M. Campbell et al., 2016; M O Ezenwa et al., 2015; Eufemia Jacob et 
al., 2015). Further, this study found significant and positive predictive relationships between 
centralized pain and two primary outcomes—opioid consumption and pain interference. The 
positive relationship found between centralized pain and opioid consumption is supported in the 
literature (Brummett et al., 2013; Janda et al., 2015). Patients and clinicians frequently increase 
opioid dosages when an opioid is ineffective in managing pain, which consequently results in 
opioid non-responsiveness  (Brummett et al., 2013; Hanks & Forbes, 1997; Janda et al., 2015; 
Wasserman et al., 2014).  
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Despite the evidence suggesting opioid non-responsiveness in the centralized pain 
population (Corli et al., 2017; Hanks & Forbes, 1997; Wasserman et al., 2014), centralized pain 
is rarely considered when managing daily pain in the SCD population. Many studies conducted 
among patients with SCD have identified patients with and without centralized pain using 
quantitative sensory testing (QST) (C. M. Campbell et al., 2016; C. P. Carroll et al., 2016a; 
Eufemia Jacob et al., 2015). Although evidence supports the strong psychometric properties of 
QST methods, their use and feasibility within clinical and research settings is limited due to 
equipment costs, administration time, and extensive training requirements (Rolke et al., 2006).  
To our knowledge, our study is the first to evaluate centralized pain among patients with 
SCD using a patient-reported outcome (PRO) measure, the ACR 2011 Fibromyalgia Survey 
Criteria. As an alternative to QST, administering this PRO measure in clinical or research 
settings is convenient and feasible. Further, empirical evidence supports the sensitivity and 
specificity of the survey to differentiate those with and without centralized pain (Wolfe et al., 
2016). The ACR 2011 Fibromyalgia Survey Criteria could be useful to identify patients within 
clinical settings who may be at an increased risk for consuming more opioids and having more 
pain interference. Ultimately, measuring centralized pain in the clinical setting may facilitate 
individualized pain management including referrals to specialists (e.g., integrative health 
practitioners, palliative care providers) and the use of non-pharmacologic pain management 
approaches over ineffective pharmacologic therapies (opioids). 
The findings of our study also have implications for non-pharmacologic pain 
management approaches for SCD-associated pain. Empirical evidence supports the efficacy of 
non-pharmacologic pain management approaches for centralized pain (Eller-smith et al., 2018; 
Hassett & Williams, 2011). To our knowledge, only five randomized control trials (RCTs) 
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conducted among patients with SCD have tested the efficacy of non-pharmacologic interventions 
including yoga, massage, relaxation, healing touch, and CBT (L P Barakat et al., 2010; Miriam 
O. Ezenwa et al., 2016; Lemanek et al., 2009; Moody et al., 2017; Schatz et al., 2015; Thomas et 
al., 2013).  However, all five RCTs had either no or minimal effect on daily pain. 
There is a growing body of evidence supporting the effectiveness of cognitive behavioral 
therapy (CBT) to reduce pain and improve function in non-SCD centralized pain populations 
(Eller-smith et al., 2018; Hassett & Williams, 2011; Hofmann, Asnaani, Vonk, Sawyer, & Fang, 
2012). Cognitive behavioral therapy refers to a wide variety of interventions such as progressive 
muscle relaxation, hypnosis, guided visual imagery, and coping skills training (R Knoerl, Lavoie 
Smith, & Weisberg, 2015). There are several different mechanisms that may contribute to CBT 
efficacy (Eller-smith et al., 2018; Seminowicz et al., 2013). For example, CBT interventions 
have been associated with an increase in gray matter within pain processing areas of the brain 
including the subgenual anterior cingulate, sensorimotor, and prefrontal and posterior parietal 
cortices, as well as hippocampus (Seminowicz et al., 2013). An increase in gray matter within 
many of these areas has been associated with changes in pain perception and thoughts related to 
pain (e.g., decreased pain catastrophizing) (Seminowicz et al., 2013).  
Two of the non-pharmacologic RCTs conducted among patients with SCD have 
investigated the efficacy of CBT-based interventions (Lamia P. Barakat, Schwartz, Salamon, & 
Radcliffe, 2010; Schatz et al., 2015). Despite the established benefit of CBT in other centralized 
pain populations, these studies had either no or minimal effects in reducing pain (Lamia P. 
Barakat et al., 2010; Schatz et al., 2015). Minimal effects within these studies may be due to 
internal validity threats (i.e., small sample sizes, no participant blinding, lack of intervention 
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standardization). Future non-pharmacologic intervention studies are needed to evaluate the 
effectiveness of CBT among patients with SCD. 
Baseline pain catastrophizing scores were relatively low in our sample. Average scores 
pain catastrophizing scale (PCS) scores were 16.23; previous literature has reported much higher 
mean PCS scores (X̄= 28.5-29)  among patients with SCD (N Bakshi et al., 2017). In contrast to 
our hypothesis, pain catastrophizing significantly predicted less opioid use. These findings 
conflict with research supporting a predictive relationship between pain catastrophizing and 
increased opioid consumption in SCD populations (Patrick H Finan et al., 2018; M O Martel et 
al., 2013; Morasco et al., 2013). These conflicting findings may be explained by the overall low 
pain catastrophizing scores within our sample, as previously described. Total PCS scores can 
range from 0-52. However, 75% of our sample had total PCS scores ≤ 25.  
Low mean pain catastrophizing in our study may be explained by recall bias, or an 
inability to accurately remember previous events (Gendreau, Hufford, & Stone, 2003). The PCS 
asks respondents to recall their thoughts about pain from a previous painful event (Sullivan et al., 
1995). Empirical evidence suggests that emotional processes may bias the ability to recall past 
negative events (Chan, Goodwin, & Harmer, 2007; Gendreau et al., 2003; Leppanen, 2006). 
Further, the ability to recall a past painful event may have been confounded by relatively low 
pain intensity scores within our sample. Many participants within our sample reported either no 
or minimal daily pain throughout the study period. These participants may have had difficulty 
accurately recalling a previous painful event and responding to the questions within the PCS. In 
summary, low mean pain catastrophizing due to recall bias may have limited the ability of our 
statistical model to accurately predict the relationships among pain catastrophizing, opioid 
consumption and pain interference. 
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Our conflicting findings may also be explained by the way pain catastrophizing was 
measured. The PCS evaluates dispositional pain catastrophizing or the trait-like tendency of 
catastrophic thinking. Empirical evidence suggests that measuring situational pain 
catastrophizing, immediately following a painful event, may be more appropriate among patients 
who experience daily pain (C. M. Campbell, Kronfli, et al., 2011; Edwards, Campbell, & 
Fillingim, 2005). Prior research among patients with centralized pain compared measures of 
dispositional and situational pain catastrophizing and suggests that situational pain 
catastrophizing has a much stronger association with experimental pain responses (C. M. 
Campbell, Kronfli, et al., 2011). Thus, the results of our predictive models may have supported 
our hypothesis if we had measured situational catastrophizing at multiple time points throughout 
the study period.  
Our research study has several limitations. First, low pain catastrophizing severity and 
potential recall bias during baseline survey completion may have limited our ability to accurately 
predict the relationships among pain catastrophizing, opioid consumption and pain interference. 
Second, although the statistical modeling procedures used within this study were appropriate 
based on the distribution of our data, our findings should be interpreted with caution due to our 
small sample size. Further, many patients did not adhere to completing weekly opioid 
consumption and pain interference surveys. Fifteen participants did not complete any opioid 
consumption or pain interference surveys after baseline. These missing data may have biased the 
findings of our study and reduced the representativeness of our sample. Our study is also limited 
by the discrepancies found in our self-reported opioid consumption data. One baseline self-
reported opioid consumption diary was excluded from our analyses due to a suspected entry error 
of 700 MME. Also, a number of participants reported taking opioid prescriptions that were either 
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discontinued or absent from the EMR. The discrepancies in self-reported opioid consumption 
may be suggestive of recall bias which may have confounded our results. Lastly, our study only 
included patients from one academic medical center, limiting the generalizability of our findings 
to all patients with SCD.  
In conclusion, our findings did not support positive relationships among pain 
catastrophizing, opioid consumption, and pain interference. These findings should be interpreted 
with caution due to suspected recall bias and low variability of pain catastrophizing severity 
within our sample. Our study also found that the centralized pain is associated with increased 
opioid consumption. Evaluating centralized pain in clinical and research settings—perhaps with 
the ACR 2011 Fibromyalgia Survey—is vital to guide individualized pain management. 
Clinicians may use centralized pain assessments to identify those who are at an increased risk for 
consuming more opioids and having pain that interferes with social, emotional, and physical 
function. Ultimately, clinical awareness of centralized pain may reduce daily pain and ineffective 
opioid use and improve functioning among patients with SCD. 
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TABLE 6 
Demographic Characteristics, N=48 
Variable N (%) 
Age  
Mean (SD) 22.8 (5.9) 
Range 14-35 
Sex  
Female 27 (56.4) 
Male 21 (43.8) 
Race  
African American 47 (97.9) 
More than one race 1 (2.1) 
Ethnicity  
Not Hispanic or Latino 47 (97.9) 
Unknown or do not wish to report 1 (2.1) 
Education  
In middle school 1 (2.1) 
In high school 11 (22.9) 
Did not complete high school 3 (6.3) 
Completed high school 4 (8.3) 
Some college or technical training 16 (33.3) 
University undergraduate degree 12 (25) 
University post graduate degree 1 (2.1) 
Sickle Cell Genotype  
HbSS 35 (72.9) 
HbSC 10 (20.8) 
HbSβ0 1 (2.1) 
HbSβ+ 2 (4.2) 
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Table 7  
Descriptive Statistics of Baseline Variables, N=48 
Note. SD=standard deviation; FM=Fibromyalgia; MME=Morphine Milliequivalents; 
PROMIS®=Patient Reported Outcomes Measurement Information System; SF=Short Form; 
+Outlier excluded (n=47) 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Mean SD Minimum Maximum 
Pain Catastrophizing 16.23 13.36 0 50 
ACR 2011 FM Survey Criteria 8.96 5.26 1 20 
Opioid Consumption MME+ 22.1 42.58 0 246 
PROMIS® Pain Interference SF 55.56 10.91 41.6 75.6 
Pain Intensity 3.41 2.57 0 9.71 
 
 
140 
 
Table 8  
Descriptive Statistics of Longitudinal Variables 
Note. Obs=number of observations; SD=standard deviation; FM=Fibromyalgia; MME= 
Morphine Milliequivalents; PROMIS®=Patient Reported Outcomes Measurement Information 
System; SF=Short Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Obs Mean SD Minimum Maximum 
Opioid Consumption MME 91 18.58 5.37 0 150 
PROMIS® Pain Interference SF 91 54.45 1.28 40.7 77 
Average Weekly Pain Intensity 117 2.56 0.33 0 7.8 
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Table 9 
Two-part model of pain catastrophizing and centralized pain on average daily opioid 
consumption MME  
 
 
 
 
 
Note. MME= Morphine Milliequivalents; OLS= ordinary least squares;  
S.E.= standard error; OLS regression model was conditional non-zero 
outcome; a Shows the cluster-robust standard errors; *p <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Two-part model 
Logit OLS 
 Odds Ratio 
(S.E.) a 
Coefficients 
(S.E.) a 
Pain Catastrophizing 0.99 
(0.03) 
-0.03* 
(0.01) 
Centralized Pain 1.20* 
(0.09) 
0.13* 
(0.03) 
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Table 10 
Average marginal effects for pain catastrophizing and centralized pain on average daily opioid 
consumption for combined two-part model 
a Duan smearing retransformation was used to obtain fitted values; b Nonparametric 
bootstrapping was used to calculate standard errors and confidence intervals; Controlling for age, 
gender, and pain intensity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Observed 
Coefficientsa 
Std 
Error b 
Z Value p Value 
95% C.I.b 
Lower 
Limit 
Upper 
Limit 
Pain Catastrophizing -0.77 0.35 -2.24 0.03 -1.45 -0.1 
Centralized Pain 4.06 0.99 4.08 <0.00 2.11 6.01 
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Table 11 
Two-part model of pain catastrophizing and centralized pain on weekly pain 
interference 
 
 
 
Note. OLS= ordinary least squares; S.E.= standard error; OLS regression 
model was conditional non-zero outcome; a Shows the cluster-robust 
standard errors; *p <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Two-part model 
Logit OLS 
 Odds Ratio 
(S.E.) a 
Coefficients 
(S.E.) a 
Pain Catastrophizing 1.05* 
(0.02) 
-0.001 
(0.01) 
Centralized Pain 1.46* 
(0.14) 
0.06* 
(0.02) 
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Table 12 
Marginal effects of pain catastrophizing and centralized pain on weekly pain interference 
for combined two-part model 
a Duan smearing retransformation was used to obtain fitted values; b Nonparametric 
bootstrapping was used to calculate standard errors and confidence intervals; Controlling for 
age, gender, and pain intensity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Observed 
Coefficientsa 
Std 
Error b 
Z Value p Value 
95% C.I.b 
Lower 
Limit 
Upper 
Limit 
Pain Catastrophizing 0.03 0.09 0.38 0.70 -0.14 0.20 
Centralized Pain 1.05 0.28 3.78 <0.00 0.51 1.60 
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Figure 5 
Predictive margins of centralized pain on average daily opioid consumption MME 
 
Note. A score of 13 on the ACR 2011 Fibromyalgia Survey is indicative of positive 
centralized pain  
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Figure 6 
Predictive average marginal effects of centralized pain on weekly pain interference 
 
Note. A score of 13 on the ACR 2011 Fibromyalgia Survey is indicative of positive 
centralized pain  
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CHAPTER V 
Physiologic and Psychologic Predictors of  
Opioid Consumption and Pain Interference  
Abstract 
Introduction: Many patients with sickle cell disease (SCD) experience daily pain that interferes 
with physical, emotional, and social functioning. Despite the prevalence of pain among these 
patients, few pharmacologic and non-pharmacologic management approaches effectively reduce 
daily pain and improve functioning. A co-occurring centrally-mediated symptom cluster, 
S.P.A.C.E. (i.e., sleep impairment, widespread pain, affective perturbation [depression and 
anxiety], cognitive impairment, and energy deficit [fatigue]) has been associated with increased 
daily pain among other non-SCD pain populations (e.g., fibromyalgia, temporomandibular 
disorder). No research has evaluated the impact of S.P.A.C.E. on opioid consumption and pain 
among patients with SCD. 
Purpose: The purpose of this prospective, predictive study was to evaluate the predictive 
relationships among demographic characteristics, baseline S.P.A.C.E. symptoms, and two 
primary outcome variables—opioid consumption and pain interference one month post-baseline. 
Patients and Methods: Baseline S.P.A.C.E. measures were completed by 48 adolescents and 
young adults with SCD. After baseline, participants completed weekly pain interference and 
opioid consumption surveys via SMS text messaging. Multi-predictor two-part models were used 
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to evaluate the relationships among demographic characteristics, S.P.A.C.E. symptoms, opioid 
consumption, and pain interference. 
Results: The sample included 48 adolescents and young adults aged 14-35 (X̄=22.8; SD=5.9) 
with SCD. All participants completed baseline measures of S.P.A.C.E. symptoms; however, only 
33 completed opioid consumption and pain interference surveys post-baseline. Widespread pain 
significantly increased the odds of consuming opioids (OR=1.38). Contrary to our hypothesis, 
depression significantly decreased the odds of consuming opioids (OR=0.9). Widespread pain 
was the only S.P.A.C.E symptom that had a statistically significant effect on opioid consumption 
(β=0.16) in the subset of patients who used opioids; as widespread pain scores increased, daily 
opioid consumption increased by 4.62 morphine milliequivalents (MME). Within the pain 
interference model, female gender (OR=6.94) and widespread pain (OR=1.41) increased the odds 
of having pain interference. Fatigue, however, was the only S.P.A.C.E. symptom that 
significantly predicted pain interference (β=0.04) in the subset of patients who had pain 
interference scores > 0; as fatigue severity increased, total pain interference scores increased by 
0.46 points.  
Conclusion: Widespread pain, a common manifestation of centralized pain, was significantly 
predictive of opioid use. Contrary to our hypothesis, many additional S.P.A.C.E. symptoms were 
not significantly predictive of opioid consumption and pain interference. The lack of significant 
associations may be explained by the small sample size and suboptimal data completion rates. 
Further research should investigate the impact of S.P.A.C.E. symptoms on opioid consumption 
and pain in larger, more diverse sickle cell populations to guide individualized pain management. 
As in non-SCD pain populations, a focus on treating co-occurring symptoms with targeted 
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pharmacologic and non-pharmacologic approaches may be more effective in managing 
centralized pain than opioid therapy.  
Introduction 
 Sickle cell disease (SCD), a commonly inherited red blood cell disease in the United 
States, causes several complications leading to frequent health service utilization, opioid use, and 
functional impairment (Ballas et al., 2017; Brown, Weisberg, Balf-Soran, & Sledge, 2015; 
Hildenbrand et al., 2014; Soumitri Sil et al., 2016; W T Zempsky et al., 2013). Many patients 
with SCD are receiving a stable dose of opioids (Patrick H Finan et al., 2018). Despite using 
opioids, approximately 50% of patients still report significant pain, and nearly one third continue 
to report pain almost every day (W R Smith et al., 2008).  
Arising from research conducted with several chronic pain populations, empirical 
evidence suggests that pain co-occurs with several other symptoms: sleep impairment, 
widespread pain, affective perturbation (anxiety and depression), cognitive impairment, and low 
energy (fatigue), also known as the S.P.A.C.E. symptom cluster (Davis et al., 2017; Robert 
Knoerl et al., 2018; Shattuck & Muehlenbein, 2016; D. A. Williams, 2018). Attention to the 
number of symptoms experienced at one time is important because co-occurrence of multiple 
symptoms is associated with increased symptom burden and functional impairment (Davis et al., 
2017; Robert Knoerl et al., 2018; Shattuck & Muehlenbein, 2016; D. A. Williams, 2018). 
Similarly, patients with SCD also experience symptoms within the S.P.A.C.E. symptom cluster 
(Ameringer et al., 2014; C. P. Carroll et al., 2016a; Graves & Jacob, 2014; Hoff et al., 2006; 
Jerrell et al., 2011; Karafin et al., 2018; Moscou-Jackson et al., 2015; S Sil, Cohen, et al., 2016; 
Wallen et al., 2014). More specifically, SCD patients with fatigue, depression, anxiety, and 
poorer sleep continuity report increased pain severity (Ameringer et al., 2014; C. P. Carroll et al., 
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2016b; James L. Levenson et al., 2008; Moscou-Jackson et al., 2015). Further, evidence supports 
positive relationships among anxiety, depression and opioid consumption (C. P. Carroll et al., 
2016b; James L. Levenson et al., 2008).  
Although preliminary evidence supports the relationships among some centrally-
mediated symptoms, pain, and opioid consumption, most of the research conducted among 
patients with SCD has only evaluated one or two S.P.A.C.E. symptoms. Empirical evidence 
suggests that more than 50% of patients with chronic pain present with three or more centrally-
mediated symptoms (Davis et al., 2017). Given that opioids are marginally effective in treating 
SCD-associated pain, new, individualized pain management strategies are needed that will 
address interrelated symptoms that can make pain worse. Therefore, a comprehensive evaluation 
of the predictive relationships among all S.P.A.C.E. symptoms, pain, and opioid consumption is 
necessary. Using a prospective, predictive study design, the study aim was to evaluate the 
predictive relationships among baseline S.P.A.C.E. symptoms, average daily opioid 
consumption, and weekly pain interference within one month of baseline phenotyping. Based on 
empirical evidence, the overarching hypothesis was that baseline S.P.A.C.E. symptom severity 
will predict average daily opioid consumption (MME) and weekly pain interference one month 
post-baseline in adolescents and young adults with SCD. 
Methods 
Sample and Setting  
Adolescents and adults with SCD (N=48) were recruited between 8/2019-12/2020 from 
the Pediatric and Adult Comprehensive Sickle Cell Clinics at Mott Children’s Hospital and 
Michigan Medicine. Patients were included in the study if they were between the ages of 14 and 
35 and could speak and read English. Patients were excluded from the study if they did not own 
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a smartphone. The study was approved by the University of Michigan Institutional Review 
Board.  
Recruitment and Data Collection 
 Recruitment and baseline data collection procedures were previously described in 
Chapter III. Briefly, potentially eligible patients were pre-screened via chart review and 
discussion with clinic providers. The PI or trained research assistant discussed study procedures, 
obtained informed consent, and collected baseline data from all study participants during their 
outpatient clinic appointment. Two participants did not have upcoming outpatient clinic visits 
and completed all baseline procedures outside of the clinic.  
To address the study aim, participants completed electronic Qualtrics™ surveys 
quantifying demographic characteristics, sleep impairment, widespread pain, anxiety, depression, 
cognitive function, fatigue, opioid consumption, and pain interference. The order in which 
participants completed the surveys was randomized via the randomizer element within 
Qualtrics™. Following survey completion, the PI or research assistant instructed participants on 
how to download the GeoPain @ Home mobile application (app) on their personal cell phone.  
After baseline, participants were instructed to complete the body map in the GeoPain @ 
Home app every day for 30 days. Daily reminders were enabled within the app so that 
participants were reminded to complete body maps. To collect longitudinal pain interference and 
opioid consumption information, participants received a Qualtrics™ SMS text message 
containing a link to the pain interference and opioid consumption surveys every Friday for 30 
days (four times total). 
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Measures 
Baseline Survey. Participants self-reported their age, gender, education level, and sickle cell 
genotype. Sickle cell genotype was confirmed in the EMR by the PI or research assistant. 
PROMIS® Short Form v1.0-Sleep-Related Impairment 8a. The 8-item PROMIS® Short Form 
Sleep-Related Impairment uses a 5-point Likert scale to evaluate perceptions of alertness, 
sleepiness, and tiredness during usual waking hours (Cella et al., 2010). Raw scores range from 8 
to 40 with higher scores meaning greater levels of sleep-related impairment. Psychometric 
evaluation of the measure’s internal consistency reliability (α=0.92), concurrent validity, and 
sensitivity has been conducted in a variety of populations (i.e., healthy adolescents, females with 
centralized pain, and adults with SCD) (Bernstein et al., 1994; Spinhoven et al., 2014). 
ACR 2011 Fibromyalgia Survey Criteria. The 19-item Widespread Pain Index (WPI) subscale, 
included within the ACR 2011 Fibromyalgia Survey Criteria, evaluates the presence or absence 
of pain over the last 7 days in 19 different body regions. Scores from the WPI range from 0 to 19 
and were used to operationalize widespread pain in this study. Psychometric evaluation of the 
measure’s internal consistency reliability (α=0.71), sensitivity, specificity, responsiveness, and 
validity (content and convergent) has been conducted among non-SCD pain populations (Wolfe 
et al., 2016).  
PROMIS® Short Form v1.0 – Depression 8b. Participants reported negative mood, anhedonia, 
negative views of the self, and negative social cognition within the previous 7 days using the 8-
item Likert-style PROMIS® Depression Short Form. (Cella et al., 2010). Raw scores range from 
8 to 40 with higher scores indicating greater levels of depression. Psychometric evaluation of the 
PROMIS® Depression Short Form has demonstrated the measure’s internal consistency 
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reliability (α= 0.93), convergent validity, and sensitivity in adults with centralized pain and SCD 
(Keller et al., 2017; Kroenke et al., 2014). 
PROMIS® Short Form v1.0 Anxiety 8a. Participants reported their fear, anxious misery, and 
hyper-arousal within the previous 7 days using the 8-item Likert-style PROMIS® Anxiety Short 
Form scale (Cella et al., 2010). Raw scores range from 8 to 40 with higher scores indicating 
greater levels of anxiety. Psychometric evaluation of the PROMIS® Anxiety Short Form has 
demonstrated the measure’s internal consistency reliability (α= 0.85), convergent and 
discriminant validity, and unidimensionality among adults with centralized pain (Irwin et al., 
2010; Merriwether et al., 2017) 
Multidimensional Inventory of Subjective Cognitive Impairment (MISCI). Perceived cognitive 
abilities and difficulties (i.e., mental clarity, memory, attention, executive functioning, and 
language) were quantified within the 10-item Likert-style MISCI survey (Kratz et al., 2015). 
Raw scores range from 10 to 50 with higher scores indicating better perceived cognitive 
functioning or lower cognitive impairment (Kratz et al., 2015). Psychometric evaluation of the 
MISCI’s internal consistency reliability (α=0.94), and construct and convergent validity has been 
conducted among adults with centralized pain (Kratz et al., 2015). 
PROMIS® Short Form v1.0-Fatigue 8a. Participants reported the impact and experience of 
fatigue in the past week using the 8-item Likert-style PROMIS® Fatigue Short Form (Cella et 
al., 2010). Raw scores range from 8 to 40 with higher scores indicating greater levels of fatigue. 
Psychometric evaluation of the PROMIS® Fatigue Short Form has demonstrated the measure’s 
internal consistency reliability (α=0.83), test-retest reliability (ICC=0.85), concurrent and 
divergent validity, and sensitivity in adolescents and adults with SCD (Amtmann et al., 2010; 
Broderick et al., 2013; Keller et al., 2017). 
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PROMIS® Short Form v1.0 – Pain Interference 4a. The 8-item PROMIS® Pain Interference 
Short Form evaluates self-reported consequences of pain on social, cognitive, emotional, 
physical, and recreational activities within the previous 7 days using a 5-point Likert scale (Cella 
et al., 2010). Raw scores range from 8 to 40 with higher scores indicating more activity 
interference due to pain (Cella et al., 2010). Psychometric evaluation of the PROMIS® Pain 
Interference Short Form has demonstrated the measure’s internal consistency reliability (α= 0.90 
to 0.99), test-retest reliability (ICC 0.83 to 0.95), and sensitivity testing has been conducted in 
adolescents and adults with centralized pain (Amtmann et al., 2010; Broderick et al., 2013). 
Opioid Consumption. Participants self-reported which, if any, opioids they were taking, and the 
average number of pills taken per day within the previous seven days within the Qualtrics™ 
Opioid Consumption survey. The average number of pills taken per day were converted into 
average daily milligram morphine equivalents (MME) using the Oregon Pain Guidance Opioid 
Conversion Calculator (2017). Participants completed the Opioid Consumption survey at 
baseline and every Friday for 30 days (four times total). 
GeoPain @ Home Mobile Application. Participants used the interactive body map within 
GeoPain™ @ Home app (MoxyTech Inc., MI) to report daily pain intensity. Psychometric 
evaluation of the app’s convergent validity and sensitivity has supported its use among patients 
with centralized pain (DaSilva et al., 2014; Donnell et al., 2015; DosSantos et al., 2012; 
Nascimento et al., 2014). Pain intensity is assessed via a color scale from 0 to 10 (using a slider 
bar). After selecting the intensity of their pain, participants were asked to shade the area of the 
body that corresponded to the chosen intensity. Prior to conducting analyses, average weekly 
pain intensity was calculated for each participant by taking the average of the pain scores during 
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each week throughout the 4-week long study period. Each participant had one baseline pain 
intensity score and four average weekly pain intensity scores.  
Statistical Analyses 
Electronic survey and mobile application data were exported from Qualtrics™ and the 
GeoPain @ Home internet server and analyzed using Stata software (StataCorp, 2017).  
Descriptive statistics (e.g. means, frequencies, 95% confidence intervals, and standard 
deviations) were calculated for all variables including demographic characteristics, S.P.A.C.E. 
symptoms, opioid consumption MME, and pain interference. Raw total scores of all PROMIS® 
scores were converted to T-scores (mean=50, standard deviation=10) using the PROMIS® 
Health Measures Scoring Service (“PROMIS® Cooperative Group. Unpublished manual for the 
Patient Reported Outcomes Measurement Information System (PROMIS®) (Version 1.1.v 9)”). 
PROMIS® equivalent T-scores were also used to convert cognitive function raw scores based on 
previously published conversion values (Kratz et al., 2015). 
The Oregon Pain Guidance Opioid Conversion Calculator (2017) was used to convert 
opioid use to morphine milliequivalents based on the self-reported Opioid Consumption Survey 
and corresponding electronic medical record (EMR) dosages. One opioid consumption diary was 
excluded from analyses based on suspected entry error (700 MME). Six participants reported 
taking opioids that were discontinued. In these instances, average daily opioid consumption 
MME was calculated using dosages from the discontinued prescription. Further, a few 
participants (n=3) reported taking codeine with no EMR prescription history. To calculate 
average daily MME for these opioid consumption diaries we utilized standard-adult dosages of 
codeine/acetaminophen (30/300mg) from Chronic Pain Clinical Practice Guidelines (Michigan 
Medicine Clinical Care Guidelines, 2016). 
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 We used multi-predictor two-part models to evaluate the predictive relationship among 
age, sex, S.P.A.C.E. symptoms, and the two outcome variables: pain interference and opioid 
consumption. Each model incorporated the nesting of observations within person (cluster-
adjusted standard errors) due to the study’s longitudinal design. Two-part models simultaneously 
use a logit model to predict the probability of a binary zero versus a positive outcome and an 
ordinary least squares regression model to predict the positive outcome (Belotti et al., 2015). To 
represent a score of zero, or having no pain interference, raw pain interference scores were 
rescaled to a range of 0-32 for the predictive models. The distribution of each outcome variable, 
with and without positive values, was evaluated prior to analyses. Each outcome variable was 
right skewed, even when only analyzing positive values. For this reason, we evaluated the log of 
each outcome variable to predict the positive values in the two-part model. To produce 
interpretable fitted values of the two-part models, we used a nonparametric smearing 
retransformation method, Duan’s smearing retransformation (Duan, 1983). Consistent with Duan 
(1983), bootstrapping was used to re-estimate the model and re-compute unbiased standard 
errors and confidence intervals (Belotti et al., 2015). 
Demographic covariates included within the two-part models were age and sex. Further, 
to account for the effect of pain intensity on pain interference and opioid consumption, we 
included longitudinal pain intensity scores as a covariate within each model. Thirty-four 
participants completed a total of 746 pain intensity scores via the GeoPain @ Home body map 
throughout the 30-day study period. After averaging participants’ pain intensity scores each 
week throughout the 4-week study period, there was a total of 162 pain intensity scores that were 
included in the predictive analyses.   
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Results 
Demographics 
Sample demographic information of all participants (N=48) is provided in Table 1. 
Briefly, participants had a mean age of 22.8 years (range: 14-35 years). The majority of the 
sample were female (56.4%), African American (97.9%), and non-Hispanic (97.9%). Most of the 
participants had HbSS (72.9%) or HbSC (20.8%).  
Data Completion 
 All study participants (N=48) completed baseline demographics, S.P.A.C.E. symptom 
opioid consumption, and pain interference surveys. After baseline, thirty-three participants 
completed 91 pain interference and 91 opioid consumption surveys (47.4% adherence).  
Baseline Descriptive Statistics 
S.P.A.C.E variable means, standard deviations, and score ranges are provided in Table 2. 
Briefly, mean scores for sleep impairment (X̄=56.63; SD=9.05), cognitive function (X̄=50.33; 
SD=4.63), and fatigue (X̄=52.99; SD=11.24) were higher than PROMIS® (or equivalent) 
normative sample means. Mean scores for depression (X̄=47.17; SD=9.53) and anxiety (X̄=49.88; 
SD=11.42) were slightly lower than PROMIS® normative sample means. Widespread pain, or 
the number of body sites with pain, ranged from 0-12, with 4.02 body sites with pain reported, 
on average. Average daily opioid consumption varied widely at baseline among patients with a 
range of 0-246 MME per day (X̄=21.83; SD=42.61). Lastly, baseline pain interference scores 
were more than 0.5 standard deviations higher than PROMIS® normative sample means 
(X̄=55.56; SD=10.91), with a range from 41.6-75.6. 
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Longitudinal Descriptive Statistics 
 After baseline, patients reported consuming 18.58 MME of opioids per day, on average 
(SD=5.37; range=0-150). Mean pain interference scores were about 0.5 standard deviations 
higher than the PROMIS® normative sample mean throughout the 30-day study period 
(X̄=54.45; SD=1.28; range=40.7-77). 
Opioid Consumption Model Results 
Results of the two-part model which evaluated the predictive relationships among 
demographics, S.P.A.C.E. symptoms, and opioid consumption are displayed in Table 1. Further, 
Figure 7 depicts the odds ratios and confidence intervals of the logit model. Age and female 
gender were not significantly associated with opioid consumption. Among the S.P.A.C.E. 
symptoms, widespread pain significantly increased the odds of consuming opioids [Odds Ratio 
(OR)=1.38; 95% Confidence Interval (CI) = 1.11 – 1.72]. Since higher scores on the 
Multidimensional Inventory of Subjective Cognitive Impairment are indicative of better 
perceived cognitive function, better perceived cognitive function significantly increased the odds 
of consuming opioids (OR=1.17; CI = 1.01 – 1.36). Contrary to our hypothesis, increased 
depression severity significantly decreased the odds of consuming opioids (OR=0.9; CI= 0.82 – 
1). In the subset of patients who took opioids (n=30), increased symptom severity of widespread 
pain (β=0.16; CI = 0.06 – 0.26) was significantly predictive of increased opioid consumption. 
Contrary to our hypothesis, sleep impairment, anxiety, and fatigue were not significantly 
associated with opioid consumption. 
The average marginal effects of S.P.A.C.E. symptoms on average daily opioid 
consumption MME are provided in Table 2. The average marginal effect of widespread pain was 
the only S.P.A.C.E. symptom significant at the 5% level. Widespread pain had a marginal effect 
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of 4.59 on average daily MME. Thus, as widespread pain scores increased, average daily opioid 
consumption increased by 4.59 MME (Figure 8).  
Pain Interference Model Results 
Table 3 presents the results of the two-part model which evaluated the predictive 
relationships among demographics, S.P.A.C.E. symptoms and pain interference. Figure 9 depicts 
the odds ratios and confidence intervals of the logit model. The odds of having pain interference 
were significantly higher in females compared to males (OR=6.94; CI = 1.02 – 47.25). Further, 
increased widespread pain (OR=1.41; CI = 1.13 – 1.77) increased the odds of having pain 
interference. In the subset of patients who had pain interference scores > 0 (n=40), increased 
fatigue (β=0.04) significantly predicted increased pain interference. Contrary to our hypothesis, 
sleep impairment, anxiety, depression, and cognitive function were not significantly associated 
with pain interference. 
Table 4 provides the average marginal effects of S.P.A.C.E. symptoms on pain 
interference. The average marginal effect of fatigue was the only S.P.A.C.E. symptom significant 
at the 5% level. Fatigue had a marginal effect of 0.46 on pain interference. As fatigue scores 
increased, total pain interference scores increased by 0.46 points (Figure 10).  
Discussion 
Currently, no studies have evaluated the predictive relationships among S.P.A.C.E. 
symptoms, opioid consumption, and pain interference. To address this gap, we utilized a 
prospective, predictive study design to evaluate the relationships among demographics and 
baseline S.P.A.C.E. symptoms on average daily opioid consumption and weekly pain 
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interference for one month post-baseline. We hypothesized that increased severity of S.P.A.C.E. 
symptoms would predict increased opioid consumption and pain interference. 
Within the opioid consumption model, widespread pain was the only S.P.A.C.E. 
symptom that had a positive and statistically significant relationship with opioid consumption. Its 
average marginal effect on opioid consumption suggests that as widespread pain increases, 
average daily opioid consumption increases by 4.59 MME. Within the pain interference model, 
greater fatigue severity was the only S.P.A.C.E. symptom significantly predictive of increased 
pain interference. There is a paucity of literature that has evaluated the severity and impact of 
fatigue on pain among patients with SCD. To our knowledge, only one study supports a 
significant and positive association between fatigue and pain interference (Ameringer et al., 
2014). 
Our findings in both the opioid consumption and pain interference models did not fully 
support our hypothesis. First, our study found a negative relationship among depression and 
opioid consumption. The negative directions of the relationships have not been previously 
reported from prior studies of SCD and non-SCD pain populations (Brummett et al., 2013; C. P. 
Carroll et al., 2016b; Grattan et al., 2012; Janda et al., 2015; J L Levenson et al., 2008). Given 
the negative directions of this relationships, it is important to consider potential threats to internal 
validity that may have biased the results. The negative relationship between depression and 
opioid consumption may be explained by low depression severity in our sample. More than half 
of our sample (62.5%) had depression severity lower than PROMIS® normative sample means. 
Low depression severity may have limited the ability of our predictive models to accurately 
detect the relationship between depression and opioid consumption. 
 
 
166 
 
Contrary to our hypothesis, several S.P.A.C.E. symptoms (e.g., sleep impairment, 
anxiety, fatigue, and cognitive function) did not significantly predict opioid consumption or pain 
interference. These findings conflict with research suggesting predictive relationships among 
depression, pain, and opioid consumption in those with SCD (C. P. Carroll et al., 2016b; James 
L. Levenson et al., 2008). The lack of a significant predictive relationship among many of these 
S.P.A.C.E. symptoms and our outcomes may be explained by statistical conclusion validity 
threats and uncaptured day-to-day symptom severity changes. First, our small sample size may 
have increased the probability of a Type II error. Second, day-to-day changes in sleep 
impairment, anxiety, and cognitive function severity may have threatened the internal validity of 
our study. Baseline assessments of these symptoms may not have accurately captured the 
variability in symptom severity (e.g., sleep impairment, anxiety, and fatigue) throughout the 30-
day study period. Repeated measurements of S.P.A.C.E. symptoms throughout the study period 
may have more accurately captured daily variations in symptom severity.  
As described, widespread pain was the only S.P.A.C.E. symptom to significantly predict 
average daily opioid consumption. Widespread pain is a common manifestation among patients 
with centralized pain—pain arising from altered nociception with little or no tissue damage and 
no evidence of disease or lesion to the somatosensory system (Lai et al., 2017; Latremoliere & 
Woolf, 2009; Marchand, 2008; Slade et al., 2013; Woolf, 2011). Empirical evidence suggests 
that patients with centralized pain disorders (i.e., fibromyalgia, temporomandibular disorder, 
urologic chronic pelvic pain syndrome) present with pain in multiple different body regions (Lai 
et al., 2017; Slade et al., 2013). Patients with centralized pain are also at risk for increased opioid 
consumption due to opioid non-responsiveness, or a lack of pain relief following opioid use 
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(Brummett et al., 2013; Corli et al., 2017; Hanks & Forbes, 1997; Janda et al., 2015; Wasserman 
et al., 2014).  
Preliminary evidence suggests that a subset of patients with SCD (20-25%) have 
centralized pain (C. M. Campbell et al., 2016; C. P. Carroll et al., 2016b; E Jacob et al., 2015), 
and the results of the current study further validate this premise (i.e., widespread pain predictive 
of opioid consumption  [β=0.16] and pain interference [β=0.04]). However, centralized pain is 
not routinely assessed within SCD clinical settings. A body map is a clinically feasible approach 
to evaluate widespread pain, a common centralized pain manifestation. Body maps are also easy 
to administer and interpret during routine outpatient visits. Clinicians can use body maps to 
guide clinical decisions and referrals to providers that specialized in centralized pain 
management (e.g., integrative health, palliative care).  
Although there are validated measures that can be used to quantify the presence of 
centralized pain in patients with SCD, management of centralized pain, once it has been 
identified, remains a challenge. Non-opioid and non-pharmacologic treatments are two 
approaches that may be effective in managing centralized pain among patients with SCD. Non-
opioid pharmacologic approaches such as antidepressants have been effective in managing pain 
and co-occurring symptoms (e.g., sleep) in chronic and/or centralized pain populations (Arnold, 
Keck, & Welge, 2000; O’Malley et al., 2000; Verdu, Decosterd, Buclin, Stiefel, & Berney, 
2008). For example, evidence suggests that duloxetine, a serotonin and norepinephrine reuptake 
inhibitor, is effective in reducing pain among patients with chronic low back pain, 
chemotherapy-induced peripheral neuropathy, and fibromyalgia (Arnold et al., 2004, 2005; 
Skljarevski et al., 2010; Smith et al., 2013). However, no randomized control trials (RCTs) have 
evaluated the effectiveness of antidepressants on pain reduction among patients with SCD.  
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Second, non-pharmacologic interventions such as yoga, exercise, and cognitive 
behavioral therapy (CBT) have been effective in reducing daily pain and improving physical 
function among patients with centralized pain (Eller-smith et al., 2018; Hassett & Williams, 
2011). However, within the SCD population, only five randomized control trials (RCTs) have 
evaluated the effectiveness of non-pharmacologic interventions to reduce pain with minimal or 
no effects (L P Barakat et al., 2010; Miriam O. Ezenwa et al., 2016; Lemanek et al., 2009; 
Moody et al., 2017; Schatz et al., 2015; Thomas et al., 2013). Further, no RCTs have specifically 
targeted patients with SCD who are experiencing centralized pain. There is a clinical need for 
research that evaluates the efficacy of non-opioid and non-pharmacologic interventions to reduce 
pain among patients who have centralized pain. As in other centralized pain populations, 
implementation of these interventions may reduce pain-associated burden and opioid 
consumption among SCD patients.  
This research study has several limitations. First, our study included a small sample from 
one academic medical center which reduces the generalizability of our findings to all patients 
with SCD. Second, our small sample size may have limited the power to detect significant 
relationships between the predictor and outcome variables. Third, baseline assessment of 
S.P.A.C.E. symptoms may not have accurately captured daily variations in symptom severity 
throughout the study period. Fourth, adherence to weekly survey completion was 47.4% and 
fifteen participants did not complete any surveys post-baseline. Thus, missing data may have 
biased and reduced the representativeness of our findings. Our study may also be limited by 
potential recall bias and false reporting within the opioid consumption surveys. We excluded one 
opioid consumption diary with self-reported opioid consumption of 700 MME based on 
suspected entry error. Participants also reported taking opioid prescriptions that were absent or 
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discontinued from the EMR. Ultimately, our opioid consumption results should be interpreted 
with caution due to potential limitations of recall bias and false reporting. 
In conclusion, our findings suggest that widespread pain, a common manifestation of 
centralized pain, may increase opioid use over time. Comprehensive evaluation of widespread 
pain within the clinical setting may facilitate advancements in individualized clinical care 
including referrals to specialists (e.g., integrative health providers and palliative care specialists). 
As in other non-SCD centralized pain populations, enhanced assessment and monitoring of 
widespread pain may be used to inform targeted interventions to reduce pain and opioid use 
among patients with SCD. 
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TABLE 13 
 
Demographic Characteristics, N=48 
 
Variable N (%) 
Age  
Mean (SD) 22.8 (5.9) 
Range 14-35 
Sex  
Female 27 (56.4) 
Male 21 (43.8) 
Race  
African American 47 (97.9) 
More than one race 1 (2.1) 
Ethnicity  
Not Hispanic or Latino 47 (97.9) 
Unknown or do not wish to report 1 (2.1) 
Education  
In middle school 1 (2.1) 
In high school 11 (22.9) 
Did not complete high school 3 (6.3) 
Completed high school 4 (8.3) 
Some college or technical training 16 (33.3) 
University undergraduate degree 12 (25) 
University post graduate degree 1 (2.1) 
Sickle Cell Genotype  
HbSS 35 (72.9) 
HbSC 10 (20.8) 
HbSβ0 1 (2.1) 
HbSβ+ 2 (4.2) 
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TABLE 14 
Descriptive Statistics of S.P.A.C.E. Symptoms, N=48 
Note. SD=standard deviation; PROMIS®=Patient Reported Outcomes Measurement Information 
System; SF=short form; MISCI=Multidimensional Inventory of Subjective Cognitive 
Impairment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Mean SD Minimum Maximum 
PROMIS® Sleep Impairment SF 56.63 9.05 30 75 
Widespread Pain Index 4.02 3.55 0 12 
PROMIS® Depression SF 47.17 9.53 37.1 73.5 
PROMIS® Anxiety SF 49.88 11.42 37.1 80 
MISCI 50.33 4.63 44 61 
PROMIS® Fatigue SF 52.99 11.24 33.1 77.7 
 
 
172 
 
Table 15 
Two-part model of demographics and S.P.A.C.E. symptoms on average daily opioid consumption 
MME 
Variables 
Two-part model 
Logit OLS 
 Odds Ratio 
(S.E.) a 
Coefficients 
(S.E.) a 
Age 0.99 
(0.08) 
-0.02 
(0.04) 
Female 1.24 
(0.79) 
-0.5 
(0.31) 
Sleep Impairment 1.01 
(0.06) 
-0.01 
(0.02) 
Widespread pain 1.38* 
(0.15) 
0.16* 
(0.05) 
Depression 0.9* 
(0.04) 
-0.04 
(0.03) 
Anxiety 1.09 
(0.06) 
0.04 
(0.04) 
Cognitive Function 1.17* 
(0.09) 
-0.04 
(0.04) 
Fatigue 1.03 
(0.06) 
-0.006 
(0.03) 
Note. MME= Morphine Milliequivalents; OLS= ordinary least squares;  
S.E.= standard error; OLS regression model was conditional non-zero 
outcome; a Shows the cluster-robust standard errors; *p <0.05 
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Table 16 
Average marginal effects for S.P.A.C.E. symptoms on average daily opioid consumption MME 
for combined two-part model 
Variables 
Observed 
Coefficientsa 
Std 
Error b 
Z 
Value 
p 
Value 
95% C.I.b 
Lower 
Limit 
Upper 
Limit 
Sleep Impairment -0.29 0.39 -0.74 0.46 -1.05 0.48 
Widespread Pain 4.59 1.61 2.86 <0.00 1.44 7.75 
Depression -1.27 0.81 -1.58 0.12 -2.85 0.31 
Anxiety 1.22 0.76 1.6 0.11 -0.27 2.71 
Cognitive Function -0.49 0.93 -0.52 0.6 -2.31 1.33 
Fatigue -0.04 0.73 -0.06 0.95 -1.47 1.39 
a Duan smearing retransformation was used to obtain fitted values; b Nonparametric 
bootstrapping was used to calculate standard errors and confidence intervals; Controlling for age, 
gender, and pain intensity 
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Table 17 
Two-part model of demographics and S.P.A.C.E. symptoms on pain interference 
Variables 
Two-part model 
Logit OLS 
 Odds Ratio 
(S.E.) a 
Coefficients 
(S.E.) a 
Age 1.12 
(0.12) 
-0.004 
(0.02) 
Female 6.94* 
(6.79) 
-0.08 
(0.24) 
Sleep Impairment 1.03 
(0.05) 
-0.004 
(0.01) 
Widespread pain 1.41* 
(0.16) 
0.04 
(0.03) 
Depression 1.06 
(0.07) 
-0.01 
(0.02) 
Anxiety 0.96 
(0.06) 
<0.000 
(0.02) 
Cognitive Function 0.91 
(0.07) 
-0.03 
(0.04) 
Fatigue 1.03 
(0.07) 
0.04* 
(0.02) 
Note. OLS= ordinary least squares; S.E.= standard error; OLS regression  
model was conditional non-zero outcome; a Shows the cluster-robust standard  
errors; *p <0.05 
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Table 118 
Average marginal effects for S.P.A.C.E. symptoms on pain interference for combined two-part 
model 
Variables 
Observed 
Coefficientsa 
Std 
Error b 
Z 
Value 
p 
Value 
95% C.I.b 
Lower 
Limit 
Upper 
Limit 
Sleep Impairment -0.02 0.18 -0.11 0.91 -0.38 0.34 
Widespread Pain 0.75 1.03 0.72 0.47 -1.27 2.77 
Depression -0.07 0.30 -0.23 0.82 -0.66 0.52 
Anxiety -0.04 0.21 -0.19 0.85 -0.45 0.37 
Cognitive Function -0.39 0.44 -0.89 0.37 -1.24 0.47 
Fatigue 0.46 0.21 2.19 0.03 0.05 0.87 
a Duan smearing retransformation was used to obtain fitted values; b Nonparametric 
bootstrapping was used to calculate standard errors and confidence intervals; Controlling for age, 
gender, and pain intensity 
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Figure 7 
Forest plot of odds ratios and confidence intervals of  S.P.A.C.E. symptoms on average daily 
opioid consumption MME 
 
 
 
 
Note. Results from logit model; MME=morphine milliequivalents 
 
 
 
 
 
 
 
 
 
 
 
 
0 0.5 1 1.5 2
Sleep Impairment
Widespread Pain
Depression
Anxiety
Cognitive Function
Fatigue
Odds Ratios
 
 
177 
 
 
Figure 8  
Predictive margins of widespread pain on average daily opioid consumption MME 
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Figure 9 
Forest plot of Odds Ratios and Confidence Intervals of S.P.A.C.E. symptoms on pain 
interference 
 
Note. Results from logit model 
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Figure 10 
Predictive margins of fatigue on pain interference 
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CHAPTER VI  
Summary 
 
Sickle cell disease (SCD) is the most commonly inherited red blood cell disorder in the 
United States and causes several negative sequelae including organ damage, frequent health 
service utilization, and pain (Platt et al., 1991; Vacca Jr & Blank, 2017). Pain, known as the 
hallmark complication of SCD, has been associated with reduced function, poor quality of life, 
anxiety, and depression (Adam et al., 2017; Benton, Ifeagwu, & Smith-Whitley, 2007; Jerrell, 
Tripathi, & McIntyre, 2011; Smith, Penberthy, Bovbjerg, Mcclish, & Roberts, 2008). Although 
pain impacts the lives of many patients with SCD, few effective pharmacologic and non-
pharmacologic pain management strategies reduce pain in these patients. Pain is a complex 
multidimensional problem that is influenced by numerous physical (e.g., central pain 
mechanisms), psychological (e.g., anxiety, depression), and cognitive factors (e.g., cognitive 
impairmentfunction), which if addressed, might advance the science of SCD pain management. 
The literature is sparse regarding the influence of multidimensional factors on pain among 
patients with SCD. Thus, to understand the multidimensional and individualized presentation of 
pain among patients with SCD, we used a prospective, predictive, correlation study design to 
achieve the following four aims: 1) describe the incidence and severity of several pain 
influencing factors including pain catastrophizing, centralized pain, and S.P.A.C.E. symptoms 
(sleep impairment, multifocal pain, depression, anxiety, cognitive function, fatigue) in 
adolescents and young adults (14-35 years) with SCD; 2) evaluate the predictive relationships 
 
 
187 
 
among S.P.A.C.E. symptoms, opioid consumption, and pain interference; 3) examine the 
predictive relationships among pain catastrophizing, centralized pain, opioid consumption, and 
pain interference; and, 4) characterize the co-occurrence of baseline S.P.A.C.E. symptoms, pain 
interference, opioid consumption, pain intensity, and P.A.I.N.S. (a metric that combines pain 
intensity and widespread pain) among adolescents and young adults with SCD. 
Results 
Sample 
 The study sample consisted of 48 adolescents and young adults with SCD receiving care 
within the Michigan Medicine Pediatric and Adult Comprehensive Sickle Cell Clinics. 
Participants were 14-35 years old with an average age of 22.8 years (SD=5.9). The sample was 
mainly female, African American, college educated, and most had been diagnosed with the 
HbSS and HbSC genotypes. All participants completed baseline survey measures. However, 
three participants were unable to provide baseline pain intensity, widespread pain, and P.A.I.N.S. 
data from the GeoPain @ Home mobile app. After baseline, 33 participants completed 91 opioid 
consumption and 91 pain interference surveys throughout the 30-day study period (47.4% 
adherence). One baseline opioid consumption diary was excluded based on suspected entry error; 
the participant reported taking an extremely high opioid dose (700 morphine milliequivalents 
[MME]). 
Specific Aim 1 
 The first specific aim was to characterize demographic variables (i.e., age, sex, and sickle 
cell genotype), the incidence and severity of centralized pain, pain catastrophizing, and six 
S.P.A.C.E. symptoms (i.e., sleep impairment, widespread pain, anxiety, depression, cognitive 
function, fatigue) measured at baseline among adolescents and adults with SCD.  
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 Findings. Forty-eight adolescents and young adults with SCD aged 14 to 35 years 
completed baseline measures of centralized pain, pain catastrophizing, and S.P.A.C.E. 
symptoms. Mean pain catastrophizing scores were low (X̄=16.23; SD=13.36) with thirty-six 
participants (75%) reporting total pain catastrophizing scores ≤ 25 (less catastrophic thinking 
about pain). One-fourth of the participants (n=12) had a positive centralized pain score (total 
score ≥ 13). Participants reported having pain within 0 to 12 body sites, with an average of 4.02 
body sites reported. Sample means of three S.P.A.C.E. symptoms were higher than normative 
sample means (PROMIS® or equivalent) were sleep impairment (X̄=56.63; SD=9.05), cognitive 
function (X̄=50.33; SD=4.63), and fatigue (X̄=52.99; SD=11.24). The remaining S.P.A.C.E. 
symptoms had mean scores that were similar to PROMIS® normative sample means (depression 
[X̄=47.17; SD=9.53] and anxiety [X̄=49.88; SD=11.42]). 
Discussion. This study comprehensively described multidimensional physiologic and 
psychologic pain characteristics including pain catastrophizing, centralized pain, and S.P.A.C.E. 
symptoms. Sleep impairment and fatigue severity within our sample are consistent with previous 
SCD research (Ameringer et al., 2014; Daniel et al., 2010; Mann-Jiles et al., 2015; Moody et al., 
2017; Sharma et al., 2015). Low severity of depression, anxiety, and pain catastrophizing 
conflicts with research conducted among patients with SCD (N Bakshi et al., 2018, 2017; Jerrell 
et al., 2011; Laurence et al., 2006; Ozer et al., 2014). Low severity of these pain influencing 
factors may be explained by the overall low pain intensity (X̄=3.41) of our sample. Empirical 
evidence suggests that depression, anxiety, and pain catastrophizing are all associated with pain 
(C. M. Campbell, Kronfli, et al., 2011; Davis et al., 2017; Maletic & Raison, 2009; McWilliams 
et al., 2003, 2004; Strigo et al., 2008; Tsang et al., 2008). Thus, greater depression, anxiety, and 
pain catastrophizing severity may have been found if the pain intensity of our sample was higher. 
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The incidence of centralized pain described is consistent with SCD research that has evaluated 
centralized pain using quantitative sensory testing methods (C. M. Campbell et al., 2016; C. P. 
Carroll et al., 2016a; Eufemia Jacob et al., 2015). Further, variability in widespread pain, a 
common manifestation of centralized pain, is consistent with research conducted with the sickle 
cell population (McClish et al., 2009; Zempsky et al., 2017).  
Specific Aim 2  
 The second specific aim was to evaluate the predictive relationships of demographic 
variables (i.e., age and sex) and baseline S.P.A.C.E. symptoms (sleep impairment, multifocal 
pain, anxiety, depression, cognitive function, fatigue) on average daily opioid consumption and 
weekly pain interference reported longitudinally for one month post-baseline in adolescents and 
young adults with SCD. 
 Findings. Widespread pain significantly increased the odds of consuming opioids. In the 
subset of patients who used opioids, widespread pain was the only S.P.A.C.E symptom that had a 
statistically significant effect on average daily opioid consumption. Contrary to our hypothesis, 
depression significantly decreased the odds of consuming opioids. Further, better perceived 
cognitive function was significantly increased the odds of consuming opioids. Lastly, sleep 
impairment, anxiety, and fatigue were not significantly associated with average daily opioid 
consumption. Within the pain interference model, female gender and widespread pain 
significantly increased the odds of having pain interference. Fatigue was the only S.P.A.C.E. 
symptom that significantly predicted pain interference in the subset of patients who had pain 
interference scores > 0. Contrary to our hypothesis, sleep impairment, anxiety, depression, and 
cognitive function were not significantly associated with pain interference. 
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 Discussion. These findings suggest that widespread pain was the only S.P.A.C.E. 
symptom that significantly predicted opioid consumption. Patients with centralized pain 
conditions (e.g., temporomandibular disorder, fibromyalgia) frequently report widespread pain 
distributions (Cassisi et al., 2014; Lai et al., 2017; Slade et al., 2013). Further, higher centralized 
pain survey scores (i.e., American College of Rheumatology (ACR) 2011 Fibromyalgia Survey 
Criteria), which include a measure of widespread pain, have been predictive of opioid 
consumption in non-SCD populations (Brummett et al., 2013; Janda et al., 2015). If opioids are 
ineffective in reducing pain, patients commonly increase the dosage, resulting in opioid non-
responsiveness (opioid consumption with little benefit). Although evidence suggests that patients 
with centralized pain are at an increased risk for opioid non-responsiveness (Corli et al., 2017; 
Hanks & Forbes, 1997; Wasserman et al., 2014), centralized pain is rarely identified and 
evaluated among patients with SCD. Centralized pain should be evaluated in clinical and 
research settings to (1) identify patients at risk for opioid non-responsiveness, (2) facilitate 
referrals to specialists (e.g., integrative health practitioners, palliative care providers), and (3) 
support the use of alternative pharmacologic, and/or non-pharmacologic pain management 
approaches. 
 Within the pain interference model, fatigue significantly predicted pain interference, or 
pain that interferes with social, emotional, and physical functioning. Empirical evidence supports 
this predictive relationship among non-SCD pain populations (Davis et al., 2017; Robert Knoerl 
et al., 2018). Interestingly, few research studies have evaluated the impact of fatigue on pain 
among patients with SCD. Only one study supports a significant positive relationship between 
fatigue and pain interference (Ameringer et al., 2014).  
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Contrary to our hypothesis, sleep impairment, anxiety, and fatigue were not significantly 
predictive of opioid consumption. Further, widespread pain, cognitive function, and anxiety were 
not significantly related to increased pain interference. The lack of significance among these 
S.P.A.C.E. symptoms and important clinical outcomes may be explained by our small sample 
size. Our sample size may have threatened the statistical conclusion validity of our findings by 
increasing the probability of a Type II error. Further, day-to-day variations in symptom severity 
may have threatened the internal validity of our study. It is possible that baseline/cross-sectional 
measurement did not capture the variability in symptom severity (e.g., sleep impairment, anxiety, 
and fatigue) throughout the one month study period. Repeated measurements of S.P.A.C.E. 
symptoms may have more accurately captured daily variations in symptom severity, and when 
averaged over time, may result in mean scores that are more reflective of everyday life with 
SCD. For this reason, daily evaluations of symptoms are recommended to accurately capture the 
day-to-day symptom experience.  
Our study found a negative relationship among depression and opioid consumption. The 
negative directions of the relationships have not been previously reported from prior studies of 
SCD and non-SCD pain populations (Brummett et al., 2013; C. P. Carroll et al., 2016b; Grattan 
et al., 2012; Janda et al., 2015; J L Levenson et al., 2008). Given the negative directions of this 
relationships, it is important to consider potential threats to internal validity that may have biased 
the results. The negative relationship between depression and opioid consumption may be 
explained by a lack of variability in depression scores. Since a majority of our sample had 
depression severity lower than PROMIS® normative sample means, our predictive model may 
have been unable to accurately predict the relationship between depression and opioid 
consumption.  
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Specific Aim 3  
 The third specific aim was to examine the predictive relationships among baseline 
centralized pain and pain catastrophizing severity on average daily opioid consumption and 
weekly pain interference within one month of baseline phenotyping.  
Findings. Centralized pain significantly increased the odds of consuming opioids and 
having pain interference. Further, among those who consumed opioids and had pain interference, 
increased centralized pain significantly predicted more opioid use and pain interference. 
Contrary to our hypothesis, pain catastrophizing significantly predicted less opioid consumption.  
In the pain interference model, higher pain catastrophizing scores significantly increased the 
odds of having pain interference. However, pain catastrophizing scores did not significantly 
predict longitudinal pain interference in the subset of patients that had pain interference scores > 
0.  
Discussion. Our findings and emerging evidence suggest that centralized pain occurs in a 
subset of patients with SCD (Brandow, Stucky, Hillery, Hoffmann, & Panepinto, 2013; 
Campbell et al., 2016; Carroll et al., 2016; Jacob et al., 2015). As discussed, non-pharmacologic 
pain management approaches are preferred to pharmacologic agents (opioids), which are often 
ineffective in centralized pain populations. However, little is known about the efficacy of non-
pharmacological interventions among patients with SCD. Only five non-pharmacologic 
randomized control trials (RCTs) have been conducted in the SCD population with little or no 
effect on daily pain (L P Barakat et al., 2010; Miriam O. Ezenwa et al., 2016; Lemanek et al., 
2009; Moody et al., 2017; Schatz et al., 2015; Thomas et al., 2013). Limited effects found in 
these studies may be explained by the study samples. None of the RCTs specifically targeted 
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patients with centralized pain. Therefore, patients without centralized pain may have confounded 
the treatment effect found within the entire sample.  
In our study, centralized pain was significantly predictive of opioid consumption and pain 
that interferes with social, emotional, and physical functioning. These findings are consistent 
with evidence from prior studies of non-SCD centralized pain populations (Cassisi et al., 2014; 
Kristine Phillips & Clauw, 2011; Wasserman et al., 2014). When an opioid is ineffective in 
reducing pain, patients and clinicians commonly increase the dosage, which consequently results 
in opioid non-responsiveness; patients take greater opioid dosages but experience little benefit 
(Brummett et al., 2013; Hanks & Forbes, 1997; Janda et al., 2015; Wasserman et al., 2014). To 
reduce the use of ineffective pharmacologic agents like opioids, non-pharmacologic 
interventions are encouraged (Hassett & Williams, 2011; Winfried Hauser, Bernardy, Arnold, 
Offenbacher, & Schiltenwolf, 2009). 
Although emerging evidence suggests that centralized pain impacts opioid consumption 
and function among patients with SCD, it is rarely evaluated and considered within clinical 
practice. Our study utilized a more feasible approach to evaluate centralized pain—a reliable and 
valid patient-reported outcome (PRO) measure. The PRO measure used within our study, the 
ACR 2011 Fibromyalgia Survey Criteria, may be a useful tool to identify patients experiencing 
centralized pain. Ultimately, centralized pain evaluation could guide clinicians in the 
implementation of individualized non-pharmacologic interventions, such as exercise and 
cognitive behavioral therapy, that have been efficacious in reducing pain and improving function 
in non-SCD centralized pain populations (Hassett & Williams, 2011; Robert Knoerl, Lavoie 
Smith, & Weisberg, 2016). 
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The negative relationships among increased pain catastrophizing and opioid consumption 
conflicts with empirical evidence in SCD and non-SCD populations. Our conflicting findings 
may be explained by low symptom severity and recall bias. First, there was a lack of variability 
in pain catastrophizing scores within our sample. Mean pain catastrophizing scores found within 
our study were much less than those previously reported among patients with SCD (N Bakshi et 
al., 2017). Low symptom severity may have limited the ability of our statistical models to 
accurately predict the effects of pain catastrophizing on opioid consumption and pain 
interference. Second, our pain catastrophizing findings may have been confounded by recall bias. 
Participants are asked to recall a past painful event when answering the pain catastrophizing 
survey questions. Since many participants in our sample reported no pain at baseline, it may have 
been difficult to accurately recall a past painful event when answering the questions. In 
summary, the negative relationships found among pain catastrophizing, opioid consumption, and 
pain interference should be interpreted with caution due to low symptom severity and potential 
recall bias. 
Specific Aim 4 
 The fourth specific aim was to characterize the co-occurrence of baseline S.P.A.C.E. 
symptoms, average daily opioid consumption, pain interference, pain intensity, and Pain Area 
and Intensity Number Summation (P.A.I.N.S.) measured via an interactive body map within the 
GeoPain @ Home mobile application. 
 Findings. Many S.P.A.C.E. symptoms (i.e., sleep impairment, anxiety, depression, 
cognitive function, and fatigue) were moderately and significantly correlated with one another. 
Pain interference was moderately and significantly correlated with all but one S.P.A.C.E. 
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symptom (depression). Widespread pain was the only S.P.A.C.E. symptom that was significantly 
associated with average daily opioid consumption, pain intensity, and P.A.I.N.S.  
Discussion. This study is the first to evaluate the co-occurrence of all symptoms within 
the S.P.A.C.E. symptom cluster. Consistent with research conducted in non-SCD pain 
populations, many S.P.A.C.E. symptoms were moderately and significantly correlated (Davis et 
al., 2017; Robert Knoerl et al., 2018; Shattuck & Muehlenbein, 2016). Surprisingly, widespread 
pain was the only S.P.A.C.E. symptom that was not correlated with any other symptoms. Limited 
research has investigated the relationships among S.P.A.C.E. symptoms and widespread pain in 
patients with SCD. Our findings suggest that widespread pain may not be a significant 
contributor to the S.P.A.C.E. symptom cluster. These findings may also be explained by our 
small sample size and low symptom severity of our sample. First, our small sample size may 
have increased the probability of a Type II error (false negative). Further, correcting for multiple 
comparisons (Bonferroni) led to a reduction in the level of significance. A reduced level of 
significance may have subsequently increased the probability of a Type II error. Second, low 
pain and symptom severity within our sample may have biased the precision of our statistical 
analyses. The only S.P.A.C.E. symptoms that were higher than PROMIS® (or equivalent) 
normative sample means were sleep impairment, cognitive function, and fatigue. Further, 
baseline pain severity of our sample was low (X̄=3.41). Ultimately, our findings may have been 
biased due to our small sample size and low symptom severity. 
Interestingly. widespread pain was the only S.P.A.C.E. symptom that significantly 
correlated with average daily opioid consumption, pain intensity, and P.A.I.N.S. Our study was 
unable to detect any statistically significant correlations between the remaining S.P.A.C.E. 
symptoms, opioid use, and pain. These findings conflict with empirical evidence that suggests 
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positive and significant relationships between S.P.A.C.E. symptoms, opioid consumption, and 
pain (Ameringer et al., 2014; C. P. Carroll et al., 2016a; James L. Levenson et al., 2008; 
Moscou-Jackson et al., 2015). As discussed previously, the lack of statistically significant 
associations found within our study may be explained by an increased probability of a Type II 
error (i.e., small sample size and correction for multiple comparisons). 
Many S.P.A.C.E. symptoms were significantly associated with pain that interferes with 
social, cognitive, emotional, and physical functioning. These findings highlight the importance 
of evaluating multidimensional symptoms, like S.P.A.C.E., during routine clinical visits. Early 
identification of severe S.P.A.C.E. symptoms can facilitate individualized care management. 
Clinicians may use knowledge of S.P.A.C.E. symptom severity to guide referrals to ancillary 
psychiatric resources and specialists such as palliative care and integrative health providers. 
Ultimately, identification and management of S.P.A.C.E. symptoms may lead to reductions in 
daily pain and improvements in functioning and quality of life among patients with SCD. 
Limitations 
This dissertation study has several limitations. As described, low symptom severity of 
pain and S.P.A.C.E. symptoms (i.e., depression and anxiety) may have limited the precision of 
our statistical analyses. Further, our small sample size may have influenced the statistical 
significance of our findings by increasing the probability of Type II errors. Adherence to 
longitudinal data collection was suboptimal (47.3%) within our sample. Thus, our findings may 
have been biased by missing data. Another limitation of our study is evidence of false reporting 
and entry error within opioid consumption surveys. Many participants reported taking opioids 
that were discontinued in the electronic medical record (EMR). For these instances, we utilized 
discontinued dosages to calculate MME. Additionally, some participants (n=3) reported taking 
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codeine with no evidence of prescription history. Since it is plausible that these three participants 
received codeine prescriptions from outside institutions, we used standard-adult dosages of 
codeine/acetaminophen (30/300mg) from Chronic Pain Clinical Practice Guidelines to calculate 
their MME (Michigan Medicine Clinical Care Guidelines, 2016). Lastly, we excluded one 
baseline opioid consumption diary (700 MME) due to suspected entry error. Ultimately, self-
reported opioid consumption may have been biased due to false reporting and entry error. 
Although this research evaluated a wide variety of multidimensional symptoms that may impact 
pain and opioid consumption, there are many other pain-related factors that were not included as 
variables within this study such as sickle cell genotype, pain control beliefs, stigma, social 
support, and trauma exposure. It is possible that these factors influence pain and opioid 
consumption and confounded the findings in our study. Lastly, our study was conducted within 
one academic medical center which limits the generalizability of our findings to all adolescents 
and young adults with SCD.  
Recommendations for Future Research 
 The limitations of our research can guide the design of future SCD research studies. First, 
low symptom severity of our sample may have confounded the precision of our statistical 
analyses. Future research conducted among patients with SCD should limit inclusion to patients 
that are experiencing a certain level of daily pain (e.g., baseline pain intensity ≥ 4 out of 10).  
Second, the current study did not evaluate the relationships among several pain-
influencing factors (i.e., sickle cell genotype, pain control beliefs, stigma, social support, and 
trauma exposure), pain, and opioid consumption. Research conducted among SCD and non-SCD 
populations suggests that many of these factors may influence pain outcomes (Carter et al., 2002; 
Forgeron et al., 2010; W Hauser et al., 2011; Holtzman et al., 2004; Kanzawa-Lee et al., 2018; 
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Oram et al., 2012; K Phillips & Clauw, 2011; Schofferman et al., 1993; Snelling, 1994; Spiegel 
et al., 2015; Zaza & Baine, 2002). However, there is a paucity of literature that has evaluated the 
relationships among stigma, pain control beliefs, social support, trauma exposure, pain, and 
opioid consumption in the SCD population. (Bediako et al., 2016; P. C. Carroll et al., 2013; Ford 
et al., 2017; Martin et al., 2018). To address this gap in the literature, future SCD research should 
consider evaluating the relationships of these pain-influencing factors, pain, and opioid use. 
Third, this dissertation study was limited by low data completion rates and potential false 
reporting of opioid use. To try and address low data adherence, our study set up daily reminders 
within the GeoPain @ Home mobile application. Low adherence to daily pain diary completion 
(51.8%) suggests that daily app reminders were not effective. Further, participants received a 
weekly text message every Friday including a reminder to complete daily pain diaries. Weekly 
pain interference and opioid consumption survey links were also included within the text 
message. Adherence to weekly survey completion was also low (47.4%). Text messages were 
sent every Friday throughout the 30-day study period. It is possible that sending text messages 
during a different day of the week (e.g., Wednesday) would increase data completion rates. 
Further, future longitudinal studies may implement additional strategies to increase data 
completion rates such as reminder calls and text messages throughout the week.   
The findings of this dissertation study demonstrated the incidence of centralized pain and 
its influence on pain and opioid consumption among patients with SCD. Future research that 
specifically targets the centralized pain population is necessary to guide SCD clinical care and 
reduce pain and opioid consumption. Effective non-opioid and non-pharmacologic approaches 
used within centralized pain populations may inform future research among patients with SCD. 
First, evidence supports the effectiveness of non-opioid pharmacologic interventions such as 
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antidepressants in managing pain and co-occurring symptoms among chronic and centralized 
pain populations (Arnold, Keck, & Welge, 2000; O’Malley et al., 2000; Verdu, Decosterd, 
Buclin, Stiefel, & Berney, 2008). For example, duloxetine, a serotonin and norepinephrine 
reuptake inhibitor, has been effective in reducing pain among patients with fibromyalgia, chronic 
low back pain, and chemotherapy-induced peripheral neuropathy (Arnold et al., 2004, 2005; 
Skljarevski et al., 2010; Smith et al., 2013). Despite empirical evidence in non-SCD populations, 
no randomized control trials (RCTs) have evaluated the effectiveness of antidepressants in 
managing pain among patients with SCD. Second, non-pharmacologic interventions such as 
yoga, exercise, and cognitive behavioral therapy (CBT) are recommended for patients with 
centralized pain in non-SCD populations (Büssing et al., 2012; Hassett & Williams, 2011; Robert 
Knoerl et al., 2016). For example, CBT interventions have been effective in reducing pain and 
improving function among patients with fibromyalgia, chronic low back pain, and 
temporomandibular disorder (Hassett & Williams, 2011; Robert Knoerl et al., 2016). 
Interventions testing CBT use a wide variety of cognitive and behavioral strategies (e.g., 
hypnosis, guided imagery, coping skills training, and progressive muscle relaxation) to produce 
desired effects. 
To our knowledge, five randomized control trials (RCTs) have tested the efficacy of non-
pharmacologic interventions among patients with SCD (L P Barakat et al., 2010; Miriam O. 
Ezenwa et al., 2016; Lemanek et al., 2009; Moody et al., 2017; Schatz et al., 2015; Thomas et al., 
2013). Only two of these RCTs have tested CBT-based intervention strategies with minimal or 
no effects in pain reduction (Lamia P. Barakat et al., 2010; Schatz et al., 2015). However, these 
studies were limited by internal validity threats including small sample sizes, no participant 
blinding, and a lack of intervention standardization, which may explain the lack of efficacy. 
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Based on our findings and the established evidence supporting the use of CBT among centralized 
pain populations (Hassett & Williams, 2011; R Knoerl et al., 2015), future non-pharmacologic 
intervention research should test the effects of CBT interventions on pain and opioid 
consumption among patients with SCD.  
Lastly, the findings of aim 4 support positive relationships among centrally-mediated 
S.P.A.C.E. symptoms and pain interference. Future non-opioid and non-pharmacologic 
intervention studies should consider conducting mediation analyses of S.P.A.C.E. symptoms on 
pain. The identification of S.P.A.C.E. mediators could guide the inclusion of specific cognitive 
and/or behavioral strategies that will effectively treat S.P.A.C.E. symptoms and subsequently 
reduce pain. 
Recommendations for Clinical Practice 
 Our findings also have implications for clinical practice. The results of this study suggest 
that centralized pain influences pain and opioid consumption. Based on this evidence, we 
recommend routine screening of centralized pain among patients with SCD. Routine screening 
methods should incorporate standardized measures such as a body map or the ACR 2011 
Fibromyalgia Survey Criteria to quantify widespread pain and centralized pain. Clinical 
assessment of centralized pain can be used to identify patients who may be more likely to 
experience opioid non-responsiveness and pain that impacts functioning (i.e., social, emotional, 
and physical functioning). Further, assessments of centralized pain can guide referrals to  
specialists (e.g., palliative care providers). Ultimately, targeted treatment of centralized pain may 
reduce pain and opioid use as well as improve function and quality of like among patients with 
SCD.  
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Conclusions 
 
Limited research has evaluated multidimensional physiological and psychological 
factors, pain, and opioid consumption among patients with SCD. In this prospective, predictive, 
correlational study, we described the incidence and severity of several centrally-mediated 
symptoms and evaluated their co-occurrence with pain and opioid consumption, Further, we 
evaluated the predictive relationships among centrally-mediated symptoms, centralized pain, 
pain catastrophizing, opioid consumption, and pain interference. Our study demonstrated the 
predictive relationships among centralized pain, pain severity and opioid consumption. Our 
findings should be interpreted with caution due to our small sample size, low symptom severity, 
and suboptimal data completion rates. Individualized assessment of centralized pain can facilitate 
the recommendation of appropriate non-pharmacologic pain management strategies. Improved 
centralized pain management may ultimately lead to reductions in pain and opioid use and 
improvements in function and quality of life among patients with SCD.  
 
 
 
 
 
 
 
 
 
 
 
 
202 
 
References 
Arnold, L. M., Keck, P. E., & Welge, J. A. (2000). Antidepressant treatment of fibromyalgia. A 
meta-analysis and review. Psychosomatics, 41(2), 104–113. 
https://doi.org/10.1176/appi.psy.41.2.104 
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. 
J. (2004). A double-blind, multicenter trial comparing duloxetine with placebo in the 
treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and 
Rheumatism, 50(9), 2974–2984. https://doi.org/10.1002/art.20485 
Arnold, L. M., Rosen, A., Pritchett, Y. L., D’Souza, D. N., Goldstein, D. J., Iyengar, S., & 
Wernicke, J. F. (2005). A randomized, double-blind, placebo-controlled trial of duloxetine 
in the treatment of women with fibromyalgia with or without major depressive disorder. 
Pain, 119(1–3), 5–15. https://doi.org/10.1016/j.pain.2005.06.031 
Adam, S. S., Flahiff, C. M., Kamble, S., Telen, M. J., Reed, S. D., & De Castro, L. M. (2017). 
Depression, quality of life, and medical resource utilization in sickle cell disease. Blood 
Advances, 1(23), 1983–1992. https://doi.org/10.1182/bloodadvances.2017006940 [doi] 
Ameringer, S., Elswick Jr, R. K., & Smith, W. (2014). Fatigue in adolescents and young adults 
with sickle cell disease: biological and behavioral correlates and health-related quality of 
life. Journal of Pediatric Oncology Nursing, 31(1), 6–17. 
https://doi.org/10.1177/1043454213514632 [doi] 
Bakshi, N., Lukombo, I., Belfer, I., & Krishnamurti, L. (2018). Pain catastrophizing is associated 
with poorer health-related quality of life in pediatric patients with sickle cell disease. 
Journal of Pain Research, 947–953. 
Bakshi, N., Lukombo, I., Shnol, H., Belfer, I., & Krishnamurti, L. (2017). Psychological 
Characteristics and Pain Frequency Are Associated With Experimental Pain Sensitivity in 
Pediatric Patients With Sickle Cell Disease. The Journal of Pain, 18(10), 1216–1228. 
https://doi.org/S1526-5900(17)30599-0 [pii] 
Barakat, L P, Schwartz, L. A., Salamon, K. S., & Radcliffe, J. (2010). A family-based 
randomized controlled trial of pain intervention for adolescents with sickle cell disease. 
Journal of Pediatric Hematology/Oncology, 32(7), 540–547. 
https://doi.org/10.1097/MPH.0b013e3181e793f9 
Barakat, Lamia P., Schwartz, L. A., Salamon, K. S., & Radcliffe, J. (2010). A family-based 
randomized controlled trial of pain intervention for adolescents with sickle cell disease. 
Journal of Pediatric Hematology/Oncology, 32(7), 540–547. 
https://doi.org/10.1097/MPH.0b013e3181e793f9 
Bediako, S. M., Lanzkron, S., Diener-West, M., Onojobi, G., Beach, M. C., & Haywood, C. 
(2016). The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient 
Outcomes through Respect and Trust study. Journal of Health Psychology, 21(5), 808–820. 
https://doi.org/10.1177/1359105314539530 
Benton, T. D., Ifeagwu, J. A., & Smith-Whitley, K. (2007). Anxiety and depression in children 
and adolescents with sickle cell disease. Current Psychiatry Reports, 9(2), 114–121. 
 
 
203 
 
Brandow, A. M., Stucky, C. L., Hillery, C. A., Hoffmann, R. G., & Panepinto, J. A. (2013). 
Patients with sickle cell disease have increased sensitivity to cold and heat. American 
Journal of Hematology. https://doi.org/10.1002/ajh.23341 
Brummett, C. M., Janda, A. M., Schueller, C. M., Tsodikov, A., Morris, M., Williams, D. A., & 
Clauw, D. J. (2013). Survey criteria for fibromyalgia independently predict increased 
postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, 
observational cohort study. Anesthesiology, 119(6), 1434–1443. 
https://doi.org/10.1097/ALN.0b013e3182a8eb1f [doi] 
Büssing, A., Ostermann, T., Lüdtke, R., & Michalsen, A. (2012). Effects of yoga interventions 
on pain and pain-associated disability: A meta-analysis. Journal of Pain, 13(1), 1–9. 
https://doi.org/10.1016/j.jpain.2011.10.001 
Campbell, C. M., Kronfli, T., Buenaver, L. F., Smith, M. T., Haythornthwaite, J. A., & Edwards, 
R. R. (2011). Situational vs. dispositional measurement of catastrophizing: Associations. J 
Pain, 11(5), 443–453. https://doi.org/10.1016/j.jpain.2009.08.009.Situational 
Campbell, C. M., Moscou-Jackson, G., Carroll, C. P., Kiley, K., Haywood, C., Lanzkron, S., … 
Haythornthwaite, J. A. (2016). An Evaluation of Central Sensitization in Patients With 
Sickle Cell Disease. The Journal of Pain, 17(5), 617–627. 
https://doi.org/10.1016/j.jpain.2016.01.475 
Carroll, C. P., Lanzkron, S., Haywood, C. J., Kiley, K., Pejsa, M., Moscou-Jackson, G., … 
Campbell, C. M. (2016a). Chronic Opioid Therapy and Central Sensitization in Sickle Cell 
Disease. American Journal of Preventive Medicine, 51(1 Suppl 1), S69-77. 
https://doi.org/10.1016/j.amepre.2016.02.012 
Carroll, C. P., Lanzkron, S., Haywood, C., Kiley, K., Pejsa, M., Moscou-Jackson, G., … 
Campbell, C. M. (2016b). Chronic opioid therapy and central sensitization in sickle cell 
disease. American Journal of Preventive Medicine, 51(1), S69–S77. 
https://doi.org/10.1016/j.amepre.2016.02.012 
Carroll, P. C., Haywood, C., Hoot, M. R., & Lanzkron, S. (2013). A preliminary study of 
psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease 
patients. Clinical Journal of Pain, 29(4), 317–323. 
https://doi.org/10.1097/AJP.0b013e3182579b87 
Carter, B., Lambrenos, K., & Thursfield, J. (2002). A pain workshop: an approach to eliciting the 
views of young people with chronic  pain. Journal of Clinical Nursing, 11(6), 753–762. 
Cassisi, G., Sarzi-Puttini, P., Casale, R., Cazzola, M., Boccassini, L., Atzeni, F., & Stisi, S. 
(2014). Pain in fibromyalgia and related conditions. Reumatismo, 66(1), 72–86. 
https://doi.org/10.4081/reumatismo.2014.767 
Corli, O., Roberto, A., Bennett, M. I., Galli, F., Corsi, N., Rulli, E., & Antonione, R. (2017). 
Nonresponsiveness and Susceptibility of Opioid Side Effects Related to Cancer Patients’ 
Clinical Characteristics: A Post-Hoc Analysis. Pain Practice. 
https://doi.org/10.1111/papr.12669 [doi] 
Daniel, L. C., Grant, M., Kothare, S. V, Dampier, C., & Barakat, L. P. (2010). Sleep Patterns in 
 
 
204 
 
Pediatric Sickle Cell Disease. Pediatr Blood Cancer, (October 2009), 501–507. 
https://doi.org/10.1002/pbc 
Davis, L. L., Kroenke, K., Monahan, P., Kean, J., & Stump, T. E. (2017). The SPADE Symptom 
Cluster in Primary Care Patients with Chronic Pain. Clinical Journal of Pain, 32(5), 388–
393. https://doi.org/10.1097/AJP.0000000000000286.The 
Ezenwa, M. O., Yao, Y., Engeland, C. G., Molokie, R. E., Wang, Z. J., Suarez, M. L., & Wilkie, 
D. J. (2016). A randomized controlled pilot study feasibility of a tablet-based guided audio-
visual relaxation intervention for reducing stress and pain in adults with sickle cell disease. 
Journal of Advanced Nursing, 72(6), 1452–1463. https://doi.org/10.1111/jan.12895 
Ford, J. D., Grasso, D. J., Jones, S., Works, T., & Andemariam, B. (2017). Interpersonal 
Violence Exposure and Chronic Pain in Adult Sickle Cell Patients. Journal of Interpersonal 
Violence, 886260517691521. https://doi.org/10.1177/0886260517691521 
Forgeron, P. A., King, S., Stinson, J. N., McGrath, P. J., MacDonald, A. J., & Chambers, C. T. 
(2010). Social functioning and peer relationships in children and adolescents with chronic 
pain: A systematic review. Pain Research and Management, 15(1), 27–41. Retrieved from 
https://www.scopus.com/inward/record.uri?eid=2-s2.0-
77950464526&partnerID=40&md5=1b217295f888cc94f5cc4d05615801ae 
Grattan, A., Sullivan, M. D., Saunders, K. W., Campbell, C. I., & Von Korff, M. R. (2012). 
Depression and prescription opioid misuse among chronic opioid therapy recipients with no 
history of substance abuse. Annals of Family Medicine, 10(4), 304–311. 
https://doi.org/10.1370/afm.1371 
Hanks, G. W., & Forbes, K. (1997). Opioid responsiveness. Acta Anaesthesiologica 
Scandinavica, 41(1 Pt 2), 154–158. 
Hassett, A. L., & Williams, D. A. (2011). Non-pharmacological treatment of chronic widespread 
musculoskeletal pain. Best Practice & Research. Clinical Rheumatology, 25(2), 299–309. 
https://doi.org/10.1016/j.berh.2011.01.005 
Hauser, W, Kosseva, M., Uceyler, N., Klose, P., & Sommer, C. (2011). Emotional, physical, and 
sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis 
Care & Research, 63(6), 808–820. https://doi.org/10.1002/acr.20328 [doi] 
Hauser, Winfried, Bernardy, K., Arnold, B., Offenbacher, M., & Schiltenwolf, M. (2009). 
Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of 
randomized controlled clinical trials. Arthritis and Rheumatism, 61(2), 216–224. 
https://doi.org/10.1002/art.24276 
Holtzman, S., Newth, S., & Delongis, A. (2004). The role of social support in coping with daily 
pain among patients with rheumatoid arthritis. Journal of Health Psychology, 9(5), 677–
695. https://doi.org/10.1177/1359105304045381 
Jacob, E, Chan, V. W., Hodge, C., Zeltzer, L., Zurakowski, D., & Sethna, N. F. (2015). Sensory 
and Thermal Quantitative Testing in Children With Sickle Cell Disease. Journal of 
Pediatric Hematology/Oncology, 37(3), 185–189. 
https://doi.org/10.1097/MPH.0000000000000214 [doi] 
 
 
205 
 
Jacob, Eufemia, Chan, V. W., Hodge, C., Zeltzer, L., Zurakowski, D., & Sethna, N. F. (2015). 
Sensory and Thermal Quantitative Testing in Children With Sickle Cell Disease. J Pediatr 
Hematol Oncol (Vol. 37). Retrieved from www.jpho-online.com 
Janda, A. M., As-Sanie, S., Rajala, B., Tsodikov, A., Moser, S. E., Clauw, D. J., & Brummett, C. 
M. (2015). Fibromyalgia survey criteria are associated with increased postoperative opioid 
consumption in women undergoing hysterectomy. Anesthesiology, 122(5), 1103–1111. 
https://doi.org/10.1097/ALN.0000000000000637 [doi] 
Jerrell, J. M., Tripathi, A., & McIntyre, R. S. (2011). Prevalence and treatment of depression in 
children and adolescents with sickle cell disease: a retrospective cohort study. The Primary 
Care Companion for CNS Disorders, 13(2), 10.4088/PCC.10m01063. 
https://doi.org/10.4088/PCC.10m01063 [doi] 
Kanzawa-Lee, G. A., Knoerl, R., Williams, D. A., Clauw, D. J., Bridges, C. M., Harte, S. E., … 
Lavoie Smith, E. M. (2018). Childhood Trauma Predicts Cancer Treatment-Related Pain in 
Breast Cancer Survivors. Cancer Nursing. https://doi.org/10.1097/NCC.0000000000000687 
Knoerl, R, Lavoie Smith, E. M., & Weisberg, J. (2015). Chronic Pain and Cognitive Behavioral 
Therapy: An Integrative Review. Western Journal of Nursing Research, (Journal Article). 
https://doi.org/0193945915615869 [pii] 
Knoerl, Robert, Chornoby, Z., & Smith, E. M. L. (2018). Estimating the Frequency , Severity , 
and Clustering of SPADE Symptoms in Chronic Painful Chemotherapy- Induced Peripheral 
Neuropathy. Pain Management Nursing, 19(4), 354–365. 
https://doi.org/10.1016/j.pmn.2018.01.001 
Knoerl, Robert, Lavoie Smith, E. M., & Weisberg, J. (2016). Chronic Pain and Cognitive 
Behavioral Therapy: An Integrative Review. Western Journal of Nursing Research, 38(5), 
596–628. https://doi.org/10.1177/0193945915615869 
Lai, H. H., Jemielita, T., Sutcliffe, S., Bradley, C. S., Naliboff, B., Williams, D. A., … Landis, J. 
R. (2017). Characterization of Whole Body Pain in Urological Chronic Pelvic Pain 
Syndrome at Baseline: A MAPP Research Network Study. The Journal of Urology, 198(3), 
622–631. https://doi.org/10.1016/j.juro.2017.03.132 
Laurence, B., George, D., Woods, D., & Baltimore, D. (2006). Association between Elevated 
Depressive Symptoms and Clinical Disease Severity in African-American Adults with Sickle 
Cell Disease. 
Lemanek, K. L., Ranalli, M., & Lukens, C. (2009). A randomized controlled trial of massage 
therapy in children with sickle cell disease. Journal of Pediatric Psychology, 34(10), 1091–
1096. https://doi.org/10.1093/jpepsy/jsp015 
Levenson, J L, McClish, D. K., Dahman, B. A., Bovbjerg, V. E., de A Citero, V., Penberthy, L. 
T., … Smith, W. R. (2008). Depression and anxiety in adults with sickle cell disease: the 
PiSCES project. Psychosomatic Medicine, 70(2), 192–196. 
https://doi.org/PSY.0b013e31815ff5c5 [pii] 
Levenson, James L., McClish, D. K., Dahman, B. A., Bovbjerg, V. E., De A. Citero, V., 
Penberthy, L. T., … Smith, W. R. (2008). Depression and anxiety in adults with sickle cell 
 
 
206 
 
disease: The PiSCES project. Psychosomatic Medicine, 70(2), 192–196. 
https://doi.org/10.1097/PSY.0b013e31815ff5c5 
Maletic, V., & Raison, C. L. (2009). Neurobiology of depression, fibromyalgia and neuropathic 
pain. Frontiers in Bioscience, 14, 5291–5338. 
Mann-Jiles, V., Thompson, K., & Lester, J. (2015). Sleep impairment and insomnia in sickle cell 
disease: A retrospective chart review of clinical and psychological indicators. Journal of the 
American Association of Nurse Practitioners, 27(8), 441–449. https://doi.org/10.1002/2327-
6924.12212 
Martin, S. R., Cohen, L. L., Mougianis, I., Griffin, A., Sil, S., & Dampier, C. (2018). Stigma and 
Pain in Adolescents Hospitalized for Sickle Cell Vasoocclusive Pain Episodes. The Clinical 
Journal of Pain, 34(5), 438–444. https://doi.org/10.1097/AJP.0000000000000553 [doi] 
McClish, D. K., Smith, W. R., Dahman, B. A., Levenson, J. L., Roberts, J. D., Penberthy, L. T., 
… Bovbjerg, V. E. (2009). Pain site frequency and location in sickle cell disease: The 
PiSCES project. Pain, 145(1–2), 246–251. https://doi.org/10.1016/j.pain.2009.06.029 
McWilliams, L. A., Cox, B. J., & Enns, M. W. (2003). Mood and anxiety disorders associated 
with chronic pain: An examination in a nationally representative sample. Pain, 106(1–2), 
127–133. https://doi.org/10.1016/S0304-3959(03)00301-4 
McWilliams, L. A., Goodwin, R. D., & Cox, B. J. (2004). Depression and anxiety associated 
with three pain conditions: Results from a nationally representative sample. Pain, 111(1–2), 
77–83. https://doi.org/10.1016/j.pain.2004.06.002 
Moody, K., Abrahams, B., Baker, R., Santizo, R., Manwani, D., Carullo, V., … Carroll, A. 
(2017). A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-
Occlusive Crisis. Journal of Pain and Symptom Management, 53(6), 1026–1034. 
https://doi.org/10.1016/j.jpainsymman.2016.12.351 
Moscou-Jackson, G., Finan, P. H., Campbell, C. M., Smyth, J. M., & Haythornthwaite, J. A. 
(2015). The effect of sleep continuity on pain in adults with sickle cell disease. Journal of 
Pain, 16(6), 587–593. https://doi.org/10.1016/j.jpain.2015.03.010 
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000). 
Treatment of fibromyalgia with antidepressants: A meta-analysis. Journal of General 
Internal Medicine, 15(9), 659–666. https://doi.org/10.1046/j.1525-1497.2000.06279.x 
Oram, S., Ostrovschi, N. V, Gorceag, V. I., Hotineanu, M. A., Gorceag, L., Trigub, C., & Abas, 
M. (2012). Physical health symptoms reported by trafficked women receiving post-
trafficking  support in Moldova: prevalence, severity and associated factors. BMC Women’s 
Health, 12, 20. https://doi.org/10.1186/1472-6874-12-20 
Ozer, C., Yengil, E., Acipayam, C., & Kokacya, M. H. (2014). Relationship between depression, 
anxiety, quality of life and vaso-occlusive crisis in adolescents with sickle cell disease. Acta 
Medica Mediterranea, 30(2), 335–339. Retrieved from 
https://www.scopus.com/inward/record.uri?eid=2-s2.0-
84898471979&partnerID=40&md5=7d617897f2596c49705119a3d2b85bcf 
Phillips, K, & Clauw, D. J. (2011). Central pain mechanisms in chronic pain states--maybe it is 
 
 
207 
 
all in their head. Best Practice & Research.Clinical Rheumatology, 25(2), 141–154. 
https://doi.org/10.1016/j.berh.2011.02.005 [doi] 
Phillips, Kristine, & Clauw, D. J. (2011). Central pain mechanisms in chronic pain states-maybe 
it is all in their head. Best Pract Res Clin Rheumatol, 25(2), 141–154. 
https://doi.org/10.1016/j.berh.2011.02.005 
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & 
Kinney, T. R. (1991). Pain in sickle cell disease. Rates and risk factors. The New England 
Journal of Medicine, 325(1), 11–16. https://doi.org/10.1056/NEJM199107043250103 [doi] 
Schatz, J., Schlenz, A. M., McClellan, C. B., Puffer, E. S., Hardy, S., Pfeiffer, M., & Roberts, C. 
W. (2015). Changes in coping, pain, and activity after cognitive-behavioral training: a 
randomized clinical trial for pediatric sickle cell disease using smartphones. The Clinical 
Journal of Pain, 31(6), 536–547. https://doi.org/10.1097/AJP.0000000000000183 [doi] 
Schofferman, J., Anderson, D., Hines, R., Smith, G., & Keane, G. (1993). Childhood 
psychological trauma and chronic refractory low-back pain. The Clinical Journal of Pain, 
9(4), 260–265. 
Sharma, S., Efi, J. T., Knupp, C., Kadali, R., Liles, D., & Shiue, K. (2015). Sleep Disorders in 
Adult Sickle Cell Patients, 11(3), 1–5. 
Shattuck, E. C., & Muehlenbein, M. P. (2016). Towards an integrative picture of human sickness 
behavior. Brain, Behavior, and Immunity, 57, 255–262. 
https://doi.org/10.1016/j.bbi.2016.05.002 
Skljarevski, V., Desaiah, D., Liu-Seifert, H., Zhang, Q., Chappell, A. S., Detke, M. J., … 
Backonja, M. (2010). Efficacy and safety of duloxetine in patients with chronic low back 
pain. Spine, 35(13), E578-85. https://doi.org/10.1097/BRS.0b013e3181d3cef6 
Slade, G. D., Smith, S. B., Zaykin, D. V, Tchivileva, I. E., Gibson, D. G., Yuryev, A., … 
Diatchenko, L. (2013). Facial pain with localized and widespread manifestations: separate 
pathways of vulnerability. Pain, 154(11), 2335–2343. 
https://doi.org/10.1016/j.pain.2013.07.009 
Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., … Oncology, A. 
for C. T. in. (2013). Effect of duloxetine on pain, function, and quality of life among 
patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical 
trial. Jama, 309(13), 1359–1367. https://doi.org/10.1001/jama.2013.2813 
Smith, W. R., Penberthy, L. T., Bovbjerg, V. E., Mcclish, D. K., & Roberts, J. D. (2008). Daily 
Assessment of Pain in Adults with Sickle Cell Disease. Annals of Internal Medicine, 148, 
94–101. https://doi.org/10.7326/0003-4819-148-2-200801150-00004 
Snelling, J. (1994). The effect of chronic pain on the family unit. Journal of Advanced Nursing, 
19(3), 543–551. 
Spiegel, D. R., Chatterjee, A., McCroskey, A. L., Ahmadi, T., Simmelink, D., Oldfield 4th, E. 
C., … Raulli, O. (2015). A Review of Select Centralized Pain Syndromes: Relationship 
With Childhood Sexual Abuse, Opiate Prescribing, and Treatment Implications for the 
Primary Care Physician. Health Services Research and Managerial Epidemiology, 2, 
 
 
208 
 
2333392814567920-Dec. https://doi.org/10.1177/2333392814567920 [doi] 
Strigo, I. A., Simmons, A. N., Matthews, S. C., Craig, A. D. B., & Paulus, M. P. (2008). 
Association of major depressive disorder with altered functional brain response during 
anticipation and processing of heat pain. Archives of General Psychiatry, 65(11), 1275–
1284. https://doi.org/10.1001/archpsyc.65.11.1275 
Thomas, L. S., Stephenson, N., Swanson, M., Jesse, D. E., & Brown, S. (2013). A pilot study: 
the effect of healing touch on anxiety, stress, pain, pain medication usage, and physiological 
measures in hospitalized sickle cell disease adults experiencing a vaso-occlusive pain 
episode. Journal of Holistic Nursing, 31(4), 234–247. 
https://doi.org/10.1177/0898010113491631 
Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., … Watanabe, M. 
(2008). Common chronic pain conditions in developed and developing countries: gender 
and  age differences and comorbidity with depression-anxiety disorders. The Journal of 
Pain : Official Journal of the American Pain Society, 9(10), 883–891. 
https://doi.org/10.1016/j.jpain.2008.05.005 
Verdu, B., Decosterd, I., Buclin, T., Stiefel, F., & Berney, A. (2008). Antidepressants for the 
treatment of chronic pain. Drugs, 68(18), 2611–2632. Retrieved from 
https://link.springer.com/content/pdf/10.2165%2F0003495-200868180-00007.pdf 
Vacca Jr, V. M., & Blank, L. (2017). Sickle cell disease: Where are we now? Nursing, 47(4), 26–
34. https://doi.org/10.1097/01.NURSE.0000513609.79270.74 [doi] 
Wasserman, R. A., Brummett, C. M., Goesling, J., Tsodikov, A., & Hassett, A. L. (2014). 
Characteristics of chronic pain patients who take opioids and persistently report high pain 
intensity. Regional Anesthesia and Pain Medicine, 39(1), 13–17. 
https://doi.org/10.1097/AAP.0000000000000024 [doi] 
Zaza, C., & Baine, N. (2002). Cancer pain and psychosocial factors: a critical review of the 
literature. Journal of Pain and Symptom Management, 24(5), 526–542. 
Zempsky, W. T., Wakefield, E. O., Santanelli, J. P., New, T., Smith-Whitley, K., Casella, J. F., 
& Palermo, T. M. (2017). Widespread Pain Among Youth With Sickle Cell Disease 
Hospitalized With Vasoocclusive Pain: A Different Clinical Phenotype? The Clinical 
Journal of Pain, 33(4), 335–339. https://doi.org/10.1097/AJP.0000000000000403 [doi] 
 
 
 
 
209 
 
APPENDICES 
Appendix A-1 
Pain Influencing Factors in Patients with SCD 
Table 19 
Pain Influencing Factors in Patients with SCD 
Author Study type Sample and 
Setting 
Influencing 
factor(s) 
Pain 
Measures 
Influencing Factor Results Limitations 
(Bakshi et 
al., 2018) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cross-
sectional 
N=47 adults with 
SCD 
n=33 those with 
pain 3 or more 
days per week 
• Median age: 
35 years 
n=14 those with 
pain <3 days per 
week 
• Median age: 
36.5 years 
 
Setting: regional 
and national SCD 
conferences and 
local SCD clinics 
Physiological: 
age, sex 
 
Psychological: 
depression, 
anxiety 
Pain on 3 or 
more days 
per week 
(dichotomous 
variable) 
 
PROMIS 
Pain 
interference 
There was no significant 
difference between those 
with pain 3 or more days per 
week and those with pain <3 
days per week based on age 
and sex. Statistically 
significant differences were 
found in depression 
(52 vs. 43.35; p=0.029) and 
anxiety  (55.6 vs. 48.8; 
p=0.0178) scores among 
those who reported pain on 3 
or more days per week vs. 
those who did not. When 
adjusting for age and sex, 
pain on 3 or more days per 
week significantly predicted 
greater anxiety (p<0.05). 
Sample included 79% 
women  
 
Pain outcome 
dichotomous variable 
 
Those with who did 
not adhere to filling 
out PRO measures 
were significantly 
younger than those 
that did not 
 
No corrections for 
multiple comparisons 
 
No power analysis 
reported 
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(Finan et al., 
2018) 
Longitudinal N=45 adults with 
SCD 
• Mean age: 
37.49 years 
 
 
Setting: Sample 
recruited from local 
SCD clinics and 
from posted flyers 
and advertisements 
Psychological: 
catastrophizati
on 
Daily diary 
• Numeric 
Rating 
Scale 
• Dichotomo
us VOC 
variable 
• Pain 
Catastrophi
zing Scale 
Daily levels of pain (p= 
0.006) and catastrophizing 
(p < 0.001) were 
significantly associated 
with daily levels of short-
acting opioid use. Daily 
pain and catastrophizing 
were not associated with 
long-acting opioid use. 
Patients in the 
sample reported 
low levels of pain, 
on average  
 
No corrections for 
multiple 
comparisons 
 
No comparison 
between those 
with and without 
centralized pain 
 
 
(Martin et 
al., 2018) 
Cross-
sectional 
N=92 
• Mean age: 
15.02 years 
 
Setting: Inpatient 
unit at children's 
hospital  
Situational: 
sickle cell 
stigma 
PROMIS Pain 
Interference 
Scale 
 
Pain Intensity: 
Numeric Pain 
Rating Scale 
 
Change in pain: 
Pain at 
discharge 
subtracted from 
pain at 
admission 
Higher stigma was 
significantly associated 
with increased pain 
interference (p≤0.01) and 
less change in pain scores 
(p≤0.05) while in the 
hospital. 
Preliminary data 
from newly 
developed PRO 
stigma measure 
 
No comparison 
between those 
with and without 
centralized pain 
(Antunes et 
al., 2017) 
Cross-
sectional 
N=56 with SCD 
n=14 with NP 
• Mean age: 
22.7 years 
n=42 without NP 
• Mean age: 
19.8 years 
Physiological: 
sex, age 
Leeds 
assessment of 
neuropathic 
symptoms and 
signs (LANSS) 
scale; scores of 
> 11 were 
Patients with NP were 
significantly older than 
those without NP (p<0.05). 
There were no significant 
differences based on sex 
between groups. 
Evidence suggests 
that total scores 
<12 on LANSS 
scale suggests 
unlikely 
neuropathic 
pain(Rutherford, 
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Setting: Brazil 
outpatient university 
clinic 
classified as 
evidence of 
neuropathic 
pain (NP) 
 
Nixon, Brown, 
Briggs, & Horton, 
2016) 
 
No power analysis 
reported 
 
Small sample size 
within the NP 
group 
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(Bakshi et 
al., 2017) 
Case-control N=52  
n=29 with SCD 
• Median age: 
15 years 
n=29 controls 
 
Setting: large 
academic 
children's hospital 
Physiological: 
age, sex 
 
Psychological: 
depression, 
anxiety, 
catastrophization 
QST: 
• Pressure 
pain 
threshold 
• Mechanical 
detection 
threshold 
• Thermal 
detection 
thresholds 
• Thermal 
pain 
thresholds 
 
PROMIS Pain 
Intensity Scale 
 
Gracely Box 
Scale: Pain 
intensity and 
unpleasantness 
 
VOC incidence 
during 3-years 
prior to QST 
testing 
Age was significantly 
associated with 
pressure (p=0.004) 
and heat pain 
tolerance (p=0.028) in 
patients with SCD. In 
those with SCD, 
increased age was 
associated with lower 
mechanical temporal 
summation (p=0.045). 
In patients with SCD, 
male sex was 
significantly 
associated with higher 
heat detection 
threshold (p=0.023). 
Depressive symptoms 
(p<0.01) and anxiety 
(p<0.01) were 
associated with higher 
cold pain thresholds. 
However, depressive 
symptoms were 
significantly 
associated with lower 
heat pain thresholds 
(p<0.01) in those with 
SCD. 
Catastrophization 
scores were associated 
with higher cold pain 
thresholds (p<0.01)  
No 
corrections 
for multiple 
comparisons  
 
Possible 
selection bias 
since 
participants 
needed to 
come in for 
separate QST 
appointment  
 
Authors 
reported 
relatively low 
incidence of 
pain within 
the sample 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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and lower mechanical 
pain tolerance 
(p<0.01) in those with 
SCD.  In multiple 
regression models 
adjusted for age and 
sex, increased VOC 
was independently 
associated with 
increased heat pain 
thresholds (p<0.01) 
and tolerance 
(p<0.05), decreased 
mechanical temporal 
summation (p<0.05), 
and decreased cold 
detection thresholds 
(p<0.01). 
(Ford et al., 
2017) 
Cohort N=50 
n=34 exposed to 
trauma 
• Mean age: 
34.9 years 
n=16 nonexposed 
• Mean age: 
24.9 years 
 
Setting: University 
of Connecticut 
Health Center's 
adult 
comprehensive 
SCD program 
Psychological: 
depression, 
anxiety 
 
Situational: 
trauma exposure 
(interpersonal 
violence) 
Self-reported 
chronic pain: 
presence of 
moderate to 
severe pain on 
more than 50% 
of days in the 
last 6 months 
 
Daily opiate 
use:   
prescription for 
long- or short-
acting oral, 
subcutaneous, 
While controlling for 
age and depression, 
patients who reported 
interpersonal violence 
were nearly 5x more 
likely to self-report 
chronic pain (p=0.05) 
and to take a daily 
opiate (p=0.023). Self-
reported chronic pain 
was not significantly 
associated with 
depression and 
anxiety.  
Dichotomous 
outcome 
measure 
 
Significant 
differences 
between those 
exposed and 
unexposed to 
interpersonal 
violence 
could have 
influenced the 
incidence of 
chronic pain 
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or transdermal 
opiates 
prescribed for 
use on a daily 
basis from 
medical record 
 
Opiate use 
was based on 
prescriptions 
and not self-
reported 
opiate use 
 
No power 
analysis 
reported 
 
No 
corrections 
for multiple 
comparisons 
described 
(Moody et 
al., 2017) 
RCT N=73 with SCD 
admitted to 
hospital with pain 
≥ 7 
n=35 yoga group 
• Mean age: 
15 years 
n=35 control 
group 
• Mean age: 
14 years 
 
Setting: Children's 
hospital in Bronx, 
NY 
 
Psychological: 
anxiety 
FACES pain 
scale 
There were no 
significant differences 
in anxiety between 
groups. 
No blinding 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
 
Evidence 
suggests this 
Intervention 
targets central 
pain 
mechanisms, 
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Intervention:  yoga 
intervention 
(n=35) vs attention 
control (n=35);  
Intervention 
delivered by 
instructor for 30 
minutes daily 
Monday through 
Friday. Four 
elements of yoga 
were incorporated 
into the 
intervention: 
mindfulness, 
asanas, breathing 
exercises, and 
guided relaxation. 
but it was 
delivered 
among those 
experiencing 
acute VOC 
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(Zempsky 
et al., 
2017) 
Cross-
sectional 
N=156 with SCD 
 
n=34 widespread 
pain group 
• Mean age: 
15.56 years 
n= 122 without 
widespread pain 
• Mean age: 
15.72 years 
 
Patients with SCD 
ages 7-21 
 
Setting: 4 
children’s 
hospitals; inpatient 
Physiological:  
SCD genotype, 
sex, age 
Pain location: 
Adolescent 
pediatric pain 
tool 
Widespread 
Pain: WSP 
Index 
Pain Intensity: 
Average pain 
score during 
hospitalization 
No significant 
differences between 
patients with and 
without widespread 
pain among sex, age, 
and SCD genotype. 
Post hoc 
analysis 
 
No 
corrections 
for multiple 
comparisons 
 
Small sample 
size within 
the 
widespread 
pain group 
 
No power 
analysis 
reported 
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(Bediako et 
al., 2016) 
Cross-
sectional 
N=262 
• Mean age: 
34.5 years 
 
Setting: two 
comprehensive 
SCD centers in the 
Baltimore/Washin
gton are 
Situational: sickle 
cell stigma 
Acute care 
service 
utilization: # of 
times in ED or 
infusion clinic 
for pain in the 
past year (self-
report) 
 
Hospital 
admissions: # 
of hospital 
admissions for 
pain in the past 
year (self-
report) 
Sickle cell stigma 
factors including 
social exclusion 
(p<0.01), internalized 
stigma (p<0.05), and 
expected 
discrimination 
(p<0.05) were 
significantly 
associated with acute 
care visits for SCD 
pain.  
Self-reported 
health care 
utilization and 
hospital 
admission 
assessments 
could be 
subject to 
recall bias 
 
No 
corrections 
for multiple 
comparisons 
described 
 
No power 
analysis 
reported 
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(Carroll et 
al., 2016) 
Longitudinal N=83 with SCD 
n=54 no chronic 
opioid therapy 
(COT) 
• Median age: 
38 years 
n=29 COT 
• Median age: 
40.6 years 
 
Setting: Sickle 
Cell Center for 
Adults at Johns 
Hopkins 
Physiological: 
genotype,  sex, 
age 
 
Psychological: 
depression 
QST: 
• Heat pain 
thresholds 
• Pressure 
pain 
thresholds 
• Temporal 
summation 
 
Brief Pain 
Inventory 
 
Daily pain 
diary:  
• Pain 
intensity 
(0-100) 
Pain 
interference 
Patients with chronic 
opioid therapy had 
significantly greater 
depression compared 
to those without (20.2 
vs. 12; p<0.01). There 
were no significant 
differences between 
those with and without 
chronic opioid therapy 
regarding genotype, 
sex, and age.  
Lack of 
information 
regarding pain 
prior to COT, 
prior opioid 
exposure, and 
duration of 
COT prior to 
the study 
 
Reduced 
power for 
some analyses 
due to small 
sample in 
COT group 
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(Campbell 
et al., 
2016) 
Longitudinal n=17 with low 
central 
sensitization (CS) 
• Mean age: 
35.6 years 
n=21 with high CS 
• Mean age: 
42.8 years 
 
Setting: Sickle 
Cell Center for 
Adults at Johns 
Hopkins 
Physiological: 
sleep 
 
Psychological: 
depression, 
catastrophization 
QST: 
• Heat Pain 
Threshold 
• Pressure 
Pain 
Threshold 
• Temporal 
summation 
• Conditione
d Pain 
Modulation 
 
Pain Intensity 
following 
QST: 0-100 
scale 
 
Daily pain 
diary: 
• Pain 
intensity: 0-
100 
• Pain 
interference 
Presence of 
VOC 
Patients in the high CS 
group reported 
significantly poorer 
sleep continuity on all 
components of the  
Pittsburgh Sleep 
Quality Index (all p< 
0.05). Also, those in 
the high CS group 
reported increased 
insomnia (p=0.005). 
There were no 
significant differences 
between the high and 
low CS groups in 
genotype, age, sex, 
depressive symptoms, 
and pain 
catastrophizing.  
Patient report 
of # of VOC 
 
Pain 
interference 
measure not 
reliable and 
valid 
 
No power 
analysis 
reported 
 
Small sample 
size within 
the NP group 
 
 
Strict 
inclusion 
criteria 
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(Schlenz, 
Schatz, & 
Roberts, 
2016) 
Cross-
sectional 
N=76 
• Mean age: 
14.05 years 
 
Setting: Children’s 
Center for Cancer 
and Blood 
Disorders 
(CCBD) in 
South Carolina 
Physiological: 
genotype 
Pain History 
Interview 
(parent and 
child  
retrospective 
reports): 
• Pain 
Intensity 
• Pain 
Duration 
• Pain 
Frequency  
 
Health service 
utilization 
(previous 12 
months)  
 
Patients with high risk 
genotypes (HbSS and 
HbSβ0  had higher 
pain intensity (7.48 vs. 
6.58; p<0.05) and 
health care utilization 
(4.02 vs. 2.08; p<0.05) 
ratings than those with 
low risk genotypes 
(HbSC and HbSβ+). 
Pain History 
Interview 
retrospective 
assessments 
could be 
subject to 
recall bias 
 
 
Small sample 
reduced 
power 
(Sil et al., 
2016) 
Cross-
sectional 
N=100 (n=40 
chronic pain, n=40 
episodic pain, 
n=20 no pain) 
• Mean age: 
13.54 years 
 
Setting: outpatient 
sickle cell clinic 
Physiological: 
genotype, sex, 
age 
 
Psychological: 
depression, 
catastrophizing 
Pain intensity: 
average pain in 
last 2 weeks 
 
Pain 
frequency: # of 
pain days in 
last month 
(patient and 
parent report) 
 
Health care 
utilization: 
number of 
hospitalization
There were no 
significant differences 
in genotype and sex 
among the three 
groups. Patients in the 
chronic pain group 
were significantly 
older than those in the 
no SCD pain group  
(14.41 vs. 11.62). 
Chronic pain group 
had higher levels of 
depressive symptoms 
than those in the no 
pain group  (13.40 vs. 
Possibility for 
recall bias 
based on pain 
outcome 
measures 
 
Definition for 
chronic pain 
was based on 
pain 
frequency and 
not central 
pain 
mechanisms  
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s, and ED 
visits related to 
pain within last 
year 
4.35; p<0.001) and the 
episodic pain group 
(13.40 vs. 9.13; 
p<0.001).  Also, the 
no pain group had 
significantly less 
levels of pain 
catastrophizing than 
those in the episodic 
pain group  (17.85 vs. 
24.98; p<0.01) and the 
chronic pain group 
(17.85 vs. 28.13; 
p<0.01). No 
significant differences 
were found in 
catastrophizing scores 
between the chronic 
and episodic groups. 
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(Jacob et 
al., 2015) 
Cross-
sectional 
N=48 children 
with SCD 
 
n=35 normal QST 
• Mean age: 
13.9 years 
n=13 abnormal 
QST 
• Mean age: 
12.8 years 
 
Setting: Sickle 
Cell Disease 
Foundation of 
California 
Physiological: 
genotype, sex, 
age 
 
Psychological: 
depression, 
anxiety 
QST: 
• Nonpainfu
l 
mechanica
l stimulus 
• Painful 
mechanica
l stimulus 
• Thermal 
detection 
thresholds 
Pain Intensity: 
Visual 
Analogue 
Scale 
Patients with normal 
QST did not differ 
from those with 
abnormal results based 
on genotype, sex, age, 
depression, and 
anxiety. 
Only one 
body site was 
analyzed 
using QST 
 
No power 
analysis 
reported 
 
No 
corrections 
for multiple 
comparisons 
 
Small sample 
size within 
the abnormal 
QST group 
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(Moscou-
Jackson et 
al., 2015) 
Longitudinal N=75 
• Mean age: 
35.5 years 
 
Setting: SCD 
clinics 
Physiological: 
sleep 
Daily pain 
diary: 
• Pain 
intensity: 0-
100 
• Pain 
interference 
• Presence of 
VOC 
Pain severity 
significantly 
correlated with the 
following sleep 
continuity variables: 
total sleep time 
(p<0.01), mean time in 
bed (p<0.05), mean 
sleep onset latency 
(p<0.01), mean wake 
after sleep onset 
(p<0.01), and mean 
sleep efficiency 
(p<0.01). Lower total 
sleep time (p<0.001), 
lower sleep efficiency 
(p=0.02), lower time 
in bed (p=0.01), and 
higher wake after 
sleep onset (p<0.001) 
all predicted increased 
next-day pain. For 
every 30-minute 
decrease in wake after 
sleep onset, next-day 
pain severity was 
estimated to be lower 
by 0.60 points. 
Pain 
interference 
measure not 
reliable and 
valid 
 
No power 
analysis 
reported 
 
Strict 
inclusion 
criteria 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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(Ameringer 
et al., 
2014) 
Cross-
sectional 
N=60 with SCD 
• Mean age: 
22.5 years 
Physiological: 
fatigue 
Brief Pain 
Inventory 
Fatigue scores 
assessed via the Brief 
Fatigue Inventory 
were significantly 
associated with worst 
pain, average pain, 
and pain interference 
(all p≤0.001). 
Setting not 
described 
 
(Brandow 
et al., 
2014) 
Cross-
sectional 
N=56 with SCD 
• Median age: 
20.3  
 
Setting: Outpatient 
sickle cell center 
Physiological: 
sex, age 
PainDETECT Age was positive 
correlated with total 
PainDETECT score 
(p=0.001). Females 
had significantly 
higher scores than 
males (13 vs. 8.4; 
p=0.04). 
Descriptive 
design with 
one PRO 
measure 
(Graves & 
Jacob, 
2014) 
Cross-
sectional 
N=66 
n=39 children 
• Mean age: 
11.9 years 
n=27 adolescents 
• Mean age: 
15.5 years 
 
Setting: Sickle 
Cell Disease 
Foundation of 
California 
Physiological: 
age, sex, sleep 
 
Psychological: 
catastrophizing 
Pain Intensity: 
electronic 
Visual Analog 
Scale 
 
Pain 
Frequency: # 
of pain 
episodes in the 
previous 12 
months that 
required 
hospitalization 
(parent report) 
There were significant 
negative correlations 
in males between 
worst pain severity 
and positive 
behavioral distraction 
(r= −0.432; p=0.01)  
and negative 
internalizing/ 
catastrophizing (r= 
−0.457; p=0.049), but 
not in females. There 
were no significant 
differences in pain 
Parent report 
pain 
frequency 
measurement 
may be 
subject to 
recall bias 
 
Convenience 
sampling was 
used which 
could reduce 
generalizabilit
y of findings 
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Pediatric Pain 
Coping 
Questionnaire 
intensity or frequency 
based on age and 
gender. There were no 
significant differences 
in sleep scores based 
on pain intensity and 
pain severity. 
 
No 
corrections 
for multiple 
comparisons 
described 
 
No power 
analysis 
reported 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
 
(Wallen et 
al., 2014) 
Cross-
sectional 
N= 328 with SCD 
• Median age: 
34 years 
 
Setting: NIH 
Clinical Center 
Physiological: 
sleep 
 
Psychological: 
depression 
# of VOC 
within the past 
12 months 
Increased sleep 
disturbance was 
significantly 
associated with 
increased pain 
frequency (p=0.003) 
and health care 
utilization (p=<0.001). 
Mild/moderate pain 
was significantly 
associated with 
depression (p=0.001). 
Potential 
recall bias 
with patient 
report of # of 
VOC 
 
Surveys were 
administered 
at  two 
separate times 
during a 
larger parent 
study  (at 
initiation and 
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study follow-
up).This 
variable was 
not controlled 
for among 
patients 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
(Brandow 
et al., 
2013) 
Cross-
sectional 
n=55 with SCD 
• Mean age: 
15.4 
n=57 controls 
• Mean age: 
16.3 
 
Setting: Wisconsin 
Sickle Cell Center 
Physiological: 
sex, age 
QST: 
• Thermal 
pain 
thresholds 
• Thermal 
detection 
thresholds 
• Mechanica
l detection 
threshold 
Mechanical 
pain threshold 
Older age was 
significantly 
associated with lower 
cold (p=0.02), heat 
(p=0.004), and 
mechanical (p=0.03) 
pain thresholds. There 
were no significant 
differences in sex. 
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(Carroll et 
al., 2013) 
Cross-
sectional 
N=56 with SCD 
n=29 high health 
service utilizers 
• Mean age: 
28.6 years 
n=27 comparison 
group 
• Mean age: 38 
years 
 
Setting: 
Sickle Cell Center 
for Adults at Johns 
Hopkins 
Physiological: 
genotype, age 
 
Psychological: 
depression,  
 
Situational: 
trauma exposure, 
social support 
High utilizers: 
4 acute or 
emergency 
care visits 
within the past 
12 months 
Patients in the high 
health service utilizer 
group were 
significantly younger 
than the comparison 
group (p=0.002). No 
significant differences 
between high health 
service utilizers and 
the comparison group 
regarding genotype, 
depression, social 
support, trauma 
exposure. 
All acute care 
or emergency 
visits were 
included, not 
solely ones 
for pain 
 
Low power 
due to small 
sample 
 
No 
corrections 
for multiple 
comparisons 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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(Thomas et 
al., 2013) 
RCT N=17 adults with 
SCD experiencing 
VOC 
• Mean age: 
31.5 years 
 
Setting: 
Southeastern 
North Carolina 
Health Care 
System 
 
Intervention:  
Healing Touch 
with Music (HTM) 
(n=11) vs. 
Attention Control 
with Music 
(ACM) group 
(n=6); Intervention 
delivered over 30 
minutes for four 
consecutive days  
Psychological: 
anxiety 
Numeric rating 
scale 
There were no 
significant differences 
in anxiety between the 
intervention and 
control groups. 
Within-group 
comparisons showed 
that the control group 
had a significant 
reduction in anxiety 
from Day 1 to 4 
(p=0.01).  
Small sample 
reduced the 
power to 
detect 
differences 
between 
groups 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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(Jerrell et 
al., 2011) 
Cohort N=2194 
n=1017 depression 
cohort 
• Mean age of 
major 
depressive 
disorder 
diagnosis: 
14.2 years 
n=1177 control 
cohort 
 
Setting: Medicaid 
claims data from 
South Carolina's 
Medicaid program 
Psychological: 
depression 
VOC pain 
visits per year 
Those diagnosed with 
depression were more 
likely to have vaso-
occlusive pain (OR = 
1.06; 95% CI, 1.03–
1.08; p<0.0001) than 
those in the control 
cohort. 
No centrally-
mediated 
covariates 
included in 
the regression 
models 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
(Brousseau 
et al., 
2010) 
Longitudinal N= 21,112 with 
SCD 
• Age range: 1-
65+ 
 
Setting: 
Emergency 
Department and 
inpatient units 
Physiological: 
age 
N/A Patients ages 18-30 
had the acute care 
encounters per year 
(3.61; 95% CI, 3.47-
3.75) and re-
hospitalization rates 
(28.4%; 95% CI, 
27.8%- 29.0%) 
compared to all other 
age groups.  
All ED visits 
and 
hospitalizatio
ns were 
included, not 
solely ones 
for pain 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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(Daniel et 
al., 2010) 
Case control n=54 parents of 
children with SCD 
• Mean age: 
6.56 years 
n=52 healthy 
controls 
• Mean age: 
6.71 years 
 
Setting: urban 
children's hospital 
Physiological: 
sleep 
Derived from 
medical 
record: 
• Health 
Utilization 
Score 
SCD 
Complications 
Score 
SCD complications 
score was significantly 
correlated with reports 
of parasomnias 
(p= 0.003), sleep‐
disordered Breathing 
(p = 0.003), and the 
Total Sleep Problems 
score (p=0.021). The 
Healthcare Utilization 
summary score was 
also significantly 
correlated with the 
parasomnia subscale 
items (p= 0.021). SCD 
complications and 
health utilization 
scores did not 
significantly predict 
restless sleep and 
sleep-disordered 
breathing within 
regression models. 
Parent 
reported sleep 
habits of 
children 
 
Some 
significant 
results were 
based on 
subscales 
rather than 
total sleep 
scale scores 
 
No 
corrections 
for multiple 
comparisons 
described 
 
(Lemanek 
et al., 
2009)  
RCT N=34 with SCD 
and their 
caregivers 
n=18 massage 
group 
• Mean age: 
9.97 years 
n=16 control 
group 
Psychological: 
depression, 
anxiety 
Pediatric Pain 
Scale 
After the 30-day study 
period, participants in 
the intervention group 
had significantly less 
depression (p=0.05), 
anxiety (p=0.01), and 
pain ratings (p=0.05) 
compared to the 
control group. There 
were no significant 
Not blinded  
 
Lack of 
standardizatio
n of 
intervention 
 
No 
comparison 
between those 
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• Mean age: 
11.55 years 
 
Setting: Sickle 
Cell Disease 
program at 
children's hospital 
 
Intervention: 
Massage group vs 
attention control 
group; massage 
therapist visited 
home weekly for 4 
weeks and trained 
the caregiver how 
to give massages. 
Children received 
massages by 
caregiver between 
therapist days. 
Massage 
intervention lasted 
30 days. 
differences between 
groups based on health 
care utilization. 
with and 
without 
centralized 
pain 
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(McClish 
et al., 
2009) 
Longitudinal 
cohort study 
N=260 with SCD 
  
Patients with SCD 
• Mean age: 
33.9 years 
 
 
Setting: specialty 
sickle cell clinics 
and community 
centers 
Physiological: 
genotype, sex, 
age 
 
Psychological: 
Depression 
Pain diary: 
• Pain 
intensity- 
0-9 scale 
• Incidence 
of sickle 
cell crisis 
• Health 
service use 
• Body chart 
Significant differences 
in multifocal pain 
based on age 
(p=0.0120) and 
depression 
(p=0.0111). There 
were no significant 
differences based on 
SCD genotype and 
sex. 
Missing diary 
data not 
reported 
 
No 
description of 
how 
depression 
was identified 
 
Outcome 
measures not 
reliable and 
valid 
 
No 
comparison 
between those 
with and 
without 
centralized 
pain 
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Appendix A-2 
Critical Appraisal for Pain Influencing Factors in SCD:  
Randomized Controlled Trials 
 
Table 20 
Critical Appraisal for Pain Influencing Factors in SCD: Randomized Controlled Trials 
Author Randomized Allocation 
concealed 
Similar 
groups 
Blinding Groups 
treated 
identically 
Follow
-up 
Analyzed 
within 
groups 
Measures 
Reliable 
Appropriate 
Statistics 
Appropriate 
Design 
(Moody et 
al., 2017) 
Yes Yes Yes No Yes No Yes Yes Yes Yes 
(Thomas 
et al., 
2013) 
Yes ? Yes No Yes Yes Yes Yes Yes Yes 
(Lemanek 
et al., 
2009) 
Yes No No  No Yes No Yes Yes Yes No 
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Appendix A-3 
Critical Appraisal for Pain Influencing Factors in SCD:  
Case Control Studies 
 
Table 21 
Critical Appraisal for Pain Influencing Factors in SCD: Case Control Studies 
Author Similar 
groups 
Appropriate 
matching 
Same 
inclusion 
criteria 
Measures 
reliable 
and valid 
Confounders 
identified 
Strategies 
to deal with 
confounders 
Appropriate 
statistics 
(Brandow 
et al., 
2013) 
Yes Yes Yes Yes Yes Yes Yes 
(Daniel et 
al., 2010) 
Yes ? Yes No Yes Yes ? 
(Bakshi 
et al., 
2017) 
Yes No No No Yes Yes No 
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Appendix A-4 
Critical Appraisal for Pain Influencing Factors in SCD:  
Cross-Sectional Studies 
 
Table 22 
Critical Appraisal for Pain Influencing Factors in SCD: Cross-Sectional Studies 
Author Inclusion 
Defined 
Sample and 
Setting 
Described 
Exposure 
measure 
reliable and 
valid 
Objective 
criteria for 
measuring 
condition 
Confounders 
listed 
Strategies 
to deal with 
confounders 
Outcome 
measures 
reliable 
and valid 
Appropriate 
statistics 
(Bakshi et al., 
2018) 
Yes Yes Yes Yes Yes Yes No No 
(Martin et al., 
2018) 
Yes Yes Yes Yes Yes Yes Yes Yes 
(Antunes et 
al., 2017) 
Yes Yes Yes Yes No No No Missing power 
analysis 
(Zempsky et 
al., 2017) 
Yes Yes Yes Yes Yes Yes Yes No 
(Bediako et 
al., 2016) 
Yes Yes Yes Yes No No No Missing power 
analysis 
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(Schlenz, 
Schatz, & 
Roberts, 
2016) 
Yes Yes Yes Yes Yes Yes No Reduced power 
(Sil et al., 
2016) 
Yes Yes Yes Yes Yes Yes No Yes 
(Jacob et al., 
2015) 
Yes Yes Yes Yes Yes Yes Yes No 
(Ameringer et 
al., 2014) 
Yes No Yes Yes Yes Yes Yes Yes 
(Brandow et 
al., 2014) 
Yes Yes Yes Yes No No Yes Yes 
(Graves & 
Jacob, 2014) 
Yes Yes Yes Yes Yes Yes No Missing power 
analysis 
(Wallen et al., 
2014) 
Yes Yes Yes Yes No No No Yes 
(Carroll et al., 
2013) 
Yes Yes Yes Yes Yes Yes Yes No 
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Appendix A-5 
Critical Appraisal Pain Influencing Factors in SCD:  
Cohort Studies 
 
Table 23 
Critical Appraisal Pain Influencing Factors in SCD: Cohort Studies 
Author Similar 
groups 
Exposure 
measure 
standardized 
Confounders 
identified 
Strategies 
to deal with 
confounders 
Measures 
reliable 
and valid 
Follow-up 
time 
appropriate 
Follow-up 
complete, or 
lack of 
follow-up 
explained 
Strategies 
to address 
incomplete 
follow-up 
Appropriate 
statistics 
(Finan et 
al., 2018) 
N/A Yes Yes Yes Yes Yes Yes Yes No 
(Ford et 
al., 2017) 
No Yes Yes Yes No Yes Yes No ? 
(Campbell 
et al., 
2016) 
No Yes Yes Yes No Yes Yes Yes Missing 
power 
analysis 
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(Carroll et 
al., 2016) 
No Yes Yes Yes Yes Yes ? ? Reduced 
power 
(Moscou-
Jackson et 
al., 2015) 
N/A Yes Yes Yes No Yes Yes Yes Missing 
power 
analysis 
(Jerrell et 
al., 2011) 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
(Brousseau 
et al., 
2010) 
N/A Yes Yes Yes Yes Yes Yes N/A Yes 
(McClish 
et al., 
2009) 
N/A Yes Yes Yes No Yes No No Yes 
 
